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Panic disorder, a short historical sketch
The syndrome of panic disorder (PD) as it is nowadays classified in the DSM-IV only
exists for several decades. In the DSM-III (1980) for the first time the diagnosis PD
is delimited from anxiety neurosis. The concept of anxiety as a separate entity did
not exist in the medical literature until about 1850. From the ancient times until the
midnineteenth century the diagnosis wherein the contemporary anxiety symptoms
were classified was defined as melancholia. Melancholia not only incorporated
anxiety, but also included several other psychiatric symptoms presently classified as
depressive and psychotic symptoms, and it had a strong somatic component.
Around 1850, the attention for anxiety as a separate psychopathological phenome-
non marked the fact that psychiatry was developing as a separate specialty within
the medical sciences (Glas 2003). In 1866 Morel described several cases of what he
called emotional delusions (délire emotif) (Morel 1866). He introduced the view
that the subjective and somatic symptoms of anxiety might result from a disorder of
the autonomic nervous system. At that time there was a strong tendency to medica-
lization of symptoms, resulting in the fact that the somatic symptoms of anxiety
were often considered and described as separate diseases, e.g. as cardiovascular
pathology because of the palpitations (Da Costa 1871) or as inner ear disease becau-
se of the dizziness (Benedikt 1870). In 1881 Beard described a new disease called
neurasthenia, in which all symptoms of anxiety were incorporated (Beard 1881).
Around the same period the term agoraphobia was mentioned for the first time in a
description of three cases of men who could not cross places unaccompanied
(Westphal 1872). The clinical status of the concept was not clear, partly because
there were no distinctions made between e.g. phobias and obsessions. Only 20 to
25 years later some distinction was made in the concept of anxiety. In 1890 Brissaud
proposed separate symptoms with different origins. He defined the more psycholo-
gical concept of anxiety (comparable with the idea of generalized anxiety) as deri-
ving from cortical processes, and the more organic concept of anguish (comparable
with the present idea of panic) stemming from processes in the brainstem. Freud
(1895a) was the first to note the concurrence of panic attacks and agoraphobia.
Furthermore, also in 1895 he laid the foundations for the modern classification of
anxiety disorders by separating out “anxiety neurosis” from neurasthenia (Freud
1895b). Freud considered anxiety neurosis to be a disease of the nervous system. He
also regarded phobias and obsessions to be different symptoms. Freud saw panic
attacks as “occasional eruptions from a volcanic sea of anxiousness”. Klein (1981)
put forward a new conceptualization of the anxiety disorders by regarding panic
attacks as a disease entity of its own. In this new concept, anticipatory anxiety is
regarded as the consequence of panic attacks, and not as their predecessor, and
agoraphobia follows both panic attacks and anticipatory anxiety. Thus, he brought
panic attacks and agoraphobia into one concept. However, in the DSM-III (1980)
agoraphobia was maintained as a separate category, and only some years later
Klein’s suggestion was acknowledged in the DSM-III-R (1987) and the DSM-IV
(1994), with the diagnosis of panic disorder taking the lead, and subclassifications
of panic disorder with and without agoraphobia (Katschnig 1999).
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Panic disorder, epidemiology and definition
Panic disorder is an invalidating and rather common psychiatric disorder.
Epidemiological studies throughout the world consistently indicate the lifetime pre-
valence to be between 1.5% and 3.5%. One year prevalence rates are between 1%
and 2%. Approximately one third to one-half of individuals diagnosed with PD in
community samples also have agoraphobia, although a much higher rate of agora-
phobia is encountered in clinical samples (American Psychiatric Association
Committee on Nomenclature and Statistics 1994). The female to male ratio of panic
disorder is approximately 2 to 1. Panic disorder most commonly develops in young
adulthood, the mean age of presentation being about 25, but both panic disorder
and agoraphobia can develop at virtually any age.
The DSM-IV (1994) describes symptoms of PD in the section “anxiety disorders”.
Because panic attacks and agoraphobia occur in the context of several anxiety disor-
ders as stated in the DSM-IV, the criteria defining a panic attack and agoraphobia
are listed separately at the beginning of the section. 
A panic attack is a discrete period in which there is the sudden onset of intense
apprehension, fearfulness, or terror, often associated with feelings of impending
doom. During these attacks, symptoms such as shortness of breath, palpitations,
chest pain or discomfort, choking or smothering sensations, and fear of “going
crazy” or losing control are present. 
There are three characteristic types of panic attacks with different relationships
between the onset of the attack and the presence or absence of situational triggers:
(1) unexpected or uncued panic attacks, in which the onset of the panic attack is not
associated with a situational trigger (occurring “out of the blue”); (2) situational
bound or cued panic attacks, in which the panic attack almost invariably occurs
immediately on exposure to, or in anticipation of, the situational cue or trigger; and
(3) situational predisposed panic attacks, which are more likely to occur on exposu-
re to the situational cue or trigger, but are not invariably associated with the cue and
do not necessarily occur immediately after exposure. The occurrence of unexpected
panic attacks is required for the diagnosis of panic disorder. Situational bound panic
attacks are most characteristic of social and specific phobias. Situational predispo-
sed panic attacks are especially frequent in panic disorder, but may at times occur in
specific phobia or social phobia. 
The criteria for a panic attack are listed in table 1.
Agoraphobia is anxiety about, or avoidance of, places or situations from which
escape might be difficult (or embarrassing) or in which help may not be available in
the event of having a panic attack or panic-like symptoms. 
The essential feature of PD is the presence of recurrent, unexpected panic attacks
followed by at least one month of persistent concern about having another panic
attack, worry about the possible implications or consequences of the panic attacks,
or a significant behavioral change related to the attacks. 
9
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Table 1 
a discrete period of intense fear or discomfort, in which four or more of the 
following symptoms developed abruptly and reached a peak within 10 minutes:
1 Palpitations, pounding heart or accelerated heart rate
2 Sweating
3 Trembling or shaking
4 Sensations of shortness of breath or smothering
5 Feeling of choking
6 Chest pain or discomfort
7 Nausea or abdominal distress
8 Feeling dizzy, unsteady, lightheaded or faint
9 Derealization (feelings of unreality) or depersonalization (being detached from 
oneself)
10 Fear of losing control or going crazy
11 Fear of dying
12 Paresthesias (numbness or tingling sensations)
13 Chills or hot flushes
Treatment strategies in panic disorder 
According to the practice guideline for the treatment of panic disorder of the American
Psychiatric Association, the treatment of first choice for PD at this moment is either
cognitive behavioral therapy (CBT) or pharmacotherapy (American Psychiatric
Association Committee on Nomenclature and Statistics 1998). According to the afore-
mentioned practice guideline it is not known currently whether a combined treatment
of CBT and pharmacotherapy is superior to either treatment alone. For agoraphobic
avoidance the combination of antidepressants with exposure in vivo therapy was signi-
ficantly more effective than all other treatments evaluated in a meta-analysis of 5011
PD patients with or without agoraphobia (van Balkom et al 1997). 
Pharmacologically antidepressants such as tricyclic antidepressants (TCAs), monoa-
mine oxidase (MAO) inhibitors and selective serotonin reuptake inhibitors (SSRIs)
and benzodiazepines (BDZs) have been shown to be effective in relieving anxiety in
PD patients (For review see: Den Boer et al 2002). TCAs like imipramine and clomi-
pramine were the first found to be beneficial in PD. Imipramine played a role in the
sixties in the pharmacological dissection of panic and anxiety, as it was discovered
that in patients suffering from anxiety neurosis, panic attacks disappeared during
treatment with imipramine. The efficacy of imipramine has been the subject of
many studies and this drug was used as a reference drug for years. TCAs, in spite of
their proven efficacy, have many drawbacks, including high rates of non-compliance
due to anticholinergic side-effects, weight gain, sedation, orthostatic hypotension,
lethality in overdose and withdrawal reactions (Bennett et al 1998; Den Boer et al
2000). Many studies have also been performed with BDZs in PD, and there is a
large database indicating that high potency BDZs such as clonazepam and alprazo-
lam are efficacious in PD. The onset of the effect of BDZs is rapid, but due to their
10
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side-effects, risk of dependency and withdrawal reactions, it has been questioned
whether BDZs should be the first choice in the treatment of PD (Den Boer et al
2002). The different SSRIs were shown to be as effective and have fewer adverse
effects compared to traditional treatments, such as BDZs and TCAs, in a large num-
ber of studies (Bakker et al 2000; Den Boer et al 1987; Pollack and Marzol 2000;
Sheehan 1999; van Vliet et al 1996; For review see: Den Boer et al 2002). Although
the etiology of PD is unclear, it has been suggested that besides serotonergic dys-
function noradrenergic dysfunction is also associated with PD. Therefore newer
drugs were developed to combine noradrenergic and serotonergic mechanisms of
action (Den Boer et al 2002). These dual action antidepressants have a different
side effect profile. The efficacy of mirtazapine, one of these dual action drugs, was
studied in PD, and preliminary evidence suggests it is an effective treatment alterna-
tive for SSRIs in panic disorder (Boshuisen et al 2001). 
Different neuroimaging studies have addressed the question whether the effects of
treatment on the nervous system can be visualized. Different neuroimaging studies
evaluated the effect of SSRIs in obsessive compulsive disorder (OCD) (Baxter et al
1992; Benkelfat et al 1990; Saxena et al 1998; Saxena et al 2002; Swedo et al 1992),
social phobia (Furmark et al 2002; Van der Linden et al 2000), and PD (Nordahl et
al 1998). The majority of these studies showed decreases in the caudate nucleus
and/or the orbitofrontal cortex after successful treatment. Furthermore, the effect of
behavioral treatment in OCD and in social phobia was evaluated by neuroimaging
and compared with the effect of pharmacological treatment (Baxter et al 1992; Brody
et al 1998; Furmark et al 2002). In all these studies the two treatment strategies
showed similar effects, both in symptom improvement and in decreases in brain
activation in different anxiety related brain regions. Changes in rCBF were noted into
the direction of the rCBF pattern of healthy control subjects. In addition, in social
phobia patients this design was combined with a symptom provocation test
(Furmark et al 2002). Significant posttreatment decreases in rCBF during symptom
provocation were observed in responders to both treatment strategies in the
amygdala, hippocampus and parahippocampal cortex. Two case studies using
symptom provocation in PTSD patients before and after SSRI treatment were publis-
hed (Fernandez et al 2001; Levin et al 1999). The subjects in both studies felt signifi-
cantly less anxious during the posttreatment challenge, and in both subjects chan-
ges in brain activation were noted. In the study of Levin et al (1999) increases in
rCBF were observed after treatment during the challenge in the anterior cingulate
cortex and the left frontal lobe as compared to the pretreatment condition. In the
study of Fernandez et al (2001) it was noted that in the untreated condition trauma
reminders resulted in rCBF decreases in several anxiety related brain regions like the
insula, the inferior frontal and the prefrontal cortex, while after treatment this was
normalized. In PD patients only one study has been performed studying treatment
effects with neuroimaging, and no provocation test was used in this case (Nordahl
et al 1998). Furthermore, the patients were not studied before and after treatment.
The study group comprised only successfully treated patients and was compared to
a previous study group of unmedicated PD patients (Nordahl et al 1990). Recently,
Paquette and colleagues (2003) showed that there was normalization of rCBF in the
prefrontal and parahippocampal cortex after CBT in patients with spider phobia.
11
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Neurobiological basis of anxiety and panic
In 1937 a neuroanatomist named Papez suggested that a complex set of specific
connections between structures of the limbic lobe formed an anatomical circuit for
emotion. The circuit of Papez included several brain structures that nowadays are
still named to be involved in the processing of anxiety, such as the hypothalamus,
the thalamus, the cingulate gyrus and the hippocampus (Papez 1937). Papez’ theory
of emotion was extended in 1949 by Maclean, who included other structures such
as the amygdala, the septum and the orbitofrontal cortex (Maclean 1949). At this
moment the notion of fear processing is that there exists a fear network in the brain,
wherein the amygdala plays a central role. In figure 1, a schematic presentation of
the brain structures involved in the processing of fear responses is shown, modified
after Windmann (1998). Of course most fear responses are generated more com-
plexely, and therefore in most cases more brain structures are involved than can be
shown in this figure. Normally fear originates from some sort of fear inducing sti-
mulus. The sensory input is processed through the anterior thalamus to the lateral
nucleus of the amygdala and is then transferred to the central nucleus of the
amygdala. The central nucleus of the amygdala is the central point for disseminati-
on of information and coordinates autonomic and behavioral responses, for exam-
ple the increase in respiratory rate (the parabrachial nucleus), the activation of the
sympathetic nervous system causing autonomic arousal (the lateral nucleus of the
hypothalamus), an increase in noradrenaline release contributing to increases in
blood pressure, heart rate and the behavioral fear response (the locus coeruleus),
the increase in release of adrenocorticoids (the paraventricular nucleus of the hypo-
thalamus), and additional behavioral responses such as defensive behaviors or
postural freezing (the periaqueductal gray matter in the brainstem) (Davis 1998;
Gorman et al 2000; LeDoux 1998; LeDoux et al 1988; LeDoux et al 1990; Windmann
1998). Under normal circumstances this system will be tuned by information pro-
cessed by different cortical areas, such as the inhibiting influence of the prefrontal
cortex and the anterior cingulate cortex on the amygdala shows. In PD there may be
a cognitive deficit in the cortical processing of sensory stimuli which leads to cogni-
tive misinterpretation. The amygdala receives and passes on false information lea-
ding to the development of physiological symptoms (Gorman et al 2000). More rea-
sonable, however, is the idea that there exists an oversensitive fear network in PD,
conditioned for the reaction to aversive stimuli (Den Boer et al 2003). 
Studying the neurobiology of anxiety and panic
Neurobiological research is most easily conducted in laboratory animals. Of course
it is difficult to generalize the conclusions of animal research to humans. Therefore
neurobiological research is also performed in humans, patients as well as healthy
control subjects. In humans this subject can be studied by methods such as phar-
macological challenges and neuroimaging combined with psychopharmacological
treatment strategies. Until recently the most widely used technique to explore the
neurobiology of PD was to pharmacologically induce panic attacks in PD patients 
12
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Legend: Fear network: cognitive and physiological symptoms of anxiety elicited by the amygdala (modified after
Windman, 1998). PAG = periaqueductal grey matter, PVN = paraventricular nucleus, HR = heart rate, CRH =
corticotropin-releasing hormone, ACTH = adrenocorticotropic hormone, BP = blood pressure.
and healthy control subjects, by combining the knowledge of receptor binding profi-
les and measuring behavioral changes induced by pharmacological challenge. At
this moment however, neuroimaging is the most widely used technique to further
explore the neurobiology of psychiatric diseases like PD. Neuroimaging research
conducted in panic and anxiety disorders has studied cerebral blood flow (CBF), glu-
cose metabolism and benzodiazepine receptor functioning in anxious patients
during anxiety and at rest, as well as during provoked anxiety in healthy control sub-
jects (Bisaga et al 1998; Malizia et al 1998; Nordahl et al 1990; Nordahl et al 1990;
Reiman et al 1989b; Schlegel et al 1994; Stewart et al 1988). Furthermore, using neu-
roimaging as a research tool the effect of different treatment strategies was also
evaluated (see the paragraph on neuroimaging and pharmacological agents). 
Pharmacological challenges
In PD several challenge agents have been used, such as sodium lactate (Liebowitz
et al 1985), CO2 (Pols et al 1994), yohimbine (Charney et al 1992), caffeine (Lee et al
1988), cholecystokinin (CCK) (Bradwejn and Koszycki 1994b; van Megen et al
1996b) and pentagastrin (van Megen et al 1994). It is suggested that a valid experi-
mental model for PD should satisfy seven criteria (Gorman et al 1987; Guttmacher
et al 1983): 
• The panic attack should combine physical symptoms of panic with a subjective
sense of terror and a desire to flee and should be distinguished from states of anti-
cipatory or generalized anxiety.
• The provoked attack should be judged as symptomatically very similar to the
patient’s regularly occurring spontaneous panic attacks (particularly with respect to
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• The induction of panic should be specific to patients with a history of spontaneous
attacks. This may be expressed in two ways. Either only patients with a history of
panic attacks occurring spontaneously have panic attacks under provocation (abso-
lute specificity) or such patients routinely panic at a lower dose than other subjects
(threshold specificity).
• The agent, in the panicogenic dose, should be safe for routine administration to
human subjects.
• The effect of the agent provoking panic should be consistent in a given patient. If a
desensitization effect to the panicogenic effects of an agent occurs, this should be
predictable and the same in all patients. 
• Drugs that block spontaneous panic attacks when given for prolonged periods,
such as TCAs, SSRIs, MAO inhibitors and alprazolam, should also block the acute
pharmacologically induced attack.
• Agents that do not block clinical panic acutely or chronically should not block the
pharmacologically induced panic. 
The different panicogenic agents satisfy the above criteria to a variable degree. 
Sodium lactate
Sodium lactate is one of the most thoroughly studied challenge agents in PD. Based
on the believe that anxiety patients were exercise intolerant and thus developed unu-
sually high blood levels of lactic acid, which were the cause of the panic attack, the
first experiment with lactate as a challenge agent was performed in 1967 (Pitts and
McClure 1967). The findings of this well-designed study were replicated in different
studies since. Lactate fulfills some of the criteria for an ideal panicogenic agent
(Coplan and Klein 1996; Guttmacher et al 1983), however, it is impossible to identify
the starting point of panic (den Boer et al 1989). Another disadvantage of the use of
sodium lactate as a panicogenic agent is the relatively protracted infusion interval,
which has been associated with physiological alterations such as volume-overload,
and metabolic changes that can introduce nonspecific psychological effects
(Margraf et al 1986). Sodium lactate challenge is still used to induce panic and
anxiety in PD patients and in control groups (Layton et al 2001; Massana et al 2001;
Olsson et al 2002; Otte et al 2002; Strohle et al 2003; Tarlo et al 2002; Yeragani et al
2002).
CO2 challenge
This challenge agent also has a long history in the research into the neurobiology of
PD. During the exploration of the role of hyperventilation in panic accidentally the
panicogenic effect of inhalation of a 5% CO2 mixture was detected (Gorman et al
1984). At the same time another group explored the effects of a mixture of 35% CO2,
that was supposed to be anxiolytic, and discovered that this mixture could induce
the symptoms of a panic attack (van den Hout and Griez 1984). These two procedu-
res have been studied and developed further to be used as panicogenic agents. The
14
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5% CO2 challenge consists of continuous breathing of a 5% CO2 mixture for 10-20
minutes, while 35% CO2 challenge comprises a single vital-capacity inhalation of a
35% CO2 mixture. The CO2 challenge also seems to meet most criteria set for an
ideal panicogenic agent (Coplan and Klein 1996). The CO2 challenge is still frequent-
ly used to induce panic in PD patients and control subjects to study different
aspects of panic and PD (Battaglia et al 2001; Bertani et al 2001; Bertani et al 2003;
Gorman et al 2001; Kent et al 2001; Perna et al 2002; Valenca et al 2002a; Valenca
et al 2002b; Valenca et al 2002c). Recently, the CO2 challenge in the research of PD
was reviewed by Rassovsky and Kushner (2003). 
CCK4 and pentagastrin
The gastrin-like peptide CCK was first found in 1928 in the digestive tract (Ivy and
Oldberg 1928). Vanderhaegen et al. discovered in 1975 a similar peptide in the mam-
malian brain. This appeared to be CCK8s, the most abundant CCK fragment in the
brain. Presently, CCK is recognized as the most widely distributed neuropeptide in
the brain. Two different CCK receptors are present in the brain, the CCKA (nowadays
called CCK1) receptor, and the CCKB (or CCK2) receptor. The CCK1 receptor was ori-
ginally found to be present most abundant in the alimentary tract, the CCK2 receptor
was originally found in the brain. The finding of CCK receptors in central nervous
system (CNS) structures, important in anxiety regulation (brainstem, hippocampus,
amygdala and hypothalamic structures), strengthened the idea of a role for CCK in
anxiety regulation and probably in PD. CCK receptors were furthermore found to be
colocalized with GABA receptors. There is evidence that the GABA-ergic system can
influence CCK neuronal functioning in different ways. Since the role of GABA in the
regulation of anxiety is well established (Haefely 1994), these findings strengthen
the idea of a possible role of CCK in the neurobiology of anxiety. Evidence has been
found in preclinical and clinical research for an anxiogenic role of CCK4, a rather
specific CCK2-agonist (Bradwejn et al 1990; de Montigny 1989), and for the use of
this peptide for research in PD. Pentagastrin, a widely used peptide for diagnostic
evaluation of gastric acid function, is also a specific CCK2-agonist. It contains CCK4
as its carboxyl terminal sequence. Because of the better availability, pentagastrin is
often used as a challenge agent instead of CCK4 (Abelson et al 1994; Abelson and
Nesse 1994; Brawman et al 1997; de Leeuw et al 1996).
CCK4 as a challenge agent offers several advantages over other challenge agents
such as sodium lactate, CO2, yohimbine and caffeine. Unlike these agents, CCK is a
neurotransmitter present in the human central nervous system, for which neuronal
pathways and receptors have been identified. CCK is synthesized and stored in
nerve terminals and cell bodies, it is released by depolarization, it has specific bin-
ding sites, it can affect the firing rate of other CNS neurons and its effects can be
interfered with by analogues (Bradwejn et al 1990). CCK4 and pentagastrin provoke
panic attacks in a dose-dependent matter (Bradwejn et al 1991b). PD patients have
an increased sensitivity for the anxiogenic properties of CCK4 and pentagastrin, as
compared to healthy volunteers (Bradwejn et al 1992a; van Megen et al 1994). The
phenomenology of the symptoms of the CCK4 or pentagastrin induced panic attack
15
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has been reported to be very similar to naturally occurring panic attacks (Abelson et
al 1994; Abelson and Nesse 1994; Bradwejn et al 1990; Bradwejn et al 1992b;
Bradwejn 1993; Brawman et al 1997; Koszycki et al 1991; McCann et al 1997; van
Megen et al 1994; van Megen et al 1996b). Endogenous CCK, and therefore the CCK
receptor, is especially abundant in brain regions involved in the fear network in the
brain, including the brainstem, hippocampus, amygdala and cerebral cortex
(Karkanias et al 1989). CCK is injected intravenously in small quantities as a bolus
injection, whereas the relatively protracted infusion interval of particularly sodium
lactate infusion has been associated with physiological alterations such as volume-
overload, and metabolic changes that can introduce nonspecific psychological
effects (Margraf et al 1986). Another technical advantage is that the potency to indu-
ce symptoms of panic with CCK4 is rapid and predictable, permitting measurement
of central and peripheral nervous system activity during the interval associated with
peak panic symptoms. The panic attack following CCK4 administration appears wit-
hin seconds after its injection, and the effect disappears again within a few minutes. 
CCK4 and pentagastrin satisfy almost all criteria for a valid panicogenic agent: it is
safe for humans, induces emotional and somatic symptoms of a panic attack, repro-
duces symptoms of spontaneous panic attacks, displays specificity for panic disor-
der, shows dose-dependent and reproducible effects, is antagonized by antipanic
agents and is not antagonized by non-antipanic agents (Bradwejn 1993; van Megen
et al 1996a). The anxiogenic-like action of CCK-agonists in rodents and monkeys is
antagonized by CCK2 antagonists such as L-365,260, CI-988 and LY262691 (Chen et
al 1992; Harro et al 1990; Harro et al 1993). In patients with PD CCK4-induced panic
attacks are antagonized by L-365,260 (Bradwejn et al 1994b). It was not possible to
find any anxiolytic action of CCK-antagonists in patients with PD, probably because
of the low bioavailability of oral preparations and the toxicity of high oral doses
(Kramer et al 1995). Bradwejn et al. (1994a) tested the effect of chronic treatment of
imipramine on the outcome of the CCK4-challenge. After treatment there were mar-
ked reductions in the number of symptoms and the sum intensity of symptoms
induced by CCK4, and symptom duration was significantly shorter (Bradwejn and
Koszycki 1994a). Van Megen et al (1997a) studied the effect of the SSRI fluvoxamine
on CCK4-induced panic attacks. Twenty-six panic disorder (PD) patients received,
before and after a double blind 8-week treatment period with fluvoxamine (n = 17) or
placebo (n = 9), a single blind bolus injection with 50 micrograms CCK4. Treatment
with fluvoxamine (150 mg daily) significantly decreased the sensitivity of PD patients
for CCK4 while placebo was without effect. Of the patients who responded to treat-
ment, 83% no longer experienced a panic attack when rechallenged with CCK4, whe-
reas in the non-responders group this was only 28%. 
The mechanism of action through which CCK4 and pentagastrin induce panic in PD
patients is yet unclear. Rehfeld (2000) considers CCK4 and pentagastrin as exoge-
nous test substances that happen to pass the blood-brain barrier fairly easily.
However, there are reports that the substances cannot pass the blood brain barrier,
and then a direct central effect is unlikely unless CCK binds to the CCK-receptors
located in the circumventricular organs that lack a blood-brain barrier, for example
the area postrema. Evidence for this idea was found in animal studies (Karkanias et
al 1989). Recently, Sanchez-Fernandez et al (2003) showed that CCK, via the CCK2
16
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receptor located presynaptically on cerebral arteries, mediates the release of nitric
oxide, which induces vasodilatation. The findings may provide a neural mechanism
by which CCK may increase cerebral blood flow and therefore exert effects in the
central nervous system (Sanchez-Fernandez et al 2003). 
Another explanation for the panic inducing effect of CCK may be cognitive mediati-
on. Clark (1993) suggests cognitive mediation of the peripheral manifestations of
panic attacks to be the underlying working mechanism of all biological challenge
tests. Bradwejn and colleagues (1991b) describe that some of their subjects clearly
indicated that the subjective experience of anxiety induced by CCK4 preceded the
physical symptoms. Therefore, they suggest that a more direct central effect of CCK4
is possibly the anxiety inducing mechanism. Pentagastrin has been used recently to
induce panic attacks in PD patients during sleep. Even in the absence of elevated
baseline arousal and without the effects of cognition is was possible to induce panic
attacks in PD patients (Geraci et al 2002), suggesting that environmental stressors
and anticipatory anxiety are not necessary for the expression of pentagastrin indu-
ced panic. 
Lately a lot of research is focused on the relationship between the CCK receptor
genes and PD, but the results are controversial (Ebihara et al 2003; Hamilton et al
2001; Hattori et al 2001a; Hattori et al 2001b; Ise et al 2003; Yamada et al 2001).
Furthermore other studies have been performed with CCK4 or pentagastrin as panic
inducing agents, to shed more light on PD and the mechanisms of panic and anxie-
ty (Flint et al 2002; Katzman et al 2002; Kellner et al 2002; Knott et al 2002;
Kronenberg et al 2001; Le Melledo et al 2001a; Le Melledo et al 2001b; McManus et
al 2001; Radu et al 2002; Radu et al 2003; Strohle et al 2001; Strohle et al 2003;
Wiedemann et al 2001; Zwanzger et al 2001). 
In conclusion, CCK4 and pentagastrin both seem to fulfill most criteria for an ideal
panicogenic agent, as described above (see for extensive reviews about CCK and
pentagastrin also: (Bradwejn and Koszycki 2001; Rehfeld 2000)). 
Other provocative agents
Abnormalities in the noradrenergic (NA) system of PD patients have been extensive-
ly studied, partially with the help of NA probes. Ingestion of yohimbine, an a2
receptor antagonist, produced panic attacks in PD patients, but the effect of yohim-
bine is not very consistent (Albus et al 1992). The agent fails to fulfill most criteria
for an ideal panicogenic agent (Coplan and Klein 1996). Partly based on the finding
of the efficacy of SSRIs, the serotonergic (5-HT) system is suggested to play an
important role in PD. Therefore challenges with 5-HT agonists were performed.
Challenges using mCPP and fenfluramine, direct and indirect 5-HT agonists respec-
tively, showed increased anxiety but no panic attacks in PD patients (Coplan and
Klein 1996). High potency benzodiazepines are effective in blocking panic attacks,
thus flumazenil, a benzodiazepine antagonist, was used as a pharmacological probe
to induce panic with remarkable success in patients with PD (Nutt et al 1990).
These positive results could not be reproduced nine years later (Strohle et al 1999),
although this may have been an effect of differences in study population. Caffeine
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also possesses anxiogenic properties, but the results of provocation studies suggest
poor modeling of spontaneous panic and similarity to the effects of yohimbine and
mCPP (Coplan and Klein 1996). A complete review of these pharmacological chal-
lenge studies is beyond the scope of this thesis. 
Neuroimaging in general
Brain imaging fills the gap between physiological studies of brain function (animal
experimental studies, psychopharmacological studies and postmortem studies) and
psychological studies of brain function (cognitive tests). In the last two decades a
large number of brain imaging studies have been conducted investigating both
structural and functional aspects of the brain. Structural brain imaging methods
comprise e.g. computed tomography (CT) and magnetic resonance imaging (MRI).
These techniques provide insight in the structural (morphometric or volumetric)
aspects of the brain. MRI offers better resolution of soft tissues, such as the brain’s
white matter, than CT. 
Functional imaging is possible by nuclear medicine techniques such as positron
emission tomography (PET) or single photon emission computed tomography
(SPECT), but also with functional MRI (fMRI). Nuclear medicine techniques involve
the recording of signals emitted by a radiolabeled compound that has been admini-
stered to the subject. This radiolabeled compound can be administered to study
brain activity, by generating maps of glucose metabolism (direct imaging of the
metabolic derivations of mental processes) or cerebral blood flow (more indirect
imaging of mental processes by depicting the cerebral blood flow, which is coupled
to the oxygen consumption of the brain). The resulting functional imaging maps are
thought to represent changes in energy requirements at synaptic sites, because
synapses are the neuronal elements that consume the most energy. It is essential to
realize that these maps represent the summation of synaptic energy over hundreds
of thousands of neurons and that this can therefore lead to seemingly paradoxical
effects (Nutt et al 1999). Another way of using nuclear medicine techniques in brain
mapping is to measure neurochemical parameters, such as receptor distribution or
transporter density. In these situations ligands are labeled with a radiation-emitting
nucleus to produce maps of their brain distribution after injection. A review about
the blood-brain barrier, brain metabolism and cerebral blood flow by Paulson (2002)
addresses these subjects nicely.
The technique of fMRI is based on the different magnetic charge of hemoglobin
when it is fully oxygenated or partly deoxygenated. The changes in deoxyhemoglobin
are associated with neuronal activation through oxygen consumption. This techni-
que is free of the use of ionizing radiation and it also provides images with a better
spatial and temporal resolution than the nuclear medicine techniques. 
Neuroimaging in anxiety and panic disorder
Structural brain imaging in anxiety has been performed with e.g. MRI to study mor-
phological and volumetric differences in brain structures supposed to play a role in
anxiety, between patients with anxiety disorders and healthy subjects. Examples of 
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Ontiveros et al. (1989) 20/30 Correlation between temporal lobe 
abnormality and severity of PD 
Fontaine et al. (1990) 20/30 Increased incidence of abnormalities, 
especially in the temporal lobe in PD 
patients compared to controls
Vythilingam et al. (2000) 14/13 Temporal lobe volume of PD patients < 
controls; trend for whole brain volume 
PD patients < controls; hippocampus no
sign. differences
Massana et al. (2003) 18/18 Gray matter density L PHG patients < 
controls
133Xenon SPECT
Stewart et al. (1988) 5/10 Lactate infusion: PD lactate sensitive 
gGBF  compared to  lactate 
insensitive pts and controls
Mathew and Wilson (1990) 9/9 In review: No overall sign differences, 
only sign R/L differences
Mathew and Wilson (1990) 9/9 + 8 GAD No anxiety, but significant  in global 
CBF after caffeine in all subjects, not 
related to CO2 or mood changes 
99mTc HMPAO SPECT
Cristofaro et al. (1993) 5/7 L/R asymmetry inferior frontal; L 
occipital ; hippocampal 
Woods et al. (1988) 6/6 Yohimbine:  frontal and thalamic 
blood flow in PD patients experiencing 
anxiety 
123I Iomazenil SPECT 
Schlegel et al. (1994) 10/10 Compared to epilepsy pts: frontal ; 
occipital ; temporal 
Kaschka et al. (1995) 9/9 PD + MD compared to dysthymic 
patients:  inferior temporal cortex ; 
inferior frontal 
Kuikka et al. (1995) 17/17 L/R asymmetry medial and inferior 
frontal cortex
Malizia et al. (1998) 8/7 Global , largest decrease: R orbito-
frontal and R insula
Bremner et al (2000) 16/13 L hippocampus ; precuneus 
PD lactatepositive vs lactatenegative: 
prefrontal 
18FDG PET
Nordahl et al. (1990) 30/12 L/R asymmetry  PHG; L inferior 
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Bisaga et al. (1998) 6/6 L hippocampus ; L PHG ; R superior
temporal ;  R inferior parietal 
Nordahl et al. (1998) 43/21 L/R asymmetries in hippocampal and 
posterior inferior prefrontal rCMRglc 
ratios in PD patients (acute or remitted) 
compared to controls and posterior 




Reiman et al. (1984) 6/10 L/R asymmetry PHG
Reiman et al. (1986) 25/16 L/R asymmetry PHG; Global 
Reiman et al. (1989) 18/24 PD lactate positive: temporal ; insular 
; claustrum ; superior colliculis ; 
L anterior  vermis cerebelli 
Meyer et al. (2000) 18/9 Baseline:  left superior temporal- 
posterior parietal cortex
d-Fenfluramine:  in patients > controls
in left superior temporal-posterior parie
tal cortex 
Fischer et al. (1998) Case Unexpected panic attack:  in right 
orbitofrontal, prelimbic, anterior 
cingulate and anterior temporal cortices 
Ponto et al. (2002) 12/14 CO2: PD patients:  gCBF and stable 
pCO2-adjusted gCBF; controls: stable 
gCBF and  pCO2-adjusted gCBF
Boshuisen et al. (submitted) 21/16 Baseline: pts  in precentral gyrus, 
inferior frontal gyrus and anterior insula,
and  in the parahippocampal gyrus, 
superior temporal lobe, anterior 
cingulate gyrus and midbrain vs controls
Pentagastrin: both PD pts and 
controls: rCBF in the parahippocampal 
gyrus, basal ganglia and prefrontal 
cortex, controls  in hypothalamus and 
amygdala;  rCBF in the precentral 
gyrus, insula, thalamus and prefrontal 
cortex.
fMRI
Bystritsky et al (2001) 6/6 PD patients:  in inf. frontal cortex, 
hippocampus, ant. and post. cingulate 
and orbitofrontal cortex 
MRS
Massana et al. (2002) 11/11 creatine and phosphocreatine  in right 
medial temporal lobe PD pts compared 
to controls; no sign diff in medial 
prefrontal cortex
Legend: controls/PD means number of control subjects and patients; Findings are reported as PD patients compa-
red to healthy controls, unless stated otherwise.  
L = left; R = right; PHG = parahippocampal gyrus 
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functional brain imaging in anxiety research are the investigation of baseline brain
metabolism in patients with anxiety disorders, or studying the effect of anxiety pro-
vocation on the cerebral blood flow in healthy volunteers and patients with anxiety
disorders. The neuroimaging of treatment strategies in anxiety disorders is covered
in this introduction in the paragraph concerning treatment strategies. 
Neuroimaging techniques have not been used as extensively in panic disorder as in
other anxiety disorders such as obsessive compulsive disorder (OCD) and posttrau-
matic stress disorder (PTSD). An overview of the neuroimaging studies in PD is
given in table 2.
Structural neuroimaging
Structural brain imaging methods revealed that PD patients do not appear to be
characterised by anatomical abnormalities that could be detected with computerised
tomography (CT) (De Cristofaro et al 1993; Lepola et al 1990; Uhde and Kellner
1987). Two studies, using qualitative MRI, reported an increased rate of focal atro-
phy or abnormal signal intensities in the temporal lobes, as compared to healthy
controls (Fontaine et al 1990; Ontiveros et al 1989). More recently, two quantitative
MRI studies were carried out reporting temporal lobe differences in PD patients
compared to healthy control subjects. In the study of Vythilingam et al (2000) the
mean volume of the temporal lobes in PD patients was smaller compared to healthy
subjects, but no differences were found in the hippocampus. The authors speculate
on the relation between panic disorder symptoms and decreased temporal lobe
volumes. The study of Massana et al (2003) showed that the gray matter density of
the parahippocampal gyrus of PD patients was significantly lower compared with
healthy subjects. These results provide further support for the role of the parahippo-
campal area in the pathophysiology of PD. 
Functional neuroimaging 
Reiman and co-workers were the first to report on functional neuroimaging in PD
patients (1984; 1986). They examined PD patients with a positive response on lacta-
te challenge during H215O PET scan, and compared them with patients with a negati-
ve response on lactate challenge and healthy control subjects. Especially in the hip-
pocampal and the parahippocampal region differences in rCBF were seen.
Furthermore, they reported a left to right asymmetry in the rCBF in the right
(para)hippocampal region of lactate-sensitive patients, as compared to lactate-
insensitive patients and controls. A study of Drevets et al. (1992) revealed that some
of the temporopolar cortex CBF activation peaks found in the studies of Reiman et
al (1984; 1986) may have been of vascular and/or muscular origin (teethclenching).
Other functional neuroimaging studies performed with PD patients are single pho-
ton emission computer tomography (SPECT) studies. In these studies similar
results were reported, although these studies also were performed during or after
lactate challenge (De Cristofaro et al 1993; Stewart et al 1988). The only study with
PD patients in resting non-panic state without any previous manipulation such as
lactate challenge, was the study of Nordahl et al (1990). This group studied PD
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patients during an auditory discrimination task with [18F]-2-fluoro-2-deoxyglucose
(FDG) scan. They found metabolic differences between patients and controls in the
hippocampal region, the anterior cingulate gyrus, the inferior parietal lobule and the
orbital frontal cortex. Bisaga et al. (1998), using FDG PET, also reported on the
involvement of the hippocampal and parahippocampal areas in PD. They also repor-
ted a decrease in metabolic rate in the right inferior parietal and the right superior
temporal areas. Stewart et al. (1988), using 133Xe-SPECT, and Reiman et al. (1989b),
using H215O PET, reported on changes in rCBF during sodium lactate infusion, but
with conflicting results. Stewart and co-workers (1988) noted an increase in rCBF in
healthy volunteers and lactate-insensitive PD patients. Lactate-sensitive PD patients
either showed a minimal increase, or a decrease in rCBF. Reiman et al. (1989b)
reported an increased rCBF in panicking PD patients in several brain areas such as
the temporal poles, the insular cortex, the claustrum, the superior colliculus and the
left anterior cerebellar vermis. This increase in rCBF was not seen in healthy volun-
teers or lactate-insensitive PD patients.
Several studies have investigated the benzodiazepine receptor function in PD with
SPECT (Bremner et al 2000; Kaschka et al 1995; Kuikka et al 1995; Schlegel et al
1994) or PET (Malizia et al 1998). All the SPECT studies used 123I-iomazenil as a
ligand. In the PET study 11C-flumazenil was used. Schlegel and co-workers (1994) 
found lower 123I-iomazenil uptake rates in the frontal, occipital and temporal cortex,
as compared to epileptic patients. Kaschka et al. (1995) compared PD patients with
a comorbid depression with a group of dysthymic patients. They reported a decrea-
sed regional activity in the lateral and the medial inferior temporal lobes and in the
interior frontal lobes. Apart from the decrease in the medial inferior temporal lobe,
which was only evident on left side of the brain, all effects were bilateral.
Kuikka and co-workers (1995) compared PD patients to healthy controls and repor-
ted an increased right-to-left ratio of benzodiazepine uptake in a majority of the
patients. Magnetic resonance imaging (MRI) indicated that the affected region was
located in the right middle and inferior frontal gyri. Bremner and co-workers (2000)
recently reported on decreased benzodiazepine receptor binding in the left hippo-
campus. A significant decrease was also evident in the precuneus. They also had the
opportunity to compare the receptor binding of PD patients who had a panic attack
at the time of the scan with PD patients who did not. The panickers showed a dec-
reased binding in the prefrontal cortex. In the only receptor binding PET study to
date, Malizia and co-workers (1998) reported a global decrease in benzodiazepine
receptor binding, with the greatest magnitude in the right orbitofrontal cortex and
insula. All the imaging studies which investigated benzodiazepine receptor function
in PD patients consistently report on a reduced uptake/ binding in the frontal cor-
tex. Findings in other brain regions are less consistent. 
Differences in study design might explain inconsistent findings, but the fact remains
that most studies imply the hippocampal region in PD. Other regions, like the ante-
rior cingulate or the inferior frontal/orbital frontal cortex, are also often, but less
consistently, reported to be implicated in PD. The subject of the caveats that apply
to the interpretation of increases and decreases in blood flow in functional neuroi-
maging studies is addressed in the article of Malizia (1999). He reviews several fac-
tors that influence the direction of change in the final calculation of brain activity,
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such as the relativity of an increase in a patient group being an actual decrease in
the control group or vice versa, or the effects of the timing of the paradigm or scan-
ning. Furthermore, in some brain areas there seems to be no proportional relations-
hip between the intensity of the stimulus and effort or activation. This leads some
investigators to believe that in studies of affect or mood the direction of the change
could be of less heuristic value than the location of the changes. 
Neuroimaging and anxiety provocation
The number of studies combining neuroimaging techniques with anxiety provocati-
on is limited, although recently the number has strongly increased. 
The first report on functional neuroimaging combined with symptom provocation in
PD patients was published in 1984 (Reiman et al 1984). In this study PD patients
and control subjects were examined with H215O PET after lactate challenge.
Differences in rCBF were observed in the parahippocampal gyrus in the resting non-
panic state between PD patients who did (lactate-positive) and who did not (lactate-
negative) experience a panic attack after lactate challenge, and normal control sub-
jects. Furthermore, a neuroimaging study performed during a lactate-induced panic
attack showed increases in the rCBF of the temporal pole, the insular cortex, the
claustrum and the cerebellar vermis (Reiman et al 1989b). Single-photon-emission
computerized tomography (SPECT) studies, performed during or after lactate chal-
lenge, showed similar results (De Cristofaro et al 1993; Stewart et al 1988). PET stu-
dies during anxiety provocation in healthy volunteers, with CCK4 as provocative
agent, showed a robust increase in rCBF in the anterior cingulate gyrus, the claus-
trum-insular-amygdala region and the cerebellar vermis, and one of the studies
showed a decrease in the medial frontal areas during anxiety (1995; 1999). In several
studies rCBF changes during or after panic in PD patients were shown. After yohim-
bine administration a decrease was observed in frontal cortical flow and a probable
change in thalamic flow (Woods et al 1988), while after lactate infusion a decrease
was observed of whole hemispheric blood flow (Stewart et al 1988). Also during lac-
tate-induced panic an increase was seen in bilateral temporal flow, bilateral
insula/basal ganglia, superior colliculus and cerebellar vermis flow (Reiman et al
1989b). Later a large part of these data were considered to be an artifact (Drevets et
al 1992). Finally, a case-study was published of a PD patient experiencing a sponta-
neous panic attack while in the PET scanner. Regional CBF decreases were observed
in the right orbitofrontal, prelimbic, anterior cingulate and anterior temporal cortices
(Fischer et al 1998). Challenges in other anxiety disorders showed rCBF differences
in almost the same anxiety-related brain regions. In posttraumatic stress disorder
(PTSD) patients cerebral blood flow changes were studied after yohimbine admini-
stration, and an overall decrease in CBF was observed, focussing on the temporal
cortex (Bremner et al 1997). Another study in relatively recent traumatized PTSD
patients showed increases in right sensorimotor areas and sensory cortex, and in
the cerebellar vermis, the amygdala and the PAG. Decreases were seen in the right
retrosplenial cortex (Pissiota et al 2002). In this study the PTSD patients experien-
ced full blown panic attacks during the provocation, therefore these data may not
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only show effects specific for PTSD but also results that are interesting for the study
of panic disorder. Pooled data of different PET scan studies of PTSD, obsessive
compulsive disorder and social phobia patients after different behavioral challenges
showed increases in the right inferior frontal and orbitofrontal cortex, the insula, the
lenticular nucleus and the brainstem (Rauch et al 1997). A symptom provocation
study in subjects with social phobia showed increased subcortical blood flow, as
opposed to increased cortical blood flow in nonphobic controls (Tillfors et al 2001).
Data of healthy control subjects during the challenge often showed changes in
anxiety related areas as well, even if there was no anxiety experienced by the sub-
jects (Bremner et al 1997; Reiman et al 1989b; Stewart et al 1988; Woods et al 1988).
In healthy volunteers a study was recently performed investigating the neural corre-
lates of anxiety associated with obsessive-compulsive symptomlike provocation
(Mataix-Cols et al 2003). The brain systems implicated in the mediation of anxiety in
response to symptom-related material in normal subjects are similar to those identi-
fied in OCD patients during symptom provocation. 
Aim of this thesis
The aim of the research founding this thesis was to characterize the neurobiological
substrate of panic disorder (PD), and to characterize the effects of treatment on the
recovery of the affected neural circuitry. We tried to realize this aim by performing
the studies described in this thesis, using neuroimaging (H215O PET scanning) and
pharmacological challenge (pentagastrin) in PD patients and healthy control sub-
jects.
Outline of this thesis
Chapter 1 “introduction”
Chapter 2 “rCBF differences between panic disorder patients and controls during anti-
cipatory anxiety and rest”
This chapter deals with the subject of anticipatory anxiety in PD patients and healthy
control subjects. Anticipatory anxiety was studied with H215O PET scan, before a pen-
tagastrin challenge. Furthermore, the data of the PD patients in relative rest are
compared with the data of healthy controls in rest, after the challenge. 
Chapter 3 “pentagastrin induced panic does not increase cerebral blood flow in the
amygdala of panic disorder patients: a PET study”
In this chapter the effect of pentagastrin on regional cerebral blood flow (rCBF) is
described in PD patients and healthy control subjects. The behavioral effects and
the effects in rCBF are discussed. The rCBF results show that different anxiety rela-
ted areas are (de)activated during pentagastrin-induced panic in PD patients, as
well as during pentagastrin-induced tension in the healthy control subjects. All acti-
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vated and deactivated regions are part of the fear network in the brain as described
by LeDoux in 1998. 
Chapter 4 “Partial normalization of rCBF patterns after successful pharmacological tre-
atment of PD patients; an H215O PET scan study”
This chapter deals with the effects of successful SSRI treatment in PD. We evaluated
the effect of 12-week therapy with sertraline, an SSRI, on three different levels: a cli-
nical level (the effect of treatment on the anxiety level and the number of spontane-
ous panic attacks),  a pharmacological level (the effect of treatment on the penta-
gastrin challenge) and with neuroimaging (the effect in rCBF, before, during and
after a pentagastrin challenge). We compared the rCBF data also with the data of
the healthy control subjects, collected in the study described in the previous chapter. 
Chapter 5 “Pentagastrin induced panic and spontaneous panic attacks are mediated by
the same fear network”
The fifth chapter deals with the question whether pentagastrin, the pharmacological
challenge agent we used to induce panic attacks, provided a valid model for the in
vivo study of the neurobiology of panic and anxiety. This question has been addres-
sed several times before. In our study, five patients experienced a spontaneous
panic attack while being scanned. The clinical and the rCBF data of these five spon-
taneous panic attacks were compared with the data of the pentagastrin-induced
panic attacks. No significant differences could be observed between the spontane-
ous panic attacks and the pentagastrin-induced panic attacks. Thus, we have
demonstrated that pentagastrin leads to a similar pattern of brain activation as in
spontaneous panic attacks. 
Chapter 6 “Summary and concluding remarks”
In this part of the thesis an overview is given of the different issues discussed in this
thesis in relation to anxiety and panic disorder. More specifically, this chapter will
focus on the fact that in this thesis we demonstrate that the neurobiology of panic is
shown to be almost the same as the neurobiology of other forms of anxiety, howe-
ver, thus far nosologically PD was seen as a different clinical entity. At the end of
this chapter, I will conclude with directions and suggestions for further research. 
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rCBF differences between panic disorder patients 
and controls during anticipatory anxiety and rest
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Abstract 
Background: Our goal was to identify brain structures involved in anticipatory anxie-
ty in panic disorder (PD) patients compared to controls. 
Methods: Seventeen PD patients and 21 healthy control subjects were studied with
H215O PET scan, before and after a pentagastrin challenge. 
Results: During anticipatory anxiety we found hypoactivity in the precentral gyrus,
the inferior frontal gyrus, the right amygdala and the anterior insula in PD patients
compared to controls. Hyperactivity in patients compared to controls was observed
in the parahippocampal gyrus, the superior temporal lobe, the hypothalamus, the
anterior cingulate gyrus and the midbrain. After the challenge, the patients showed
decreases compared to the control subjects in the precentral gyrus, the inferior fron-
tal gyrus and the anterior insula. Regions of increased activity in the patients com-
pared to the controls were the parahippocampal gyrus, the superior temporal lobe,
the anterior cingulate gyrus and the midbrain. 
Conclusion: The pattern of rCBF activations and deactivations we observed both
before and after the pentagastrin challenge was the same, although different in
intensity. During anticipatory anxiety more voxels were (de)activated than during
rest after the challenge.  
Introduction
Panic disorder (PD) is a common and invalidating psychiatric disease. Several biolo-
gical theories of PD have been proposed, including dysfunction of serotonergic and
noradrenergic neurotransmitter systems, but till now the neurobiology of PD is
unclear. Several groups have contributed to the discussion by providing data from
animal studies, studies in humans using neurobiological challenges, post-mortem
brain material, electroencephalogram (EEG), cerebrospinal fluid (CSF) and neuroi-
maging. At this moment different neuroimaging techniques are being used to furt-
her elucidate the role of different structures/neural networks in the brain involved in
anxiety and panic.
Thus far, different neuroimaging techniques have been used to study PD. Structural
neuroimaging (MRI) revealed abnormalities in brain structure in PD patients that
correlated with the severity of PD, especially the temporal lobe abnormalities
(Fontaine et al 1990; Ontiveros et al 1989).
Reiman et al (1984; 1986) were the first to report on functional neuroimaging in PD
patients. They examined PD patients and controls with H215O PET scan after lactate
challenge. They observed differences in the resting non-panic state between PD
patients reacting with a panic attack on lactate challenge (lactate-positive), PD
patients not experiencing a panic attack on lactate challenge (lactate-negative) and
normal controls. In the right (more than in the left) (para)hippocampal region inc-
reases in rCBF were seen in lactate-positive patients compared to lactate-negative
patients and controls. Nordahl et al (1990) have studied PD patients at rest using
an auditory discrimination task with [18F]-2-fluoro-2-deoxyglucose (FDG) PET scan.
They observed increases in glucose metabolic rate in patients compared to controls
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in the right hippocampal region and the orbitofrontal cortex. Decreases in patients
compared to controls were seen in the anterior cingulate gyrus and the left inferior
parietal lobule. Bisaga et al (1998) found similar results with FDG PET scan in 6
women with PD. They observed hyperactivity of the left hippocampal and parahippo-
campal region and hypoactivity of the right superior temporal lobe and the right
inferior parietal lobe in patients compared to controls. Single-photon-emission com-
puterized tomography (SPECT) studies showed similar results, although these stu-
dies were performed during or after lactate challenge (De Cristofaro et al 1993);
(Stewart et al 1988). 
Since benzodiazepines possess anxiolytic effects, several groups have investigated
whether changes in benzodiazepine receptor function were present in patients suffe-
ring from PD. One of these studies (Abadie et al 1999) observed no difference in
binding potential, albeit this group not only included PD patients, but social phobia
and generalized anxiety disorder patients as well. Others observed a decreased bin-
ding of the labeled compound to the benzodiazepine receptor in PD patients com-
pared to controls. Overall global decreases were found in the studies of Malizia et al
(1998) and Bremner et al (2000). Decreases in specific regions were found in the
temporal lobe, in the inferior frontal region, the occipital region and the insula
(Bremner et al 2000; Kaschka et al 1995; Kuikka et al 1995; Malizia et al 1998;
Schlegel et al 1994). In a recent magnetic resonance spectroscopy study, Goddard et
al (2001) observed reductions in total occipital cortex GABA levels. It is yet unclear
if this abnormality is limited to certain cortical regions or present throughout the
cortex, as this group only studied the GABA levels in a single occipital region of inte-
rest. 
The results of the above mentioned neuroimaging studies are still inconclusive al-
though hyperactivity of the parahippocampal gyrus seems to be one of the most
consistent findings in PD patients. Based on data from clinical and preclinical stu-
dies we know that brain structures that are likely to be involved in anxiety are the
prefrontal cortex, the anterior cingulate gyrus, the amygdala, the hippocampus, mid-
brain structures like the periaqueductal gray (PAG) and the locus coeruleus (LC),
the hypothalamus and the (mainly dorsal) thalamus (for review see: LeDoux, 1998
and Davis, 1998). 
We hypothesized that PD patients show increased anticipatory anxiety in the situati-
on immediately before a pentagastrin challenge, and studied this in comparison
with healthy control subjects. Furthermore, we studied the differences in brain acti-
vity between PD patients and healthy controls after the pentagastrin challenge at
rest. Pentagastrin is a five-amino-acid long peptide very much alike to cholecystoki-
nin-4 (CCK4). CCK4 and pentagastrin have a high affinity for the so-called CCKB
receptors, the CCK receptors in the brain. These receptors may play a role in anxiety:
neuroanatomical studies have revealed that CCKB receptors are most abundant in
the hippocampus (Beinfelt and Palkovits 1981; Dodd and Kelly 1981), there is an evi-
dent close relationship between CCK- and GABA-containing neurons in this brain
region and CCKB receptors have an excitatory influence on hippocampal pyramidal
neurons, which can be completely abolished by benzodiazepines (Bradwejn and de
Montigny 1984; Sinton 1988; Harro et al 1990). Both agents have been shown to
reliably induce panic attacks and anxiety, especially in PD patients (de Montigny
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1989; Abelson and Nesse 1990; van Megen et al 1994). PD patients typically expe-
rience anticipatory anxiety before pentagastrin administration, expecting that they
may have a panic attack during injection. In this study we used pentagastrin challen-
ge to distinguish two states. The first state, before the pentagastrin was given, was
hypothesized to be an anticipatory anxiety state, especially in the patient group.
rCBF images were acquired during this state. Pentagastrin was then given, and a
second state, after the effects of pentagastrin had subsided, was defined as a resting
state. Resting state rCBF images were also acquired. 
We expected to see rCBF differences in brain regions that are known to play a role in
the fear network in the brain. 
Methods and Materials
Subjects
Seventeen patients with PD (5 men/12 women) and 21 healthy controls (9 men/12
women) participated in the study (for demographic data see table 1). All patients
met the DSM-IV criteria of PD with or without agoraphobia, as diagnosed by a psy-
chiatrist with a structured interview based on the DSM-IV criteria (American
Psychiatric Association 1994). The subjects were physically healthy, as determined
by history, physical and neurological examination, and had no comorbid psychiatric
or neurological diseases (determined by a psychiatrist on the basis of a structured
interview based on the DSM-IV diagnoses). All patients were free from psychoactive
medication for at least three weeks prior to the PET scan (in the case of fluoxetine
for at least 6 weeks). The patients were allowed to use oxazepam in the week before
the PET scan, but not during the last 24 hours before the scan. The levels of anxiety
and depression in the patients were obtained by the Hamilton rating scales for
anxiety (Hamilton 1959) and depression (Hamilton 1967). The healthy control sub-
jects had never experienced anything like a panic attack in their lives, and had no
relatives with panic disorder or any other psychiatric disorder. All subjects were 18
years or older. None of the subjects was taking medication (other than oral contra-
ceptives) or had a history of substance abuse. Other exclusion criteria were: DSM-IV
mental disorder (other than PD in the PD patients), Hamilton depression rating
scale score above 15, serious physical illnesses, radiological workers, participation in
a trial with radioactive radiation exposure in the past year and pregnancy.
One of the male PD patients was excluded from the analysis because of too much
movement during the scans. One male and two female PD patients experienced a
spontaneous panic attack during the first scan; these three scans were excluded
from the analysis. We choose to define a panic attack in this study with stricter crite-
ria than stated in the DSM-IV: moderate to severe anxiety had to be present during
the panic attack, in addition to the criterion of at least 4 out of the 13 symptoms, as
described in the DSM-IV. Using this criterion sixteen of the seventeen PD patients
had a panic attack during the pentagastrin challenge, while only two of the control
subjects experienced a panic attack. None of the controls subjects experienced a
panic attack either during rest after the challenge or in the anticipatory anxiety con-
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dition before the challenge procedure. 
All subjects gave oral and written informed consent after complete explanation of
the nature and possible consequences of the study (in accordance with the provisi-
ons of the pertinent excerpt from the Declaration of Helsinki, South Africa 1996).
The study was approved by the medical ethics committee of the Groningen
University Hospital. 
Procedure
Subjects were positioned in the scanner using a molded head rest with a strap over
the head to minimize head movement. Two marks were placed on the forehead and
nose of the subject to check for movement between the scans. The subjects were
instructed to lie quietly during the scan with their eyes open in a dimly lit room, wit-
hout conversation or noise, other than the noise from the scanner. They were not
allowed to speak, and no other person was present in the scanning-room during the
scan. They knew, however that a psychiatrist was watching via an infrared camera
and would be back in the room as soon as the 120-minute scanning time was over.
First a 20-minute transmission scan, used for attenuation correction, was made.
After this scan all subjects were scanned about 20 minutes before and 20 minutes
after a pentagastrin challenge (this was when the effects of the pentagastrin had
subsided). The pentagastrin was injected intravenously as a bolus injection of 40
µg, injected within 10 seconds. Immediately after each scan blood pressure (BP)
and heart rate (HR) were measured, and the subjects were asked about panic-rela-
ted symptoms experienced during the scan, with a semi-structured interview based
on the DSM-IV criteria for panic attacks. 
Scanning was done between 11.30 am and 2.30 p.m., with a Siemens ECAT EXACT
HR+ whole-body PET camera operating in high sensitivity 3D mode. Subjects recei-
ved a total of 500 MBq of H215O per scan over 20 seconds through a forearm canula.
The scans were started at the moment of injection and lasted 120 seconds. Since
the time required for the radioactive water to reach the brain is between 20 and 25
seconds in the injection system used, the effective scanning time is 95-100 seconds. 
Data are reconstructed by filtered backprojection with a zoom factor of 2.25. A
Hanning filter with a cut-off frequency of 0.5 cycles/pixel was used. The resulting
images have a nearly isotropic spatial resolution of roughly 5 mm FWHM (full width
at half maximum).
Data-analysis
The data were processed and analyzed with SPM software (SPM99, Wellcome
department of Cognitive Neurology, London, UK) (Friston et al 1995), implemented
in Matlab (Mathworks, Sherborn, MA, USA). The scans of all subjects were realig-
ned and then normalized to the MNI (Montreal Neurological Institute) template
(using heavy regularization). Images were smoothed with a Gaussian kernel of 8
mm FWHM. 
Activation differences in terms of hyper- and hypoactivity of patients compared to
control subjects were tested voxel-by-voxel by analysis of variance. Group differences
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between patients and controls on the two scans were tested by a two sample t-test,
while the overall differences were tested by a multigroup analysis, wherein both
scans and both groups were compared. The multigroup analysis is named so within
SPM to show that it is to be used for comparisons about group and state interacti-
ons, and the statistical test used in this analysis is an ANOVA.
Clusters with voxel differences achieving a threshold of Z =  3.15 (corresponding to a
p-value < 0.001 uncorrected) were displayed in three orthogonal projections on
SPM glass brain projections. First the statistical parametric maps (SPMs) were
inspected for the presence of findings in unpredicted regions; these were reported
significant only if resisting correction for multiple comparisons based on the
Gaussian random field theory (p<0.05) (Friston et al 1996). Secondly the threshold
was lowered to P < 0.01 uncorrected, and the SPMs were inspected for the presence
of voxel clusters of statistical significance in anxiety-related regions where abnorma-
lities were predicted a priori. Small volume correction was used to check if the diffe-
rences detected in fear network related regions were significant. SPM99 uses the
results of the formulae described in Worsley et al (1996) to calculate corrected sta-
tistics across the whole brain, by working out the shape and size of the whole brain
volume in the analysis and calculating the correction accordingly. The stereotactic
coordinates of the peak differences were determined using the Talairach and
Tournoux atlas (1988), after translating the MNI coordinates to coordinates accor-
ding to the Talairach template, by using the matlab function mni2tal.m, described by
Brett (1999) on the website of the Cambridge Imagers Group (www.mrc-
cbu.cam.ac.uk/imaging/mnispace.html). This function performs different linear
transforms to different brain regions, taking into account that the Talairach brain is
different and somewhat smaller in several areas than the MNI brain. The outcome
of the matlab function is an estimate of the equivalent X, Y and Z coordinates in the
Talairach brain. 
Results 
rCBF differences between patients and controls during rest 
(after the pentagastrin challenge)
Hypoactivity of patients versus control subjects was seen in the precentral gyrus left
(trend, corrected p = 0.07)(figure 2-1; see colorfigure on page 119) and the insula
left more than right. Hyperactivity of patients versus control subjects was seen in
the parahippocampal gyrus, the left hippocampus, the right temporal lobe, the orbi-
tofrontal cortex, the thalamus and the midbrain (figure 2-1; see colorfigure on page
119). The Z-scores and coordinates of peak voxels are presented in table 2.
rCBF differences between PD patients and controls during anticipatory anxiety
(before the pentagastrin challenge)
Hypoactivity in PD patients compared to controls was seen in the precentral gyrus
and the inferior frontal gyrus. Both clusters were more deactivated on the left side than 
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Table 1 Demographic data and behavioral and physiological results 
Patients Controls P  
Demographic Criteria
Mean age (SD) 40.4 (13.8) 36.3 (13.3) NS
Mean no. panic attacks/2 wks (SD) 3.8 (3.9) NA
No.  / 5/12 9/12
Mean HAS (SD) 22.7 (5.1) NA
Mean HDS (SD) 9.9 (3.2) NA
Behavioral and physiological results 
Mean BP scan 1 137/85 128/76 NS
Mean BP scan 2 137/85 125/74 < 0.05
Difference BP scan 1-2 NS NS
Mean HR scan 1 (SD) 75.2 (14) 68.8 (14.1) NS
Mean HR scan 2 (SD) 73.8 (12.8) 62.7 (8.1) < 0.01
Difference HR scan 1-2 NS NS
Mean N symptoms scan 1 (SD) 4.2 (3.3) 0.6 (1.2) < 0.001
Mean N symptoms scan 2 (SD) 2.8 (2.7) 0.5 (1.4) < 0.01
Difference symptoms scan 1-2 P < 0.001 NS 
Legend: SD = standard deviation, HAS = Hamilton rating scale for anxiety, HDS = Hamilton rating scale for
depression, BP = blood pressure, HR = heart rate, N = number. 
on the right side (figure 2-2; see colorfigure on page 120). Furthermore the insula
showed bilateral hypoactivity in patients compared to controls. The amygdala was sig-
nificantly deactivated on the right side only in patients compared to controls, as shown
in figure 2-3 (see colorfigure on page 121). Hyperactivity in patients compared to con-
trols was seen in the parahippocampal gyrus (left more than right), the left hippocam-
pus, the right temporal lobe, the orbitofrontal cortex, the anterior cingulate gyrus, the
hypothalamus, the thalamus and the midbrain (figure 2-2; see colorfigure on page 120,
and for the activation of the anterior cingulate gyrus figure 2-4 on page 121). The Z-
scores and coordinates of peak voxels are presented in table 2.
Multigroup comparison of rCBF differences between patients and controls on pre- and
post-challenge conditions 
The multigroup comparison showed comparable results. Significantly increased acti-
vation was seen in patients compared to controls in the midbrain, the orbitofrontal
cortex, the left anterior cingulate gyrus and the parahippocampal gyrus bilaterally.
Significantly decreased activation in patients compared to controls was observed in
the right amygdala and the left insula. The Z-scores and coordinates of peak voxels
are presented in table 2.
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Table 2 Regions where statistical significant differences in rCBF occur-
red between PD patients and healthy control subjects, the coordinates of
maximal change, and the direction of change from rest to anticipatory
anxiety 
Regions Resting state Anticipatory Multigroup Direction of 
anxiety comparison change from rest 
to anticipatory 
anxiety
Hypoactivity Coord./Z-score Coord./Z-score Coord./Z-score
Precentral gyrus left -30 –13  41   (4.27) -40   -9  47   (4.68) More deactivated
Precentral gyrus right 38 –10  37   (3.36) 42   -8  39   (4.60) More deactivated
Inferior frontal gyrus left -55   14   7*  (3.10) -30    7  24   (3.48) More deactivated
Insula left -42   -5   8*   (1.71) 41 –15  19   (3.20) -44 –19   5*  (2.07) More deactivated
Insula right 38 –16 21   (3.32) 40   -4  35*  (2.34) More deactivated
Amygdala right 24    3   -9*  (2.24) 22   -1 –10*  (2.22)
Hyperactivity Coordinates/Z-score Coordinates/Z-score Coordinates/Z-score
Parahippocampal gyrus left -20 –37  -5   (3.26) -20 –41  -5   (3.41) -24 –51   -3*  (2.38) More deactivated
Parahippocampal gyrus right 36 –24   -6*  (2.84)
Temporal lobe right 50   8  -36   (3.20) 48    8 –37   (3.52) More deactivated
Anterior cingulate left -22  45    3*  (2.56) -14  37    2   (3.19) -32  44  29*  (2.52) More deactivated
Anterior cingulate right 12  31    6*  (3.07) 12  29   -3   (3.33) More deactivated
Orbitofrontal cortex left -4  61 –18*  (2.65) -18  61 –15* (2.23) -26  38 –24   (3.47) Less activated
Orbitofrontal cortex right 2  59  -18*  (2.67) 24  56   -4*  (2.42) 26  43 –24*  (2.41) Less activated
Hypothalamus 0   -6 –13*  (2.65)
Hypothalamus 2  -7 –16*  (2.98)
Hypothalamus 4  -5 –15*  (2.74)
Basal ganglia -16   -5  13* (2.06)
Basal ganglia 16   -1   9*   (2.29)
PAG/midbrain/pons 8 –31 –34*   (2.31) -10 –26  -9* (3.26) -6 –27   -4*  (2.04) More deactivated
Insula right 40 –15  17*   (2.23)
Legend: The coordinates of maximal change of the main voxels according to the Talairach and Tournoux atlas
(1988), after translation of the coordinates via the function mni2tal (Brett, 1999); Z-scores presented are signifi-
cant with a P < 0.05 corrected for whole brain statistics, * = after small volume correction
Differences in heart rate and blood pressure
The differences in heart rate (HR) and blood pressure (BP) between PD patients
and control subjects were only significant after the resting scan (HR: F=10.4,
df=1,36, p<0.01; BP: F=4.6, df=1,36, p<0.05), albeit the mean blood pressure and
heart rate in patients both before and after the challenge were higher than in con-
trols. There were no significant differences between the two conditions (table 1). 
Differences in experienced panic-related symptoms between patients and controls
Significant differences were seen in the number and severity of the panic-related
symptoms experienced by the PD patients and the control subjects (anticipatory
anxiety: F=22.45, df=1,36, p<0.001; at rest: F=11.7, df=1,36, p<0.01) (table 1). The PD
patients experienced on average four panic-related symptoms during the first PET
scan. According to the DSM-IV criteria this is close to a panic attack. Two actual
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panic attacks occurred in the PD patients during this scan (at least four panic-rela-
ted symptoms together with a feeling of moderate to intense fear), while no actual
panic attacks occurred in the healthy controls. The mean number of experienced
symptoms in the patient group decreased significantly from anticipatory anxiety to
at rest (F=23, df=1,15, p<0.001) (table 1).  At rest no actual panic attacks occurred in
the PD patients nor in the healthy control subjects. 
Discussion 
We observed rCBF differences between PD patients and control subjects in almost
all regions proposed by LeDoux (1998) as being connected with the fear network in
the brain. As was expected, in the resting state there were less anxiety related brain
regions in both PD patients and control subjects, that showed activation differences
than during anticipatory anxiety. The rCBF of PD patients during anticipatory anxiety
differed from controls in the amygdala, the inferior frontal gyrus and the hypothala-
mus in the prechallenge condition, while differences in these areas were not detec-
ted in the resting state. The deactivation shown during anticipatory anxiety in the
precentral gyrus and insula in patients compared to controls, was still present but
less obvious in the subjects at rest.
The PD patients in this study experienced a higher level of anticipatory anxiety than
the normal control subjects, as shown by the higher number of experienced panic-
related symptoms in the anticipatory anxiety condition, compared to the controls.
They experienced a mean number of four DSM-IV described panic-related symp-
toms, which is the criterion for a panic attack according to the DSM-IV. Anticipatory
anxiety has been associated with bilateral increases in the temporal poles (Reiman
et al 1989a; Benkelfat et al 1995). The activity in these regions was also observed to
be increased in other forms of anxiety (Reiman et al 1989b; Fredrikson et al 1993;
Wik et al 1993; Rauch et al 1995; Fredrikson et al 1995). The data concerning the
strong temporopolar hyperactivity in the studies of Reiman et al (1989a) and
Benkelfat et al (1995) was suspected to be an artifact, when Drevets et al (1992)
detected that these activation peaks were connected with extracerebral blood flow
changes associated with teeth-clenching. Even though, the temporal lobe, the para-
hippocampal gyrus and the hippocampus seem to be implicated in anxiety and
emotion regulation. Structural imaging studies discovered more abnormalities in
the temporal lobe of PD patients than in normal controls (Ontiveros et al 1989);
(Fontaine et al 1990). More recent neuroimaging studies also report temporal lobe
activation in anxiety which is often unilateral and more medially located. We replica-
ted this finding in the parahippocampal gyrus in PD patients compared to controls.
This increase was especially present during anticipatory anxiety in the PD patients.
In the resting condition the left parahippocampal region still showed more activity,
although less voxels were activated, in the PD patients compared to the controls.
Probably this region is not only related to anticipatory anxiety, but also to PD as an
illness, as detected before by Nordahl et al (1990) and Bisaga et al (1998).
Two recent EEG studies in healthy volunteers and social phobics have shown that
anticipatory anxiety might be related to right-sided hyperactivity of the brain
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(Davidson et al 2000; Nitschke et al 1999), as compared to left-sided hyperactivity
in state anxiety, e.g. related to panic (anxious arousal, Nitschke et al 1999). In our
study the hyperactivity associated with anticipatory anxiety was located on both
sides of the brain. This can be due to the fact that we studied PD patients instead of
the healthy volunteers or social phobics who were included in the EEG studies. PD
patients may have a higher state anxiety than healthy volunteers or social phobics. 
The precentral gyrus showed bilateral hypoactivity in patients compared to controls
in the anticipatory anxiety condition. This is not easily explained, because if it would
be associated with increased muscle tension, previously reported in anxiety and
anticipatory anxiety states, the precentral gyrus should have been hyperactive.
Another explanation for this hypoactivity might be that it is in fact comparable to the
hypoactivity in the inferior parietal lobe and the superior temporal lobe seen in the
studies of PD patients in rest of Nordahl et al (1990) and Bisaga et al (1998).
The inferior frontal gyrus plays a role in anxiety and emotion regulation. Stimuli lea-
ding to anxious arousal are processed in this area. The area is connected to the
amygdala, which in its turn is seen as a key structure in the processing of anxiety in
the brain (LeDoux 1998). The inferior frontal region is observed to be hypoactive
during state anxiety in patients with anxiety disorders and in normal controls (e.g.
induced by challenges) (Stewart et al 1988; Bremner et al 1997; Johanson et al 1998;
Fischer et al 1998: unexpected panic attack; Javanmard et al 1999: 1 minute after
CCK4 injection). Hyperactivity of the inferior frontal cortex has been observed in anti-
cipatory anxiety in healthy volunteers and social phobics (Benkelfat et al 1995;
Javanmard et al 1999). We detected anticipatory anxiety hypoactivity in PD patients
compared to controls in this region. In this case, this hypoactivity can probably be
attributed to the higher level of state anxiety in the PD patients compared to the
control subjects, although it is strange that we could not detect any significant diffe-
rences in this area after the challenge. 
The amygdala is thought to play a key role in anxiety. LeDoux (1998) presents a
model of anxiety processing, based on the results of studies on conditioned anxiety
in rat and cat. The lateral nucleus of the amygdala receives projections from the
sensory cortex (Inc. prefrontal cortex, anterior cingulate cortex) and the thalamus
and processes this information to the central nucleus of the amygdala. The central
nucleus of the amygdala projects to different areas in the hypothalamus and the
midbrain, where responses are generated. Gorman et al (2000) proposed a model
very similar to the above described model as a neurobiological model of PD.
Different studies tried to show activation of the amygdala related to anxiety and fear.
In studies wherein the recognition of facial expressions of fear was important, the
role of the amygdala was shown (Adolphs et al 1994; Morris et al 1999). Two groups
(Rauch et al 1996; Shin et al 1997) showed hyperactivity of the amygdala in subjects
with posttraumatic stress disorder. Birbaumer et al (1998) showed amygdala activa-
tion during a facial recognition task in social phobics, using fMRI. This was the first
study that showed activation of the amygdala in potentially fear-relevant stimuli.
Other studies concerning anxiety failed to show activation of the amygdala (Chua et
al 1999; Damasio et al 2000). An unilateral enlarged right amygdala was shown in
the study of De Bellis et al in pediatric generalized anxiety disorder (2000). Adinoff
et al showed an increase in the activity of the right amygdala in response to a pro-
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caine challenge (2001). Unilateral hyperactivity of the left amygdala during anticipa-
tory anxiety was found in the study of Phelps et al (1987). Cahill et al (2001) obser-
ved that during recall of emotionally related film-clips in women the left amygdala
was activated, while in men the right amygdala was activated. This suggests a sex-
specific effect in the activation of the amygdala. These different findings about the
amygdala activation suggest that the amygdala plays a role in anxiety, although only
amygdala activation was seen. In our study the right amygdala is deactivated in
patients compared to controls, before the pentagastrin challenge. In the resting con-
dition this hypoactivity could not be detected. It is possible that the hypoactivity of
the right amygdala is specifically related to anticipatory anxiety in PD patients, and
therefore seen only in the anticipatory anxiety condition. It is also conceivable that
hypoactivity of the amygdala during anticipatory anxiety in PD patients is a sign of a
specific functional impairment of the amygdala in PD patients only present during
anticipatory anxiety. Another explanation may be that since somatosensory cortical
areas as well as the prefrontal cortex exert inhibitory effects on the amygdala, it is
conceivable that high anticipatory anxiety (which is cortically represented) reduces
the activity of the amygdala. 
The insula is a very differentiated area with postulated roles in the processing of vis-
ceral sensory, visceral motor, motor association, vestibular, somatosensory and
language information. Projections to and from the thalamus, and projections to the
prefrontal cortex, the anterior cingulate gyrus and the hypothalamus also suggest a
role in the processing of anxiety-related information in the brain (LeDoux 1998;
Gorman et al 2000). Especially the anterior insula is often mentioned in different
studies about mood or emotion. An increase in activation in the insular region is
associated with the induction of anxiety (Benkelfat et al 1995; Javanmard et al 1999;
Rauch et al 1997; Reiman et al 1989b), and also with anticipatory anxiety (Chua et al
1999). The insula is furthermore considered as visceral sensory cortex to detect inc-
reased heart rate and visceral arousal, which is often part of anticipatory anxiety. In
this study we detected lower activity in the anterior insula, both in the  resting and
in the  anticipatory anxiety condition, in patients compared to controls. It is possible
that this relative hypoactivity in the patients is actually hyperactivity in the control
subjects as seen before in anticipatory anxiety in healthy control subjects awaiting a
challenge situation (Benkelfat et al 1995). 
Hyperactivity of the orbitofrontal cortex has been seen before in different anxiety
disorders, such as obsessive compulsive disorder (Baxter et al 1987b; Schwartz et al
1996), simple phobia (Rauch et al 1995), posttraumatic stress disorder (Rauch et al
1996) and also in panic disorder (Nordahl et al 1990). 
Lesion and functional imaging studies have implicated the anterior cingulate cortex
in the modulation of autonomic activity and emotional responses. In different stu-
dies hyperactivity has been shown in the anterior cingulate cortex during anxiety
induction or provocation (Benkelfat et al 1995; Rauch et al 1997) and in resting PD
patients (Nordahl et al 1990). Chua et al (1999) also found an increase in the anteri-
or cingulate cortex activation during anticipatory anxiety in healthy volunteers. We
observed an increase in activity in the anterior cingulate cortex in PD patients com-
pared to controls both in the anticipatory anxiety condition and in the resting condi-
tion.
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We observed increased activity in the midbrain, probably the periaqueductal gray
matter (PAG), in PD patients compared to control subjects, both before and after
the challenge situation. Stimulation of midbrain areas in rat evoked anxiety-related
behavior, and in humans a state of terror was evoked by stimulation of the midbrain
(Nashold et al 1969). The observed increase of activity in the midbrain is consistent
with this finding. 
In conclusion, in this study we observed hypoactivity during anticipatory anxiety in
PD patients compared to controls in the precentral gyrus, the inferior frontal gyrus,
the amygdala and the anterior insula. Hyperactivity in PD patients compared to con-
trols was observed in the parahippocampal gyrus, the hypothalamus, the anterior
cingulate gyrus, the basal ganglia and the PAG. In the resting condition only the pre-
central gyrus, the inferior frontal gyrus and the anterior insula were deactivated in
the patients, and the parahippocampal gyrus, the anterior cingulate gyrus and the
midbrain showed increased activity. Both before and after the pentagastrin challenge
the differences between PD patients and healthy control subjects are seen in almost
the same areas of the fear network in the brain. The main difference is that after the
challenge, during rest, less voxels were activated than before the challenge, during
anticipatory anxiety. 
Of course, a limitation of this study is the fact that the scan made after the challen-
ge is not a real resting situation, and may be influenced by the experienced challen-
ge. Therefore it is still difficult to distinguish between the effects of anticipatory
anxiety and the situation at rest. Even though, the experienced symptoms after the
challenge show that the patients felt more relaxed than before the challenge, and
that the healthy control subjects felt almost the same as before the challenge. 
Another possible confounder can be that male and female subjects were taken toge-
ther as one group. There are some, although contradictory, reports of differences
between males and females in the mean total blood flow in the brain and lateraliza-
tion of brain activity (Baxter et al 1987a; Baxter et al 1988; Cahill et al 2001; Kastrup
et al 1999). Furthermore, no teeth-clenching scan was made for correction for facial
muscle tension. We cannot completely control for the exact effect of teeth-clenching,
but we assume that the observed temporal activation can not be attributed to mus-
cle tension because the activation was more medially located and not bilateral. 
In this study small volume correction was used for multiple regions that were expec-
ted to be connected with the representation of fear in the brain (LeDoux, 2000). The
SPM99 output shows the regions P-values corrected for whole brain statistics, these
statistics are run very conservatively, while it also shows the regions P-values not
corrected for the total amount of statistical tests run, and these statistics are too
liberal. There has been a lot of discussion on the SPM mailing list about whether to
report the statistics with corrected (P < 0.05) or uncorrected  (P < 0.001) P-values.
We chose to use the corrected P-values, but then statistically significant differences
only emerge in very few areas. Thus we also used small volume correction, based on
our expectation about the regions of the fear network, but these areas were only
reported as far as they also showed an uncorrected P-value of less than 0.001.
Our conclusion is that we observed differences in brain activation between PD
patients and controls in almost all areas previously hypothesized to be involved in
anxiety. The differences in the precentral gyrus, inferior frontal gyrus, the (para)hip-
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pocampal gyrus, the amygdala and the insula can be attributed to more anticipatory
anxiety in the PD patients compared to the healthy controls. The activity in some of
the regions, such as the insula, the inferior frontal cortex and the anterior cingulate
cortex can possibly be a characteristic of anticipatory anxiety which is more chroni-
cally present in PD patients. 
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Abstract 
Context: The neurobiology of panic anxiety is incompletely understood. So far, not
much is known about the distinction between panic anxiety in panic disorder
patients and anxiety in healthy subjects. 
Objective: To examine the regional cerebral blood flow changes after pentagastrin
induced panic or anxiety in panic disorder patients and healthy control subjects. 
Participants and intervention: Seventeen panic disorder patients and 21 healthy con-
trol subjects were studied with H215O PET scan before, during and after a pentagast-
rin challenge. 
Results: Panic disorder patients showed significantly more anticipatory anxiety
during the scan before the pentagastrin challenge and significantly more anxiety and
panic during the pentagastrin challenge than the control subjects, although even the
control subjects experienced anxiety symptoms (anxious arousal). There are remar-
kable similarities in the blood flow patterns during anxious arousal, anxiety, and
panic, between the panic disorder patients compared to the healthy control sub-
jects. The same areas were activated and deactivated during panic versus anxious
arousal in patients and controls. We noted increased rCBF in the parahippocampal
gyrus, the basal ganglia and parts of the prefrontal cortex. The hypothalamus and
the amygdala only showed increased rCBF in the control subjects. Decreases in
rCBF were observed in the precentral gyrus, the insula, the thalamus and parts of
the prefrontal cortex. 
Conclusions: We conclude that even though healthy subjects do not experience the
same degree of anxiety as panic disorder patients after pentagastrin injection, they
show remarkable similarities in activation in anxiety-related brain regions. A remar-
kable finding is the increased activation of the amygdala in healthy control subjects
during pentagastrin induced anxiety, but the absence of increased rCBF in the
amygdala of panic disorder patients during pentagastrin induced panic, even though
their anxiety level is much higher. 
Introduction
In recent years there has been increasing interest in the study of the neurobiology of
various psychiatric disorders by means of neuroimaging techniques, combined with
various challenge methods. In anxiety disorders there is ongoing discussion about
the neurobiological substrate of panic and anxiety. An important issue that permea-
tes any definitive conclusion of neuropsychiatric dysfunctions in anxiety disorders is
the considerable variation in the methods used to collect neurobiological data (e.g.
analysis of cerebrospinal fluid, blood platelets, challenge studies, EEG, neuroima-
ging studies). There are limitations to constructing hypotheses about the neuroche-
mical basis of anxiety on the grounds of such different sorts of data. Especially the
detection of regional contributions within distributed networks is a problem which
can only be solved by neuroimaging studies. This study was intended to unravel
more of the neurobiology of panic and anxiety, by studying panic disorder (PD)
patients with a panic provoking agent during neuroimaging. 
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In previous clinical and preclinical studies, structures like the amygdala and other
parts of the temporal cortex, the prefrontal cortex and the periaqueductal gray mat-
ter (PAG) have been associated with panic and anxiety. These regions have been
named as part of the fear network in the brain, wherein the amygdala plays a central
role (LeDoux 1996). The first report on functional neuroimaging combined with
symptom provocation in PD patients was published in 1984 (Reiman et al 1984). In
this study PD patients and control subjects were examined with radioactively labeled
water (H215O) and positron emission scan (PET) after lactate challenge. Differences
in rCBF were observed in the parahippocampal gyrus in the resting non-panic state
between PD patients who did (lactate-positive) and who did not (lactate-negative)
experience a panic attack after lactate challenge, and normal control subjects.
Furthermore, a neuroimaging study performed during a lactate-induced panic attack
showed increases in the rCBF of the temporal pole, the insular cortex, the claustrum
and the cerebellar vermis (Reiman et al 1989b). Single-photon-emission computeri-
zed tomography (SPECT) studies, performed during or after lactate challenge, show-
ed similar results (De Cristofaro et al 1993; Stewart et al 1988). 
PET studies during anxiety provocation in healthy volunteers, with cholecystokinin
(CCK4) as provocative agent, showed a robust increase in regional cerebral blood
flow (rCBF) in the anterior cingulate gyrus, the claustrum-insular-amygdala region
and the cerebellar vermis, and one of the studies showed a decrease in the medial
frontal areas during anxiety (1995; 1999). 
Lactate challenge in combination with PET scan is hampered by methodological
problems due to volume effects, the unpredictable time of onset and duration of the
panic attack, and the rather low panic frequency in PD patients (around 60%) (den
Boer et al 1989). Combining the administration of CCK4 with neuroimaging circum-
vents the aforementioned methodological flaws. CCK4 is easy to administer as an
intravenous bolus injection; every subject receives the same dose and because of
the small quantity there is no risk of volume-overload. The onset of action is within
a few seconds, and the duration of the behavioral response is covered by the two-
minute PET scan. Furthermore it is very reliable, because a large percentage of the
PD patients (around 90%) experiences a panic attack very similar to their spontane-
ous panic attack (Rehfeld 2000). Pentagastrin is the five amino-acid CCK variant,
containing the four amino-acid CCK4. Previous studies have shown that PD patients
have an increased sensitivity for the panic inducing properties of pentagastrin (van
Megen et al 1994). 
We decided to use pentagastrin as a challenge agent in PD patients and healthy con-
trol subjects, in order to study patterns of brain activation during a panic attack in
PD patients. In addition we wanted to study differences in regional cerebral blood
flow (rCBF) during pentagastrin injection in PD patients compared to healthy con-
trol subjects. We expected to replicate the findings of the aforementioned studies,
and furthermore, we hypothesized that we would detect changes in other brain
regions previously implicated in anxiety, namely the temporal lobe, which includes
the parahippocampal gyrus, the hippocampus and the amygdala, and furthermore
the prefrontal cortex, the anterior cingulate cortex, the midbrain, the thalamus and
the hypothalamus (Gorman et al 2000; LeDoux 1996; LeDoux 1998). 
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Methods and materials
Subjects
Seventeen patients with PD (5 men/12 women) and 21 healthy control subjects
(9 men/12 women) participated in the study (for demographic data see table 1). All
patients met the DSM-IV criteria of PD with or without agoraphobia, as diagnosed
by a psychiatrist (American Psychiatric Association 1994). The subjects were physi-
cally healthy, as determined by history, physical and neurologic examination, and
had no comorbid psychiatric or neurologic diseases. All patients were free from psy-
choactive medication for at least three weeks prior to the PET scan (in the case of
fluoxetine for at least 6 weeks). The patients were allowed to use oxazepam (maxi-
mum dose 20 mg/day for maximal three days/week) in the week before the PET
scan, but not during the last 24 hours before the scan. The levels of anxiety and
depression in the patients were obtained by the Hamilton rating scales for anxiety
(Hamilton 1959) and depression (Hamilton 1967). The healthy control subjects had
never experienced anything like a panic attack in their lives, and had no relatives
with panic disorder or other psychiatric disorders. All subjects were 18 years or
older. None of the subjects was taking medication (other than oral contraceptives)
or had a history of substance abuse. Other exclusion criteria were: DSM-IV mental
disorder (other than PD in the PD patients), Hamilton depression rating scale score
over 15, serious physical illnesses, radiological workers, participation in a trial with
radioactive radiation exposure in the past year, and pregnancy.
One of the male PD patients was excluded from the analysis because of too much
head movement during the scans. One of the female patients showed head move-
ments during the pentagastrin scan. Therefore this scan had to be excluded from
the analysis. Two scans made in resting condition (one first scan in a patient and
one last scan in a control subject) showed no activity due to injection pump failure.
A few PD patients experienced a spontaneous panic attack during the first or the
second scan; these scans were labeled differently and excluded from the main
effects analyses. We choose to define a panic attack in this study with stricter criteria
than defined by the DSM-IV: moderate to severe anxiety had to be present during
the panic attack, in addition to the criterion of at least 4 out of the 13 symptoms.
All subjects gave oral and written informed consent after complete explanation of
the nature and possible consequences of the study (in accordance with the provisi-
ons of the pertinent excerpt from the Declaration of Helsinki, South Africa 1996).
The study was approved by the medical ethics committee of the Groningen
University Hospital. 
Procedure
Subjects were positioned in the scanner using a molded head rest with a strap over
the head to minimize head movement. Two marks were placed on the forehead and
nose of the subject to check for movement between the scans. The subjects were
instructed to lie quietly with their eyes open in a dimly lit room, without conversati-
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on or noise, other than the noise from the scanner. First a 20-minute transmission
scan, used for attenuation correction, was made. After this scan all subjects were
scanned four times. Once or twice before, once during and one or two times after
pentagastrin challenge. Just before each scan 1 ml fluid was injected within 10
seconds as a bolus injection through a fore-arm canula, containing 40 µg pen-
tagastrin or 0.9% sodium chloride. Immediately after each scan blood pressure (BP)
and heart rate (HR) were measured, and the subjects were asked about the anxiety
symptoms experienced during the scan, using a semi-structured interview based on
the DSM-IV criteria for panic attacks (API). The API score was derived by counting
the experienced anxiety symptoms multiplied by the severity rating each subject
gave per experienced symptom. Furthermore subjects had to point out on a separa-
te five-point scale how anxious they felt immediately after the injection. 
Scanning was done between 11.30 am and 2.30 p.m., with a Siemens ECAT EXACT
HR+ whole-body PET camera operating in high sensitivity 3D mode. Subjects recei-
ved a total of 500 MBq of H215O per scan over 20 seconds through a forearm canula.
The first scan was started at the moment of H215O injection and lasted 120 seconds.
Since the time required for the radioactive water to reach the brain is between 20
and 25 seconds in the injection system used, the effective scanning time is 95-100
seconds. The subsequent scans consisted of two frames. The first frame lasted 30
seconds and was used for background correction. The second frame lasted for 120
seconds, as in the first scan. Injection of the radioactive water was at the start of
this second frame. Data were reconstructed by filtered backprojection with a zoom
factor of 2.25. A Hanning filter with a cut-off frequency of 0.5 cycles/pixel was used.
The resulting images have a nearly isotropic spatial resolution of roughly 5 mm
FWHM (full width at half maximum).
Data-analysis
Statistical analyses for differences in the demographic, behavioral and physiological
data were performed using SPSS for Windows version 10. Within and between
group analyses were performed by analysis of variance (ANOVA), using a level of
significance of 5%.
The PET scan data were processed and analyzed with statistical parametric mapping
software (SPM99, Wellcome department of Cognitive Neurology, London, UK)
(Friston et al 1995), implemented in Matlab (Mathworks, Sherborn, MA, USA). The
scans of all subjects were realigned and normalized to the MNI (Montreal
Neurological Institute) template, using heavy regularization. Images were smoothed
with an 8 mm FWHM Gaussian kernel. 
Activation differences in terms of rCBF increases and decreases of pentagastrin
induced panic versus rest, and of patients compared to control subjects, were tested
voxel-by-voxel by ANOVA. The analyses concerning the pentagastrin scans were per-
formed on the data of the panic disorder patients who experienced a pentagastrin
induced panic attack and were compared to the data of the control subjects who did
not experience a panic attack. Differences over the scans within one group were tes-
ted by a so-called multisubject analysis, an ANOVA within-group analysis. Overall
group and state differences were tested by a multigroup analysis, wherein both
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groups were compared with ANOVA, with one between-group factor (PD patients
versus control subjects) and one within-group factor (pentagastrin versus rest). 
Clusters with voxel differences achieving a threshold of Z =  3.30 (corresponding to
a p-value < 0.001 uncorrected) were displayed in three orthogonal projections on
SPM glass brain projections. The statistical parametric maps (SPMs) were inspec-
ted for the presence of findings in unpredicted regions; these were reported signifi-
cant only if resisting correction for multiple comparisons based on the Gaussian
random field theory (Friston et al 1996) and using the statistical procedures for con-
trolling the false discovery rate (Genovese et al 2002) (p<0.05). Secondly the SPMs
were inspected for the presence of voxel clusters of statistical significance in regions
where abnormalities were predicted a priori (regions of interest were the different
regions of the fear network in the brain); these regions were reported only if the
uncorrected p-value was less than 0.001. SPM99 calculates corrected statistics
across the whole brain, by working out the shape and size of the whole brain volu-
me in the analysis and calculating the correction accordingly (Worsley et al 1996).
The stereotactic coordinates of the peak differences were determined using the
Talairach and Tournoux atlas (Talairach and Tournoux 1988), after translating the
MNI coordinates to coordinates according to the Talairach template, by using the
matlab function mni2tal.m as described by M. Brett on the website of the
Cambridge Imagers Group (http//www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html). 
Results 
Differences in symptom profile between patients and control subjects
The PD patients experienced significantly more anxiety symptoms and rated them
as being more severe according to the API scores in all different scanning conditi-
ons, when compared with the API scores of the healthy control subjects (prechallen-
ge: F=16.0, df=36, p=0.000; challenge: F=46.3, df=36, p=0.000; postchallenge:
F=13.7, df=36, p<0.001, see table 1). In 16 of the 17 PD patients the strict criteria for
a panic attack (at least four out of 13 symptoms, with moderate to intense fear) were
fulfilled after pentagastrin injection, while this was the case in only two of the con-
trol subjects. During the scan under pentagastrin challenge significantly more and
more intense anxiety symptoms were experienced than in the other conditions
(F=29.7, df=2, p=0.000). All but one of the PD patients who experienced a panic
attack on the pentagastrin injection stated that the experience was very much like
their spontaneous attacks. 
Differences in heart rate and blood pressure
Although the differences between patients and control subjects not always reached
statistical significance, the patients overall showed higher heart rate (HR) and mean
arterial blood pressure (MABP) than the control subjects after the different PET
scans (HR prechallenge NS; HR challenge NS; HR postchallenge: F=11.3, df=35,
p<0.005; MABP prechallenge: F=5.4, df=36, p<0.05; MABP challenge NS; MABP 
postchallenge: F=8.7, df=35, p<0.01). Results are summarized in table 1. 
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Table 1
Patients Controls P  
Demographic Criteria
Mean age (SD) 40.4 (13.8) 36.3 (13.3) NS
Mean no. panic attacks/2 wks (SD) 3.8 (3.9) NA
No.  males/ females 5/12 9/12
Mean HAS (SD) 22.7 (5.1) NA
Mean HDS (SD) 9.9 (3.2) NA
Behavioral and physiological results 
MABP prechallenge (SD) 111.1 (11.9) 102.1 (11.3) < 0.05
MABP challenge (SD) 113.2 (20.5) 109.6 (9.5) NS
MABP scan postchallenge (SD) 111.1 (12.8) 100.0 (9.9) < 0.01
Mean HR prechallenge (SD) 75.7 (14.3) 70.0 (12.1) NS
Mean HR challenge 78.3 (13.2) 73.7 (10.1) NS
Mean HR postchallenge (SD) 74.3 (15.1) 62.2 (8.3) < 0.005
Mean API prechallenge (SD) 5.8 (5.7) 0.6 (1.3) < 0.000
Mean API challenge (SD) 25.2 (10.7) 7.6 (4.5) < 0.000
Mean API postchall. (SD) 3.6 (3.2) 0.6 (1.7) < 0.005
Legend: SD = standard deviation, HAS = Hamilton rating scale for anxiety, HDS = Hamilton rating scale for
depression, MABP = mean arterial blood pressure, HR = heart rate, API = Acute Panic Inventory.
rCBF differences between pentagastrin challenge and rest (last scan) in PD patients
(pentagastrin induced panic) 
As shown in figure 1, increased rCBF (fig. 3-1A) during pentagastrin induced panic
compared to rest, in PD patients was seen in: the parahippocampal gyrus/fusiform
gyrus, the prefrontal cortex, the left orbitofrontal cortex, the left inferior frontal
gyrus, the cerebellum and the left basal ganglia. Regions with decreased rCBF
(fig. 3-1B) during panic compared to rest were the superior frontal gyrus, the medial
and inferior temporal lobe, the thalamus, the hippocampus, the insula and the orbi-
tofrontal/prefrontal cortex. The coordinates and z-scores are summarized in table 2.
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Table 2
Coordinates (according to Talairach and Tournoux) of maximal change of areas sig-
nificantly more or less active during panic or anxious arousal after pentagastrin
injection in PD patients and control subjects 
rCBF in PD z-score rCBF in healthy z-score Differences between z-score 
patients during control subjects PD patients
panic compared during anxious and healthy control
to rest  arousal compared subjects during 
to rest pentagastrin 
Increased rCBF
Parahippocampal gyrus right 22 3 -27 3.40
Parahippocampal gyrus left -22 –8 –42 3.45
Parahippocampal gyrus   2 –62 –5 4.38 0 –49 –8 4.50 0 –60 –4 4.16
Prefrontal cortex right 24 46 –14 3.77
Prefrontal cortex left -30 59 6 3.26
Anterior cingulate gyrus left -6 25 –5 3.46
Orbitofrontal cortex left -24 34 –25 3.53 -53 33 –10 3.16 -28 44 –21 3.35
Orbitofrontal cortex right 55 40 –12 3.99
Basal ganglia left -8 0 9 3.46
Basal ganglia right 12 8 0 4.91
Hypothalamus 4 0 –5 3.09
Amygdala right 18 –8 –8 3.91
Amygdala left -16 –4 –12 3.40
Cerebellum right 16 –64 –39 3.23
Cerebellum left -38 –56 –36 3.75 -48 –71 –22 4.62 -12 –65 –17 3.36
Inf/med frontal gyrus left -26 21 –9 3.49 -36 57 12 4.19 -24 7 59 3.67
Inferior temporal lobe right 61 7 –21 3.20 69 –22 –22 5.20
Decreased rCBF
Precentral gyrus left -8 –34 61 4.62 -20 26 58 4.94
Precentral gyrus right 22 –20 64 4.46
Insula left -32 –13 3 3.27 -36 –27 9 3.81
Insula right 38 –25 7 3.45
Temporal lobe right 40 –12 –36 4.15
Thalamus 22 –27 3 3.75 18 –9 12 3.49
Amygdala left -16 –8 –13 3.25
Pons 18 –20 –21 3.62
Prefrontal cortex right 6 56 –11 3.18
Prefrontal cortex left -2 60 3 3.23 -46 32 11 3.28
Orbitofrontal cortex left -44 40 –17 3.21 -6 58 –6 3.37
Orbitofrontal cortex right 10 46 –17 3.41 12 48 –19 3.58
Anterior cingulate cortex left -4 37 7 4.07
Anterior cingulate cortex right 10 32 17 4.24
Superior frontal gyrus right 20 31 41 4.85 22 42 31 3.49
Superior frontal gyrus left -22 7 57 5.81
Medial temporal gyrus right 51 –8 –1 4.80 53 –15 6 4.47 51 –10 –3 3.70
Medial temporal gyrus left -53 –8 0 4.26 -53 –43 0 3.93
Retrosplenial cortex 4 –5 26 4.12 0 –10 30 3.72
Posterior cingulate gyrus -2 –59 20 3.68
Hippocampus 34 –12 –9 3.57
Legend: The coordinates of maximal change of the main voxels according to the Talairach and Tournoux atlas
(1988), after translation of the coordinates via the function mni2tal (Brett, 1999); Z-scores presented are signifi-
cant with a P < 0.05 corrected with false discovery rate (Genovese et al, 2002).
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rCBF differences between pentagastrin challenge and rest (last scan) in healthy control
subjects (pentagastrin induced anxious arousal)
Different regions showed an increase in blood flow (see fig. 3-2A) during anxious
arousal in the control subjects, such as: the inferior temporal lobe, the right basal
ganglia, the cerebellum, the parahippocampal gyrus/fusiform gyrus, the amygdala,
the bilateral orbitofrontal cortex, the hypothalamus and the left anterior cingulate
cortex. Regions showing attenuation of rCBF (see fig. 3-2B) after pentagastrin injec-
tion as compared to rest in the control subjects were the bilateral precentral gyrus,
the left superior frontal gyrus, the left insula, the right superior temporal lobe, the
bilateral anterior cingulate cortex, the posterior cingulate cortex and the left orbito-
frontal cortex. These data are summarized in table 2.
rCBF differences between PD patients and control subjects during pentagastrin challen-
ge and rest (last scan) (multigroup comparison) 
The results depicted in figure 3-3 (see colorfigure on page 122) and table 2 show
that when pentagastrin induced panic in PD patients was compared with pentagast-
rin induced anxious arousal in control subjects, more activation during panic as
compared to anxious arousal was seen in the left parahippocampal gyrus/lingual
gyrus, the left orbitofrontal cortex and the cerebellum. Less activation during panic
as compared to anxious arousal was seen in the medial temporal lobe, the pons, the
prefrontal and orbitofrontal cortex, the right thalamus and the left amygdala (for
details about the amygdala localization see fig. 3-4 (see colorfigure on page 121) and 
table 2). 
49
Pentagastrin induced panic does not increase CBF in amygdala of PD patients
17355 Bosh B  22-10-2003  14:20  Pagina 49
Fig. 3-1A SPM glass brain pictures of increases in rCBF in PD patients 
(N=16) during pentagastrin challenge as compared to rest; 
the corresponding coordinates of the peak voxels are shown 
in table 2
Fig. 3-1B SPM glass brain pictures of decreases in rCBF in PD patients 
(N=16) during pentagastrin challenge as compared to rest; 
the corresponding coordinates of the peak voxels are shown 
in table 2
Fig. 3-2A SPM glass brain pictures of increases in rCBF in control subjects 
(N=21) during pentagastrin challenge as compared to rest; 
the corresponding coordinates of the peak voxels are shown 
in table 2
Fig. 3-2B SPM glass brain pictures of decreases in rCBF in control subjects 
(N=21) during pentagastrin challenge as compared to rest; 
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Discussion 
The key findings of this study are that we observed rCBF differences in PD patients
and healthy control subjects during panic and anxious arousal in different fear rela-
ted areas in the brain, such as the temporal lobe, the inferior frontal gyrus, the pre-
frontal cortex, the basal ganglia, the thalamus, the insula and the amygdala. In
accordance with previous investigations, the PD patients in our study showed an
enhanced sensitivity to the panic-inducing properties of pentagastrin as compared
to the healthy control subjects. Even though the PD patients suffered from signifi-
cantly more anxiety and anxiety-related symptoms, the pattern of brain rCBF chan-
ges after pentagastrin is quite comparable with that of the healthy control subjects.
The main difference between PD patients and control subjects in the blood flow pat-
tern after pentagastrin challenge was seen in the amygdala, where, contrary to our
expectations, no significant activation was seen during panic in the PD patients,
while the control subjects showed increased rCBF during anxious arousal. We assu-
me that the rCBF changes observed during the pentagastrin challenge in both PD
patients and control subjects have to be attributed to anxiety more than to the chal-
lenge procedure per se, because a remarkably similar rCBF pattern was also obser-
ved during anticipatory anxiety, and during a resting condition in PD patients com-
pared to control subjects (Boshuisen et al 2002). Furthermore, the differences
between PD patients and control subjects seem related to the intensity of anxiety
and the number of experienced symptoms, as shown by the behavioral and physio-
logical data obtained in this study. Therefore, the conclusion seems justified that the
main difference between PD patients and control subjects in their reaction to penta-
gastrin is a different degree of anxiety. All brain regions showing rCBF changes are
part of the fear network in the brain as described by LeDoux (LeDoux 1994). 
In several studies rCBF changes during or after panic in PD patients were shown.
After yohimbine administration a decrease was observed in frontal cortical flow and
a probable change in thalamic flow (Woods et al 1988), while after lactate infusion a
decrease was observed of whole hemispheric blood flow (Stewart et al 1988). Also
during lactate-induced panic an increase was seen in bilateral temporal flow, bilate-
ral insula/basal ganglia, superior colliculus and cerebellar vermis (Reiman et al
1989b). Later a large part of these data were considered to be an artifact (Drevets et
al 1992). Finally, a case-study was published of a PD patient experiencing a sponta-
neous panic attack while in the PET scanner. Regional CBF decreases were observed
in the right orbitofrontal, prelimbic, anterior cingulate and anterior temporal cortices
(Fischer et al 1998). We also found rCBF changes in most of these regions in our
study. 
There are some reports of challenges in other anxiety disorders showing rCBF diffe-
rences in almost the same anxiety-related brain regions. In posttraumatic stress
disorder (PTSD) patients cerebral blood flow changes were studied after yohimbine
administration, and an overall decrease in CBF was observed, focussing on the tem-
poral cortex (Bremner et al 1997). Another study in relatively recent traumatized
PTSD patients showed increases in right sensorimotor areas and sensory cortex,
and in the cerebellar vermis, the amygdala and the PAG. Decreases were seen in the
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right retrosplenial cortex (Pissiota et al 2002). In this study the PTSD patients expe-
rienced full blown panic attacks during the provocation, therefore these data may
not only show effects specific for PTSD but also results that are interesting for the
study of panic disorder. Pooled data of different PET scan studies of PTSD, obsessi-
ve compulsive disorder and social phobia patients after different behavioral challen-
ges showed increases in the right inferior frontal and orbitofrontal cortex, the insula,
the lenticular nucleus and the brainstem (Rauch et al 1997). A symptom provocation
study in subjects with social phobia showed increased subcortical blood flow, as
opposed to increased cortical blood flow in nonphobic controls (Tillfors et al 2001).
Data of healthy control subjects during the challenge often showed changes in
anxiety related areas as well, even if there was no anxiety experienced by the sub-
jects (Bremner et al 1997; Reiman et al 1989b; Stewart et al 1988; Woods et al 1988). 
Previously, CCK4 was used to induce anxiety in two neuroimaging studies albeit only
in healthy volunteers (Benkelfat et al 1995; Javanmard et al 1999). The findings des-
cribed in the study of Benkelfat et al (1995) were falsely associated with a substantial
increase in bilateral temporopolar activation. Later this turned out to be an artifact
due to muscle contraction of the jaw (Drevets et al 1992). Furthermore, an increase
was observed in the blood flow of the insula/claustrum/amygdala region, which was
suspected to be an artifact too. The only reliable rCBF increase observed was loca-
ted in the anterior cingulate cortex. In the study of Javanmard et al (1999) the rCBF
was described on two different time-points after CCK4 administration. One minute
after CCK4 administration a decrease in rCBF in the medial frontal and the medial
temporal cortex and an increase in rCBF in the hypothalamus and the cerebellum
were observed, while two minutes after administration an increase in rCBF was
found in the superior temporal cortex, the claustrum/insula region and the cerebel-
lar vermis. These findings tend to support the rather controversial findings of the
increase in rCBF of the insula/claustrum/amygdala region described in the study of
Benkelfat et al (1995). Furthermore, it was concluded that the cerebellar vermis acti-
vation might be related more to the challenge procedure per se, because it was also
seen in a previous study on lactate-induced panic in healthy volunteers who did not
experience anxiety (Reiman et al 1989b).
The observed hyper- or deactivated cortical regions will be discussed in more detail
in the light of the fear network and the results of previous neuroimaging studies in
the field of anxiety.
Mainly increased rCBF was seen in frontal cortical areas, both in this study and in
previous studies. Activation in the orbitofrontal cortex and the prefrontal cortex was
shown in many functional imaging studies in various anxiety disorders with or wit-
hout provocation tests (Nordahl et al 1990; Rauch et al 1995; Rauch et al 1996;
Reiman et al 1997; Schwartz et al 1996; Shin et al 1999; Tillfors et al 2001). Anterior
cingulate gyrus activation was demonstrated in different studies using anxiety induc-
tion or provocation (Benkelfat et al 1995; Rauch et al 1997; Reiman et al 1997; Shin
et al 1999). The inferior frontal gyrus has efferent fibers stretching to the amygdala,
and processes stimuli leading to anxious arousal. This area is the most-frequently
determined region in emotion-related experiments (Maddock 1999). Increased rCBF
was observed before in different reports (Benkelfat et al 1995; Javanmard et al 1999),
although during state anxiety more often decreased rCBF was observed (Bremner et
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al 1997; Fischer et al 1998; Johanson et al 1998).
Increases in the parahippocampal gyrus and adjacent temporal structures, as obser-
ved in this study, are frequently reported in anxiety research (Bisaga et al 1998;
Boshuisen et al 2002; Nordahl et al 1990; Reiman et al 1997; Tillfors et al 2001). In
this region the processing and evaluation of sensory information relevant to anxiety
takes place. 
Blood flow changes in the retrosplenial cortex are observed in many emotion-related
experiments. Especially in experiments with negative emotions, e.g. anxiety
(Bremner et al 1999; Fischer et al 1996; McGuire et al 1994; Perani et al 1995;
Reiman et al 1997). This region has strong afferent inputs from the anterior cingula-
te cortex and the orbitofrontal cortex, and strong efferent connections to the para-
hippocampal and entorhinal cortices (Maddock 1999). 
In anxiety research few studies used to report specific activation of the amygdala,
even though this area has been considered to be crucial in the experiencing of anxie-
ty and fear and plays a central role in the fear network in the brain. Therefore,
LeDoux expects that because changes in the way fear-arousing stimuli are perceived
and responded to characterize all anxiety disorders, increased levels of activity in the
amygdala in both panic and PTSD patients should be seen (LeDoux 2002). This in-
creased blood flow in the amygdala region is frequently reported in different studies,
but certainly not in all anxiety-related studies (Liberzon et al 1999; Pissiota et al
2002; Tillfors et al 2001). Our findings show that activation of the amygdala is not
present during pentagastrin induced panic attacks in PD patients but is present
during anxious arousal in healthy control subjects participating in the same challen-
ge procedure. In an earlier study we described a deactivation of the amygdala during
anticipatory anxiety (Boshuisen et al 2002). These differences in the response of
patients and control subjects in the amygdala might be explained by the fact that
the amygdala in PD patients is already habituated to anxious arousal in connection
with panic. Inhibition of the amygdala could probably be a consequence of the inc-
reased rCBF of the prefrontal cortex, due to a cognitive representation of anticipato-
ry anxiety, present in PD patients but not in healthy control subjects. 
The rCBF in regions as the hypothalamus and the basal ganglia is covariated with
heart rate activity, as seen in a separate analysis checking for covariate interaction of
API, HR and MABP with rCBF in different regions.
An important limitation of the present study is the challenge procedure per se, whe-
rein there is a large chance of movement artifacts distorting the results, because of
the sometimes intense anxiety and the unpleasant sensations that are induced. We
examined our data in various ways to check if movement artifacts occurred, during
or between the scans. Small differences were controlled for by statistical procedures,
but when greater differences were observed the scans were excluded from the analy-
sis. Furthermore, no structural MRI scan was made. Therefore no direct compari-
sons for localization could be made. 
To conclude, we observed that both PD patients and healthy control subjects show-
ed a rather comparable pattern of brain activation after pentagastrin injection. The
most striking observation was the lack of activation of the amygdala in PD patients
during pentagastrin induced anxiety. In healthy control subjects we did find amygda-
la activation during pentagastrin induced anxious arousal. 
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This observed pattern of brain activation seems to be related to anxiety more than
to panic as a specific entity, because all regions observed are associated with anxie-
ty, and were observed before in different clinical and preclinical studies about anxie-
ty and anxiety disorders. 
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Abstract 
Background: Selective serotonin reuptake inhibitors (SSRIs) are considered the first
line treatment of panic disorder (PD). In this study we combined neuroimaging and
pentagastrin (a challenge agent) to evaluate the effect of SSRI treatment in PD
patients.
Methods: Six patients were studied twice with H215O PET scan, once before and once
after 12 weeks of successful treatment with sertraline. Four H215O PET scans were
made, all immediately after injection of pentagastrin (once) and saline (three
times). The data were compared with other pre- and posttreatment data of patients
who only participated in the neuroimaging study once, either before or after treat-
ment. 
Results: Before treatment all patients experienced a panic attack after pentagastrin
injection, while after succesful treatment only two of the six patients panicked. After
treatment we observed increases in the rCBF in the parahippocampal gyrus, the
midbrain, the thalamus and the hypothalamus as compared to the situation before
treatment, in rest as well as after pentagastrin injection. In the prefrontal cortex and
the orbitofrontal cortex posttreatment, a decrease was seen during rest, while an
increase was noticed during pentagastrin challenge as compared to the pretreat-
ment situation. 
Conclusions: The results of this study suggest that after succesful sertraline treat-
ment of PD patients there are still changes in rCBF during pentagastrin challenge,
but these changes are comparable to the changes seen in healthy control subjects,
and thus more related to a normal reaction on pentagastrin. This confirms our
hypothesis of partial normalization of rCBF patterns in PD patients after succesful
pharmacological treatment. 
Introduction
Panic disorder (PD) is a rather common disorder with a lifetime prevalence of
approximately 2% (American Psychiatric Association 1994). The pharmacological
treatment of first choice for PD at this moment is a selective serotonin reuptake
inhibitor (SSRI) (American Psychiatric Association Committee on Nomenclature and
Statistics 1998). SSRIs were shown in a number of studies to be more effective than
placebo and as effective as earlier treatments, such as benzodiazepines and tricyclic
antidepressants (Bakker et al 2000; Pollack and Marzol 2000; Sheehan 1999).
Because of the success of these pharmacological interventions, several biological
theories of PD have been proposed, including dysfunction of serotonergic and nora-
drenergic neurotransmitter systems (Westenberg et al 1996). At this moment neu-
roimaging, sometimes combined with treatment studies and/or symptom provocati-
on, is the most widely used technique to further clinically explore the neurobiology
of psychiatric diseases such as PD. 
A decreased binding to the benzodiazepine receptor was observed in PD patients
compared to control subjects (Bremner et al 2000; Kaschka et al 1995; Kuikka et al
1995; Malizia et al 1998; Schlegel et al 1994). Several neuroimaging studies evalua-
56
The Anxious Brain
17355 Bosh B  22-10-2003  14:20  Pagina 56
ted the effect of SSRIs in obsessive compulsive disorder (OCD) (Baxter et al 1992;
Benkelfat et al 1990; Saxena et al 1998; Saxena et al 2002; Swedo et al 1992), social
phobia (Furmark et al 2002; Van der Linden et al 2000), and PD (Nordahl et al
1998). The majority of these studies showed decreases of regional cerebral blood
flow (rCBF) in the caudate nucleus and/or the orbitofrontal cortex after succesful
treatment. Furthermore, the effect of behavioral treatment (cognitive behavioral the-
rapy or CBT) in OCD and in social phobia was evaluated by neuroimaging and com-
pared with the effect of pharmacological treatment (SSRI) (Baxter et al 1992; Brody
et al 1998; Furmark et al 2002). In all these studies both treatment strategies show-
ed similar effects, in symptom improvement as well as in decreases in brain activati-
on in different anxiety related brain regions. In addition, in social phobia patients
this design was combined with a symptom provocation test (Furmark et al 2002).
Significant posttreatment decreases in rCBF during symptom provocation were
observed in responders to both treatment strategies, SSRI and CBT, in the amygda-
la, hippocampus and parahippocampal cortex. 
Two case studies using symptom provocation in posttraumatic stress disorder
(PTSD) patients before and after SSRI treatment were published (Fernandez et al
2001; Levin et al 1999). The subjects in both studies felt significantly less anxious
during the posttreatment challenge, and in both studies changes in brain activation
were noted. In the study of Levin et al (1999) increases in rCBF were observed after
treatment during the challenge in the anterior cingulate cortex and the left frontal
lobe as compared to the pretreatment condition. In the study of Fernandez et al
(2001) it was noted that in the untreated condition trauma reminders resulted in
rCBF decreases in several anxiety related brain regions like the insula, the inferior
frontal and the prefrontal cortex, while after treatment this effect was not seen. In
PD patients only one study has been performed studying treatment effects with neu-
roimaging, and no provocation test was used in this case (Nordahl et al 1998).
Furthermore, the patients were not studied before and after treatment. The study
group consisted of only succesfully treated patients and was compared to a previ-
ous study group of unmedicated PD patients (Nordahl et al 1990).
The aim of the present study was to examine rCBF changes associated with a phar-
macological treatment response in PD patients. Therefore we used H215O PET to exa-
mine rCBF in PD patients before and after 12 weeks of sertraline treatment, both
during a pentagastrin challenge and at rest. As stated above, SSRIs are the first in
line of treatment for PD. Sertraline is one of the SSRIs proven to be effective in the
treatment of PD (Hirschfeld 2000; Londborg et al 1998; Pohl et al 1998; Pollack et al
1998; Rapaport et al 2001). 
Pentagastrin is a five-amino-acid-long peptide very much like cholecystokinin-4
(CCK4). Both agents have been shown to reliably induce panic attacks and anxiety,
especially in PD patients, but dependent on the dose also in healthy volunteers
(Abelson and Nesse 1990; de Montigny 1989; Van Megen et al 1994). The effect of
succesful fluvoxamine treatment in PD patients on CCK4-induced panic and anxiety
was studied before (van Megen et al 1997a). In this study 26 PD patients received,
before and after a double blind 8-week treatment period with fluvoxamine (n = 17) or
placebo (n = 9), a single blind bolus injection with 50 micrograms CCK4. Treatment
with fluvoxamine (150 mg daily) significantly decreased the sensitivity of PD patients
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for CCK4 while placebo was without effect. Of the patients who responded to treat-
ment, 83% no longer experienced a panic attack when rechallenged with CCK4, whe-
reas in the non-responders group this was only 28%. This study, among others, also
shows that CCK4 is a reliable panic provoking agent, which provokes panic attacks in
PD patients even when challenged for the second time (Bradwejn et al 1992b; van
Megen et al 1994; van Megen et al 1996a; van Megen et al 1997a). 
Based on the outcome of previous neuroimaging studies in anxiety disorders, we
expected to observe rCBF changes during pentagastrin challenge in anxiety related
brain regions such as the amygdala, the parahippocampal gyrus, the orbitofrontal
cortex, the prefrontal cortex, the thalamus and the hypothalamus, in the pretreat-
ment condition. In the posttreatment condition we hypothesized a partial normali-
zation of the rCBF in the aforementioned regions during pentagastrin challenge. 
Methods and Materials
Subjects
Six patients with PD (2 men/4 women) participated in the study twice (for demogra-
phic data see table 1). Another group of 10 PD patients participated only once, befo-
re treatment, while a small group of 3 patients was studied once after a succesful 12-
week treatment period with sertraline. All patients met the DSM-IV criteria of PD
with or without agoraphobia, as diagnosed by a psychiatrist (American Psychiatric
Association 1994). The subjects were physically healthy, as determined by history,
physical and neurologic examination, and had no comorbid psychiatric or neurolo-
gic diseases. All patients were free from medication for at least three weeks prior to
the first PET scan (in the case of fluoxetine for at least 6 weeks). The patients were
allowed to use oxazepam in the week before the PET scans, but not during the last
24 hours before the scan. The present levels of anxiety and depression in the
patients were obtained by the Hamilton rating scales for anxiety (HAS) (Hamilton
1959) and for depression (HDS) (Hamilton 1967) on the day of the PET scan (+/-
two days). None of the subjects was taking medication (other than oral contracepti-
ves: three women) or had a history of substance abuse. 
In the week following the first PET scan the patients started with sertraline 50 mg
once daily. The dose could be increased after one and after three weeks untill the
maximum dose of 150 mg daily was reached. After twelve weeks the effect of the tre-
atment was evaluated and the subjects were asked to participate again in the PET
scan and challenge procedure. Treatment response was defined as a decrease of
more than 50% on the HAS and/or a decrease in the number of panic attacks in the
two weeks preceding the assessment of at least 50%. None of the treatment non-
responders was willing to participate in the second scanning procedure. Finally nine
treatment responders decided to participate in the procedure, six of whom also par-
ticipated in the first scanning procedure. 
Because of the nature of the challenge test, in this study we choose to define a
panic attack with stricter criteria than stated in the DSM-IV: severe anxiety had to be
present during the panic attack, in addition to the criterion of at least 4 out of the 13
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symptoms. Pentagastrin in a dose of 40 micrograms induces panic-like symptoms
in 100% of the subjects, and most of the subjects also report feelings of anxiety. 
All subjects gave oral and written informed consent after complete explanation of
the nature and possible consequences of the study. The study was approved by the
medical ethical committee of the Groningen University Hospital. 
Procedure
The scanning procedure was performed twice, once before and again after a treat-
ment period of 12 weeks of sertraline treatment. During the scanning procedure, the
subjects were positioned in the scanner using a molded head rest with a strap over
the head to minimize head movement. Two marks were placed on the forehead and
nose of the subject to check for movement between the scans. The subjects were
instructed to lie quietly with their eyes open in a dimly lit room, without conversati-
on or noise, other than the noise from the scanner. First a 20-minute transmission
scan, used for attenuation correction, was made. After this scan all subjects were
scanned twice, before and after a pentagastrin challenge. Immediately after each
scan blood pressure (BP) and heart rate (HR) were measured, and the subjects
were asked about the panic-related symptoms experienced during the scan, with a
semi-structured interview based on the DSM-IV criteria for panic attacks (Acute
panic inventory, API). The API score was derived by counting the experienced anxiety
symptoms multiplied by the severity rating each subject gave per experienced symp-
tom. Furthermore subjects had to point out on a separate five-point scale how anxi-
ous they felt immediately after the injection. 
Scanning was done between 11.30 am and 2.30 p.m., with a Siemens ECAT EXACT
HR+ whole-body PET camera operating in high sensitivity 3D mode. Subjects recei-
ved a total of 500 MBq of H215O per scan over 20 seconds through a forearm canula.
The first scan was started at the moment of injection and lasted 120 seconds. Since
the time required for the radioactive water to reach the brain is between 20 and 25
seconds in the injection system used, the effective scanning time is 95-100 seconds. 
Data are reconstructed by filtered backprojection with a zoom factor of 2.25. A
Hamming filter with a cut-off frequency of 0.5 cycles/pixel is used. The resulting
images have a nearly isotropical spatial resolution of roughly 5 mm FWHM (full
width at half maximum).
Data-analysis
Statistical analyses for differences in the demographic, behavioral and physiological
data were performed using SPSS for Windows version 10. Within and between
group analyses were performed by t-tests and analysis of variance (ANOVA), using a
level of significance of 5% in two-tailed testing.
The PET scan data were processed and analyzed with statistical parametric mapping
software (SPM99, Wellcome department of Cognitive Neurology, London, UK)
(Friston et al 1995), implemented in Matlab (Mathworks, Sherborn, MA, USA). The
scans of all subjects were realigned and normalized to the MNI (Montreal
Neurological Institute) template, using heavy regularization. Images were smoothed
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with an 8 mm FWHM Gaussian kernel. 
Activation differences in terms of hyper- and hypoactivity in rCBF pre- and posttreat-
ment were tested voxel-by-voxel by ANOVA. The analyses concerning pentagastrin-
induced panic were performed on the data of the patients who experienced penta-
gastrin-induced panic pretreatment and the patients who did not panic posttreat-
ment. Differences over the scans in the main group of six subjects who participated
twice in the procedure were analyzed by a so-called multisubject analysis, an
ANOVA within-group analysis. Overall group and state differences were also tested,
in all PD subjects scanned before treatment versus all PD subjects scanned after
succesful treatment, by a multigroup analysis, wherein both groups were compared
with ANOVA, with one between-group factor (before versus after treatment) and
one within-group factor (pentagastrin-induced panic attack versus no panic attack). 
Clusters with voxel differences achieving a threshold of Z =  3.30 (corresponding to
a p-value < 0.001 uncorrected) were displayed in three orthogonal projections on
SPM glass brain projections. The statistical parametric maps (SPMs) were inspec-
ted for the presence of findings in unpredicted regions; these were reported signifi-
cant only if resisting correction for multiple comparisons based on the Gaussian
random field theory (Friston et al 1996) and using the statistical procedures for con-
trolling the false discovery rate (Genovese et al 2002) (p<0.05). Secondly the SPMs
were inspected for the presence of voxel clusters of statistical significance in regions
where abnormalities were predicted a priori (regions of interest were the different
regions of the fear network in the brain); these regions were reported only if the
uncorrected p-value was less than 0.001. SPM99 calculates corrected statistics
across the whole brain, by working out the shape and size of the whole brain volu-
me in the analysis and calculating the correction accordingly (Worsley et al 1996).
The stereotactic coordinates of the peak differences were determined using the
Talairach and Tournoux atlas (Talairach and Tournoux 1988), after translating the
MNI coordinates to coordinates according to the Talairach template, by using the
matlab function mni2tal.m as described by M. Brett on the website of the
Cambridge Imagers Group (http//www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html). 
Results
The effects of twelve-week treatment with sertraline
The scores on the HAS and the HDS, and the number of experienced panic attacks
per week decreased significantly over the twelve-week treatment period. The mean
score on the HAS decreased more than 50%, from a mean score of 25 (4) to a mean
score of 11 (5) (mean (SD); see table 1; t = 5.4; df = 10; p < 0.000), and the score on
the HDS decreased from 12 (2) to 5 (3) (mean (SD); t = 4.2; df = 10; p = 0.002).
Only two of the patients experienced a panic attack in the week preceding the
second PET scanning procedure, while they were free of panic attacks in the two
weeks before. The other patients were free of panic attacks for at least four weeks. 
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Mean age (SD) 40 (16.7) NA
Mean no. panic attacks/2 wks (SD) 4.5 (1.0) 0.3 (0.5) < 0.01
No. males / female 2/4 NA
Mean HAS (SD) 25.3 (4.0) 10.7 (5.3) < 0.01
Mean HDS (SD) 11.8 (2.0) 4.8 (3.5) < 0.01
Behavioral and physiological results 
MABP prechallenge (SD) 115.2 (15.3) 109.2 (6.2) 0.393
MABP challenge (SD) 116.3 (18.0) 116 (7.3) 0.967
MABP postchallenge (SD) 109.8 (17.5) 116 (20.6) 0.588
Mean HR prechallenge (SD) 80.7 (21.6) 76.5 (12.3) 0.690
Mean HR challenge (SD) 81.5 (19.6) 78.7 (12.1) 0.769
Mean HR postchallenge (SD) 78.8 (18.2) 70.5 (10.1) 0.351
API prechallenge (SD)3.2 (3.2) 0.8 (1.0) 0.118
API challenge (SD) 22.3 (6.3 13.3 (5.6)) 0.026
API postchallenge (SD) 1.3 (1.8) 0.3 (0.5) 0.209
Legend: SD = standard deviation, HAS = Hamilton rating scale for anxiety, HDS = Hamilton rating scale for
depression, MABP = mean arterial blood pressure, HR = heart rate, API = Acute Panic Inventory.
The mean number of panic attacks in the two weeks preceding the scanning proce-
dure decreased from 4.5 (1) to 0.3 (0.5) (mean (SD); see table 1; t = 8.7; df = 10; p <
0.000). 
Differences in blood pressure and heart rate with treatment
No significant differences were seen in mean arterial blood pressure (MABP) and
heart rate (HR) between the pretreatment and the posttreatment state (table 1).
During the pentagastrin challenge no significant increase of MABP and HR was
seen, although there was a trend visible, especially in the posttreatment condition
(p-values between 0.06 and 0.10). 
Differences in symptomatology after pentagastrin injection following 
sertraline treatment
In the pretreatment condition all PD patients experienced a panic attack according
to DSM-IV criteria during pentagastrin challenge. After treatment only two of these
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Table 2 
Coordinates and z-scores of peak voxels of brain regions where
differences were observed in PD patients during rest and after
pentagastrin challenge after 12-week succesful treatment
Decreases posttreatment x-coord y-coord z-coord Z-score
in rest
parahippoc gyrus right 12 -46 -8 4,03
parahippoc gyrus right 32 -34 -10 2,66
parahippoc gyrus left -34 -32 -10 3,12
parahippoc gyrus left -22 -38 -8 2,69
thalamus 14 -6 12 4,13
hypothalamus 6 -4 -2 3,73
midbrain 8 -38 -16 5,23
ant cing gyrus left -4 40 0 2,51
ant cing gyrus right 6 34 2 2,36
Increases posttreatment x-coord y-coord z-coord Z-score
in rest
insula left -36 20 18 4,54
insula right 40 0 8 3,24
med frontal gyrus left -42 40 16 3,47
med frontal gyrus right 42 38 8 3,37
Decreases posttreatment x-coord y-coord z-coord Z-score
during pentagastrin
challenge
parahippoc gyrus right 8 -30 -20 5,23
parahippoc gyrus right 12 -38 -10 3,94
parahippoc gyrus left -14 -22 -24 3,27
parahippoc gyrus left -16 -30 -20 3,12
basal ganglia/thalamus 16 -4 14 3,37
hypothalamus -4 -8 -4 3,39
temporal lobe right 28 -6 -34 3,36
temporal lobe left -18 4 -30 2,49
amygdala right 20 -4 -20 2,93
Decreases posttreatment x-coord y-coord z-coord Z-score
during pentagastrin
challenge
orbitofrontal cortex right 16 32 -18 4,12
orbitofrontal cortex left -20 52 -18 3,51
ant cing gyrus ri 2 20 50 4
precentr gyrus ri 38 0 20 3,17
precentr gyrus le -40 -2 -20 2,52
Legend: The coordinates of maximal change of the main voxels according to the Talairach and Tournoux atlas
(1988), after translation of the coordinates via the function mni2tal (Brett, 1999); Z-scores presented are signifi-
cant with a P < 0.05 corrected with false discovery rate (Genovese et al, 2002).
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Fig. 4-1A Fig. 4-1B
SPM glass brain showing the regions SPM glass brain showing the
where in rest decreases were observed regions where in rest increases
after 12-week succesful sertraline were observed after 12-week 
treatment succesful sertraline treatment
patients experienced a panic attack according to DSM-IV criteria, although the num-
ber of symptoms experienced during this panic attack were less than before, and
they felt less anxious. Both before (t = 6.6; df = 5; p < 0.001) and after (t = 5.6; df =
5; p < 0.003) treatment the API score increased significantly during the pentagastrin
challenge, and decreased again during the resting condition. As can be seen in table
1, after treatment with sertraline there was a diminished increase in the API score
during the challenge procedure. 
Changes in rCBF in rest pretreatment versus posttreatment 
Figure 1 shows the differences in brain activation between the pretreatment and the
posttreatment resting state (the last scan). Posttreatment rCBF decreased (fig. 4-1A)
in the right parahippocampal gyrus, the right orbitofrontal cortex, the right anterior
cingulate cortex, the right thalamus, the hypothalamus, the right basal ganglia, the
midbrain and the pons, and increased (fig. 4-1B) in the precuneus bilaterally, and in
the left medial and inferior frontal cortex. In table 2 the coordinates and z-scores of
the peak voxels are shown. When we compared these data with the data of all sub-
jects scanned pretreatment (N=16) with all subjects scanned posttreatment (N=9) a
comparable rCBF pattern was seen. 
We used the final scan as the resting condition because anticipatory anxiety was pre-
sent during the first scan (the prechallenge scan) in the PD patients, as described in
an earlier paper (Boshuisen et al 2002). 
Changes in rCBF during pentagastrin challenge: pretreatment
During pentagastrin challenge in the pretreatment condition we observed increases
in rCBF of the inferior frontal gyrus, the right postcentral gyrus, the right thalamus,
the left cerebellum and the left orbitofrontal gyrus (for coordinates of the peak
voxels see table 2). Decreases in rCBF pretreatment during pentagastrin challenge 
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Fig. 4-2A Fig. 4-2B
SPM glass brain showing the regions SPM glass brain showing the 
where during pentagastrin challenge regions where during pentagastrin 
decreases were observed after 12-week challenge increases were observed 
succesful sertraline treatment after 12-week succesful
sertraline treatment
were seen in the right superior frontal gyrus, the right inferior parietal region, the
right inferior temporal region and the left thalamus (see table 2). This pretreatment
pattern of brain activation closely matched with the pattern found in a larger group
of untreated PD patients after the injection of pentagastrin (Boshuisen et al 2002). 
Changes in rCBF during pentagastrin challenge: posttreatment
During the pentagastrin-induced anxiety after succesful sertraline treatment we
noted increases in rCBF of the right cerebellum, the temporal region, the
lingual/parahippocampal region, the left thalamus, the basal ganglia (caudate and
putamen), the right posterior cingulate gyrus, the left inferior parietal region (see
table 2). Decreases in rCBF were determined in the inferior and superior parietal
lobulae, the right fusiform gyrus, the cuneus and the right orbitofrontal gyrus (see
table 2). 
Changes in rCBF during pentagastrin challenge pretreatment versus posttreatment
During pentagastrin rechallenge, after treatment, we observed a decrease in rCBF in
the bilateral parahippocampal gyrus, the bilateral lingual gyrus, the right thalamus,
the hypothalamus and the midbrain. An increase in rCBF after treatment was seen
in the bilateral prefrontal cortex, the bilateral orbitofrontal cortex, the medial frontal
cortex and the retrosplenial cortex. The areas of decreased and increased rCBF
during pentagastrin challenge after succesful treatment compared to the situation
before treatment are shown in figures 4-2A and 4-2B. The coordinates and z-scores
of the peak voxels are presented in table 2. A comparable pattern of activation was
also seen in the whole group of subjects scanned before and after treatment.
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Overall comparison of pentagastrin versus rest before and after treatment 
First, this multigroup analysis was performed on the data of the PD patients who
participated twice in the study (N=6). Posttreatment during the pentagastrin chal-
lenge versus rest, a decrease was seen in left parietotemporal regions, the left peria-
queductal gray (PAG), and in the right parahippocampal, lingual and fusiform gyrus.
An increase in the rCBF was noticed in the thalamus, the left amygdala, the right
inferior frontal gyrus and the posterior cingulate gyrus (see figure 4-3, colorfigure
om page 123, and table 2).
Second, this multigroup analysis was performed with data from all PD patients who
participated in the pretreatment scanning procedure and compared with the data of
all PD patients who participated in the posttreatment scanning procedure.
Posttreatment during the pentagastrin challenge versus rest a decrease in activation
was seen in the right inferior temporal lobe, the right retrosplenial cortex and the
left prefrontal cortex. An increase in rCBF during pentagastrin versus rest in the
posttreatment condition was seen in the left pre- and postcentral gyrus and the right
fusiform gyrus. 
Discussion 
After twelve weeks of sertraline treatment, PD symptom severity was significantly
reduced in all participating PD patients. The mean level of anxiety as measured by
the HAS decreased by more than 50% and the mean number of panic attacks in the
two weeks preceding the challenge procedure decreased significantly from 4.5 to
0.3. Alleviation of PD symtoms as a result of 12-week successful sertraline treatment
was associated with a significant decrease in the number and severity of the panic
attacks following pentagastrin administration. The pentagastrin-induced panic rate
decreased from 100% to 33% in this subgroup of patients. A similar effect was pre-
viously observed in a study about the effect of the SSRI fluvoxamine on CCK4-indu-
ced panic attacks (van Megen et al 1997a). Patients who were successfully treated
with fluvoxamine showed a significantly reduced response to rechallenge with CCK4.
In nonresponders to fluvoxamine however, CCK4 was still able to induce panic
attacks. In this study by van Megen et al (1997a) a lower rate of panic attacks was
noticed both before and after treatment than in our study, even though in our study
pentagastrin was used in a lower dose than the (usually more potent) CCK4. We
assume that this is a consequence of the additional anxiety-inducing effect of lying
in the PET camera and not being allowed to move or talk. This condition is more
stressful and therefore may increase the likelyhood for the subsequent development
of a panic attack. The panic rate during pentagastrin administration after treatment
with sertraline, is comparable to that observed in healthy control subjects, both in
our study and in previous studies (between 5 % and 47 %, depending on the dosa-
ge) (Boshuisen et al 2002; Bradwejn et al 1991a; van Megen et al 1994). 
During pretreatment pentagastrin challenge we observed increases in rCBF of the
inferior frontal gyrus, the right postcentral gyrus, the right thalamus, the left cerebel-
lum and the left orbitofrontal gyrus. Decreases were seen in the right superior fron-
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tal gyrus, the right inferior parietal region, the right inferior temporal region and the
left thalamus. This type of anxiety provocation study has been done before during
neuroimaging, in different anxiety disorders including PD, although PD (Reiman et
al 1989b; Stewart et al 1988; Woods et al 1988) is the least studied of the anxiety
disorders, and most studies were conducted several years ago, especially as compa-
red to the research in PTSD patients (Bremner et al 1997; Bremner et al 1999;
Fischer et al 1996; Liberzon et al 1999; Pissiota et al 2002; Rauch et al 1996; Shin et
al 1999). This is probably due to the difficulties with panic provocation in the scan-
ner, concerning timing and duration of the panic attack as well as problems concer-
ning physical movement of the patient. In our own study of (untreated) PD patients
experiencing pentagastrin-induced panic attacks we observed increases in rCBF in
the parahippocampal gyrus/fusiform gyrus, the prefrontal cortex, the left orbitofron-
tal cortex, the left inferior frontal gyrus, the cerebellum and the left basal ganglia,
while decreases were noted in the superior frontal gyrus, the medial and inferior
temporal lobe, the thalamus, the hippocampus, the insula and the orbitofrontal/pre-
frontal cortex (Boshuisen et al, submitted). In the study of Tillfors et al (2001) inc-
reases in rCBF during provoked anxiety (speaking in public) in social phobia
patients were noted in the right amygdaloid complex, while decreases were seen in
the insula, the retrosplenial cortex, the right parietal cortex, the right secondary visu-
al cortex, the perirhinal cortex and the temporal pole. The regions in which rCBF
decreases were observed, are similar to the regions in which we observed rCBF dec-
reases. All these brain regions have been implicated in anxiety processing in the
brain (Davis 1997; Gorman et al 2000; LeDoux 1998; Windmann 1998). In contrast
to this study by Tillfors et al (2001) and in contrast to our own expectation, we did
not find an increase in activation in the amygdala during anxiety, even though this
region seems to be crucial in anxiety regulation (LeDoux 2002). 
In patients suffering from combat-related PTSD, anxiety provocation by combat-rela-
ted sounds, increased rCBF in the premotor cortex, the primary motor cortex, the
primary sensory cortex, the cerebellar vermis and the PAG. Decreases were observed
in the retrosplenial cortex and the posterior cingulate cortex (Pissiota et al 2002). 
In obsessive compulsive disorder there is converging evidence suggesting the invol-
vement of the orbitofrontal cortex, and this area is also a region of interest in other
anxiety disorders. In a recent symptom provocation study in contamination-related
OCD, rCBF increases were found during symptom provocation in the orbitofrontal
cortex, and furthermore in other frontal cortical areas (including the premotor cor-
tex) and the precuneus. In this study no significant activation was observed in other
previously predicted regions participating in OCD like the anterior cingulate cortex
and the caudate nucleus (Rauch et al 2002). The only recent symptom provocation
study in PD patients was done after CO2 inhalation, but in this study the global cere-
bral blood flow (gCBF) was studied, instead of rCBF as in most other studies.
Therefore it is difficult to compare the outcome of this study with the other neuroi-
maging studies. The final conclusion of this study is that PD patients when expe-
riencing symptoms of a panic attack exhibit an abnormal pattern of gCBF (Ponto et
al 2002). 
When we compare pentagastrin challenge pretreatment with the rechallenge after
sertraline treatment, we noted an rCBF decrease in the bilateral parahippocampal
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gyrus, the bilateral lingual gyrus, the right thalamus, the hypothalamus and the mid-
brain. An increase in brain activity after treatment with sertraline was seen in the
bilateral prefrontal cortex, the bilateral orbitofrontal cortex, the medial frontal cortex
and the retrosplenial cortex. Only one study has used the same paradigm (Furmark
et al 2002). This group studied 18 social phobia patients during a stressful speaking
task (symptom provocation) both before and after treatment. The group was divided
in three different subgroups, for the different treatment conditions (SSRI, cognitive
behavioral group therapy (CBG) and a waiting list control group). They observed
within the SSRI and CBG treated groups a decreased rCBF response to public spea-
king in the amygdala, hippocampus and periamygdaloid, rhinal and parahippocam-
pal cortices. The rCBF in these regions decreased significantly more in the subjects
of the treated groups than in the control subjects, and in responders than in non-
responders, particularly in the right hemisphere. In several regions outside the tem-
poral lobe more specific treatment effects were observed. In the CBGT group, e.g.,
rCBF decreased in the PAG, while increases were noted in the cerebellum and the
secondary visual cortex. In the SSRI group the decreases were located in the thala-
mus and the inferior frontal area. Responders versus non-responders exhibited spe-
cific decreases in the inferior frontal region, the dorsolateral prefrontal region and
the anterior cingulate region. Furthermore, a case study in PTSD reported a normali-
zation of the rCBF in the insula, prefrontal cortex, inferior frontal cortex, cerebellum,
precuneus and supplementory motor cortex after succesful SSRI treatment
(Fernandez et al 2001). The rCBF pattern observed in this study is thus in several
aspects the same as described in our study, with the exception of the decrease in
the amygdala, even though we did find a decrease in the parahippocampal gyrus. 
When we compared the rCBF of PD patients at rest posttreatment with the rCBF at
rest pretreatment, we observed a decrease in the right parahippocampal gyrus, the
right orbitofrontal cortex, the right anterior cingulate cortex, the right thalamus, the
hypothalamus, the right basal ganglia, the midbrain and the pons, and an increase
in the precuneus bilaterally, and in the left medial and inferior frontal cortex. These
results indicate that even in the resting condition anxiety related brain areas show
changes in rCBF, possibly revealing the decrease of anticipatory anxiety experienced
by the patients after succesful therapy. One of the most recent comparable publicati-
ons reporting about the effect of SSRI treatment on rCBF in anxiety disorders is the
study of Saxena et al (2002) in which OCD patients were treated with paroxetine. In
this study significant rCBF decreases (no increases) were found in the right caudate
nucleus, the right ventrolateral prefrontal cortex, the orbitofrontal cortex and the tha-
lamus. Interestingly, these brain metabolic responses were confined to patients with
a diagnosis of OCD alone, and were not present in patients suffering from OCD and
comorbid major depressive disorder. 
We observed changes in rCBF in PD patients during pentagastrin challenge as com-
pared to rest in the pretreatment condition, indicating the panic attack. Even post-
treatment, different fear network related brain regions showed changes in rCBF
during pentastrin challenge as compared to rest. These rCBF changes reflect a level
of anxious arousal comparable to what we have observed previously in healthy vol-
unteers after pentagastrin or CCK4 injection (Boshuisen et al, submitted). 
Two CCK4 provocation tests were performed during neuroimaging in healthy volun-
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teers (Benkelfat et al 1995; Javanmard et al 1999). In one of the studies increases in
rCBF were found in the insula, the cerebellar vermis and the anterior cingulate cor-
tex (Benkelfat et al 1995), and no decreases were reported. In the other study the
effect of CCK4 was reported at two time points: one minute after CCK4 adminstrati-
on an increase was found in the cingulate and medial frontal cortex, and a decrease
in the occipital cortex and hippocampus. Two minutes after CCK4 administration an
increase was observed in the cerebellum and hypothalamus, and a decrease in the
medial frontal and medial temporal cortex (Javanmard et al 1999). Both studies
show rCBF changes in regions comparable to the areas in which we detected rCBF
changes in our study. Although clearly different rCBF changes were discovered at
one or two minutes after CCK4 injection, in our study scans were made immediately
after injection and we observed activation in almost the same brain regions. 
We observed rCBF changes in brain regions, considered to be part of the fear net-
work, during different conditions both pre- and posttreatment. The effect of succes-
ful treatment with sertraline also brought about some normalization of rCBF chan-
ges as shown by the comparison with the results of anxiety provocation in healthy
volunteers. This led us to believe that maybe panic and anxiety are not different enti-
ties, but neuronal fear network threshold related differences. After crossing a certain
threshold, anxiety may become panic. It is also conceivable that the threshold of
anxiety in PD patients is lower than in healthy control subjects. Based upon this,
one may argue that antipanic drugs exert their clinical effects by virtue of increasing
this threshold, for example by improving the cerebral plasticity in the brain. In a
recent study it was shown that antidepressants (imipramine and fluoxetine) in mice
increased neurotrophin signaling in the prefrontal cortex. This may induce formati-
on and stabilization of synaptic connectivity, which gradually leads to the clinical
behavioral effects of antidepressants (Saarelainen et al 2003). 
A limitation of the present study is the small sample size. Only six patients were
studied both before and after treatment, and thus suitable for paired comparison
analyses. Therefore we choose also to compare our complete pretreatment and
posttreatment PD patients groups. This resulted in an additional comparison of 16
patients pretreatment versus nine patients posttreatment. The results confirmed the
above results of the actual study group. Furthermore, because the outcome of the
study is strongly comparable to a priori predicted regions of change, we expect that
our results can nevertheless be used for conclusions. 
The panic rate on pentagastrin challenge decreased significantly after successful ser-
traline treatment. This decrease is considered to be an effect of treatment rather
than a habituation effect to the rechallenge with pentagastrin. Different studies pre-
viously have shown that the effects of CCK4 and pentagastrin are reproducible when
subjects were rechallenged (Bradwejn et al 1992b; Bradwejn and Koszycki 1994a;
van Megen et al 1994; van Megen et al 1996a; van Megen et al 1997a).
Immediately after the pentagastrin challenge no significant increase in HR and
MABP could be observed in the subjects. This was an unexpected result, because
cardiovascular effects are an important feature of panic attacks. We think that this
may be due to the time delay between the induction of the panic attack and the
measurements of HR and MABP. The panic attack had subsided when measuring
HR and MABP, and it is conceivable that therefore no significant increase could be
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detected. It has been observed before that the increase of HR and MABP induced by
pentagastrin and CCK4 is shortlived, and thus may be missed (Bradwejn et al 1990;
de Montigny 1989; Shlik et al 1999).
In conclusion, the results of this study suggest that after succesful sertraline treat-
ment of PD patients there are still changes in rCBF during pentagastrin challenge,
but these changes are comparable to the changes seen in healthy control subjects,
and thus more related to a normal reaction on pentagastrin than panic per se. This
confirms our hypothesis of partial normalization of rCBF patterns in PD patients
after succesful pharmacological treatment. It might be interesting to study the same
parameters in a larger study group, comparing pharmacological treatment with cog-
nitive behavioral therapy. 
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Abstract 
Background: Cholecystokinin in the form of CCK4 and CCK5 (pentagastrin) has been
repeatedly used as a challenge agent in panic disorder. The aim of this paper is to
further elucidate the usefulness of pentagastrin as a challenge agent in panic disor-
der research. 
Methods: Seventeen panic disorder patients were scanned with H215O PET, once
after pentagastrin injection and three times after saline injection. During the proce-
dure five panic disorder patients experienced a spontaneous panic attack while
being scanned during what was supposed to be a resting scan. We compared the
pattern of brain activity during spontaneous panic attacks with the brain activity
generated by pentagastrin induced panic attacks.
Results: No rCBF differences could be observed between the spontaneous and the
pentagastrin induced panic attacks, although the acute panic inventory score and
the heart rate were higher during the pentagastrin induced panic attack. 
Conclusion: Our observation strengthens the notion that pentagastrin is a reliable
and useful panic-inducing agent, and adequately models naturally occurring panic
attacks. 
Introduction
In panic disorder (PD), an invalidating and rather common psychiatric disease,
patients experience recurrent unexpected panic attacks, accompanied by at least one
month of persistent concern about having another attack, worrying about implicati-
ons or behavioral changes related to panic attacks (American Psychiatric
Association 1994). Nowadays, selective serotonin reuptake inhibitors (SSRIs) are
the pharmacological treatment of first choice for PD. Because of the successful
pharmacological treatment possibilities, several biological theories of PD have been
proposed, including dysfunction of serotonergic and noradrenergic neurotransmitter
systems. Nevertheless, until now the neurobiology of PD remains unclear. Until
recently the most widely used technique to explore the neurobiology of PD was to
pharmacologically induce panic attacks in PD patients and healthy control subjects.
In PD several challenge agents have been used (Bourin et al 1995), such as sodium
lactate (den Boer et al 1989; Liebowitz et al 1985), CO2 (Griez et al 1990; Pols et al
1994), yohimbine (Albus et al 1992; Charney et al 1992), caffeine (Lee et al 1988;
Mathew and Wilson 1990b), cholecystokinin (CCK) (Bradwejn et al 1991b; Bradwejn
and Koszycki 1994b; van Megen et al 1996b) and pentagastrin (Brawman et al 1997;
van Megen et al 1994). CCK analogues as challenge agents offer several advantages
over other challenge agents such as sodium lactate, CO2, yohimbine and caffeine.
CCK is a neurotransmitter present in the human central nervous system (CNS), for
which neuronal pathways and receptors have been identified (Bradwejn et al 1990).
CCK is injected intravenously in small quantities as a bolus injection. The relatively
protracted infusion interval of particularly sodium lactate infusion has been associa-
ted with physiological alterations such as volume-overload, and metabolic changes
that can introduce nonspecific psychological effects (Margraf et al 1986). CCK is
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mainly used in the four-amino-acid variant (CCK4), which has been proved to induce
panic attacks in PD patients. Pentagastrin is the five-amino-acid variant of CCK, con-
taining CCK4 amino-acids as its terminal sequence. Another technical advantage of
CCK administration is that the potentiality to effect symptoms of panic with CCK4 is
rapid and predictable, permitting measurement of central and peripheral nervous
system activity during the interval associated with peak panic symptoms. The panic
attack following CCK4 administration appears within seconds after injection, and the
effect disappears again within a few minutes. Considered together, the technical
advantage of CCK administration, coupled with its presence in the CNS, commends
its use for research into the pathophysiology of PD.  
CCK4 and pentagastrin provoke panic attacks in a dose-dependent matter (Bradwejn
et al 1991b). PD patients have an increased sensitivity for the anxiogenic properties
of CCK4 and pentagastrin, as compared to healthy volunteers (Bradwejn et al 1992a;
van Megen et al 1994). The phenomenology of the symptoms of the CCK4 or penta-
gastrin induced panic attack has been reported to be very similar to naturally occur-
ring panic attacks (Abelson et al 1994; Abelson and Nesse 1994; Bradwejn et al
1990; Bradwejn et al 1992b; Bradwejn 1993; Brawman et al 1997; Koszycki et al 1991;
McCann et al 1997; van Megen et al 1994; van Megen et al 1996b).  
It is suggested that a valid experimental model for PD should satisfy seven criteria
(Gorman et al 1987; Guttmacher et al 1983). CCK4 and pentagastrin satisfy most of
these criteria for a panicogenic agent: it is safe for humans, induces emotional and
somatic symptoms of a panic attack, reproduces symptoms of spontaneous panic
attacks, shows dose-dependent and reproducible effects, is antagonized by antipa-
nic agents and is not antagonized by non-antipanic agents (Bradwejn 1993; van
Megen et al 1996a). An important remaining question remains whether pharmaco-
logically induced panic activates the same fear network in the brain as spontaneous
panic. If so, this would add further evidence to the validity of pentagastrin induced
panic as a model for naturally occurring panic attacks. 
At this moment neuroimaging is the most widely used technique to further explore
the neurobiology of psychiatric diseases like PD. Neuroimaging research conducted
in panic and anxiety disorders has studied cerebral blood flow (CBF), glucose meta-
bolism and benzodiazepine receptor functioning in anxious patients during anxiety
and at rest, as well as during provoked anxiety in healthy control subjects (Bisaga et
al 1998; Malizia et al 1998; Nordahl et al 1990; Reiman et al 1989b; Schlegel et al
1994; Stewart et al 1988). 
In our study we induced panic in PD patients as well as anxiety in healthy control
subjects by means of pentagastrin infusion, and we observed rCBF differences
during different anxiety states. Some of the PD patients experienced spontaneous
panic attacks during the scanning procedure, and the data resulting from these
scans are compared to the data derived from the pentagastrin induced panic attack
scans. If the rCBF pattern in the brain during spontaneous panic attacks would be
similar to the pattern observed during pentagastrin induced panic, this would add
further evidence to the validity of pentagastrin induced panic as a model for natural-
ly occurring panic. In this paper we describe the results of this comparison between
spontaneous and pentagastrin induced panic. 
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Methods and Materials
Subjects
The original study consisted of four H215O scans, one of which (the second or the
third) was made after pentagastrin injection. The study was conducted to examine
rCBF during panic and anxiety in patients with PD and in healthy control subjects.
During this study, six PD patients experienced a spontaneous panic attack during
one of the non-pentagastrin scans. Five of these spontaneous panic attacks were
actually scanned. We decided to compare the rCBF during these spontaneous panic
attacks with the rCBF during the pentagastrin induced panic attacks. 
Seventeen patients with PD (5 men/12 women) were included in the original study
(for demographic data see table 1). All patients met the DSM-IV criteria of PD with
or without agoraphobia, as diagnosed by a psychiatrist (American Psychiatric
Association 1994). The subjects were physically healthy, as determined by history,
physical and neurologic examination, and had no comorbid psychiatric or neurolo-
gic diseases. All patients were free from medication for at least three weeks prior to
the PET scan (in the case of fluoxetine for at least 6 weeks). The patients were allo-
wed to use oxazepam in the week before the PET scan, but not during the last 24
hours before the scan. The present levels of anxiety and depression in the patients
were obtained by the Hamilton rating scales for anxiety (Hamilton 1959) and for
depression (Hamilton 1967). None of the subjects was taking medication (other
than oral contraceptives) or had a history of substance abuse. 
We choose to define a panic attack in this study with stricter criteria than stated in
the DSM-IV: moderate to severe anxiety had to be present during the panic attack,
in addition to the criterion of at least 4 out of the 13 symptoms.
All subjects gave oral and written informed consent after complete explanation of
the nature and possible consequences of the study. The study was approved by the
medical ethics committee of the Groningen University Hospital. 
Procedure
Subjects were positioned in the scanner using a molded head rest with a strap over
the head to minimize head movement. Two marks were placed on the forehead and
nose of the subject to check for movement between the scans. The subjects were
instructed to lie quietly with their eyes open in a dimly lit room, without conversati-
on or noise, other than the noise from the scanner. First a 20-minute transmission
scan, used for attenuation correction, was made. After this scan all subjects were
scanned four times. Once or twice before, once during and one or two times after
pentagastrin challenge. Immediately after each scan blood pressure (BP) and heart
rate (HR) were measured, and the subjects were asked about the anxiety symptoms
experienced during the scan, using a semi-structured interview based on the DSM-
IV criteria for panic attacks (acute panic inventory, API). The API score was derived
by counting the experienced anxiety symptoms multiplied by the severity rating each
subject gave per experienced symptom. Furthermore subjects had to point out on a
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separate five-point scale how anxious they felt immediately after the injection of
pentagastrin or placebo. 
Scanning was done between 11.30 am and 2.30 p.m., with a Siemens ECAT EXACT
HR+ whole-body PET camera operating in high sensitivity 3D mode. Subjects recei-
ved a total of 500 MBq of H215O per scan over 20 seconds through a forearm canula.
The first scan was started at the moment of H215O injection and lasted 120 seconds.
Since the time required for the radioactive water to reach the brain is between 20
and 25 seconds in the injection system used, the effective scanning time is 95-100
seconds. The subsequent scans consisted of two frames. The first frame lasted 30
seconds and was used for background correction. The second frame lasted for 120
seconds, as in the first scan. Injection of the radioactive water was at the start of
this second frame. Data were reconstructed by filtered backprojection with a zoom
factor of 2.25. A Hanning filter with a cut-off frequency of 0.5 cycles/pixel was used.
The resulting images have a nearly isotropic spatial resolution of roughly 5 mm
FWHM (full width at half maximum).
Data-analysis
Statistical analyses for differences in the behavioral and physiological data were per-
formed using SPSS for Windows version 10. Analyses were performed with a
Students t-test, using a level of significance of 5%.
The PET scan data were processed and analyzed with statistical parametric mapping
software (SPM99, Wellcome department of Cognitive Neurology, London, UK)
(Friston et al 1995), implemented in Matlab (Mathworks, Sherborn, MA, USA). The
scans of all subjects were realigned and normalized to the MNI (Montreal
Neurological Institute) template, using heavy regularization. Images were smoothed
with an 8 mm FWHM Gaussian kernel. 
First, activation differences in terms of rCBF increases and decreases between the
spontaneous panic attacks and baseline rest, and the differences between the penta-
gastrin induced panic attacks and baseline rest were tested voxel-by-voxel by
ANOVA. The analyses were performed with a so-called multisubject analysis, an
ANOVA within-group analysis, in the group of five subjects who experienced both a
spontaneous and a pentagastrin induced panic attack. Second, activation differen-
ces of pentagastrin induced panic attacks versus spontaneous panic attacks were
tested voxel-by-voxel by ANOVA. The analyses were performed on the data of the
panic disorder patients who experienced a spontaneous panic attack during one of
the scans made after saline injection, and were compared to the data of the penta-
gastrin induced panic attack in the same subjects. Furthermore, the data of the
spontaneous panic attacks were compared to the data of all the pentagastrin indu-
ced panic attacks in the PD patients. Differences over the scans within the group of
five patients were tested by again a multisubject analysis. Overall group and state
differences were tested by a multigroup analysis, wherein both groups (the group of
scans of the subjects who experienced a spontaneous panic attacks and the group
of scans of all pentagastrin induced panic attacks in PD patients) were compared
with an ANOVA. 
Clusters with voxel differences achieving a threshold of Z =  3.30 (corresponding to
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a p-value < 0.001 uncorrected) were displayed in three orthogonal projections on
SPM glass brain projections. The statistical parametric maps (SPMs) were inspec-
ted for the presence of findings in unpredicted regions; these were reported signifi-
cant only if resisting correction for multiple comparisons based on the Gaussian
random field theory (Friston et al 1996) and using the statistical procedures for con-
trolling the false discovery rate (Genovese et al 2002) (p<0.05). SPM99 calculates
corrected statistics across the whole brain, by working out the shape and size of the
whole brain volume in the analysis and calculating the correction accordingly
(Worsley et al 1996). If differences were observed, the stereotactic coordinates of the
peak differences were determined using the Talairach and Tournoux atlas (Talairach
and Tournoux 1988), after translating the MNI coordinates to coordinates according
to the Talairach template, by using the matlab function mni2tal.m as described by
M. Brett on the website of the Cambridge Imagers Group (http//www.mrc-
cbu.cam.ac.uk/imaging/mnispace.html). 
Results 
Behavioral and physiological differences between spontaneous panic and pentagastrin
induced panic
All six subjects who experienced a spontaneous panic attack also experienced a
panic attack after pentagastrin injection. Significant differences between the two
panic attacks were detected in the API score (t = 8.3, df = 5, p = 0.000) and the
heart rate (t = 3.5, df = 5, p = 0.018) (see table 1). These were both higher during the
pentagastrin induced panic attack (mean API = 34.7, sd = 10.3; mean HR = 74.5, sd
= 8.8) than during the spontaneous panic attack (mean API = 16.0, sd = 7.7; mean
HR = 69.7, sd = 6.8). In MABP no significant differences were detected between
pentagastrin induced panic and spontaneous panic. 
The spontaneous panic attacks as well as the pentagastrin induced panic attacks
started immediately after the injection of saline or pentagastrin, and all panic symp-
toms disappeared again within five minutes. 
Table 1 
Behavioral and physiological results 
Pentagastrin induced Spontaneous P
attack attack
HR, mean (SD) 74.5 (8.8) 69.7 (6.8) 0.018
MABP, mean (SD) 109.2 (29.6) 103.2 (7.4) NS (0.615)
API, mean (SD) 34.7 (10.3) 16.0 (7.7) 0.000
Legend: HR = Heart Rate, MABP = mean arterial blood pressure, API = Acute panic inventory
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Regional CBF differences between spontaneous panic and pentagastrin induced panic
The main brain regions showing rCBF increases during pentagastrin induced panic
compared to rest were the left anterior and posterior cingulate gyrus, the left hippo-
campus, the thalamus, the right medial and superior temporal lobe, the cerebellum,
the inferior frontal gyrus and the left amygdala, while decreases were observed in
the parahippocampal gyrus, the precentral gyrus, the temporal pole and the orbito-
frontal/prefrontal cortex. The brain regions showing rCBF increases during sponta-
neous panic compared to rest were the anterior and posterior cingulate gyrus, the
left hippocampus, the thalamus, the medial and superior temporal lobe, the cerebel-
lum and the inferior and medial frontal gyrus, and decreases were seen in the pre-
frontal/orbitofrontal gyrus, the precentral gyrus, the temporal pole and the right
inferior frontal gyrus. These results are thus rather similar. The main difference
between the two rCBF patterns is the observation of activation of the amygdala
during pentagastrin induced panic, while this was not seen during spontaneous
panic. 
After statistical comparison no significant rCBF differences were detected between
the spontaneous panic attacks and the pentagastrin induced panic attacks. The SPM
analysis showed no suprathreshold clusters. The statistical comparisons were per-
formed within the group of the five subjects experiencing both a spontaneous and a
pentagastrin induced panic attack. These results were replicated when the five scans
of the spontaneous panic attacks were compared with the scans of the pentagastrin
induced panic attacks of the whole group of PD patients in a multigroup analysis. 
Discussion 
The main regions where rCBF increases were observed during panic as compared
with the resting condition were the anterior and posterior cingulate gyrus, the left
hippocampus, the thalamus and the superior and medial temporal lobe, both
during pentagastrin induced panic as during spontaneous panic. Decreases in rCBF
were shown in the orbitofrontal cortex, the prefrontal cortex, the temporal pole and
the inferior frontal gyrus, also both during pentagastrin induced and during sponta-
neous panic. The left amygdala showed activation during pentagastrin induced
panic but not during spontaneous panic, but this difference did not reach statistical
significance when both panic states were compared in the statistical analysis. The
major finding of this study is therefore that there are no rCBF differences between
pentagastrin induced and spontaneous panic attacks, albeit there were some beha-
vioral and physiological differences. The pentagastrin induced panic attacks caused
a higher API score and a higher HR in the PD patients. There have been previous
reports of short-lived increases in HR after CCK4 injection. The HR returned to base-
line within five minutes after termination of the injection of CCK4, when symptoms
had subsided (de Montigny 1989; Shlik et al 1999). The recording of HR in our
study was performed when symptoms diminished, 120 seconds after the injection.
The pentagastrin induced panic attack also generated a higher API score.
Afterwards, PD patients reported that the pentagastrin induced panic attack feels
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much like a spontaneous panic attack, but seems to be compressed in time, in
duration as well as in intensity of the feelings. This could probably explain the high
API score. 
The rCBF findings provide further evidence for the validity of pentagastrin as a
model for naturally occurring panic. Pentagastrin seems to be equally potent to
CCK4, although once it was suggested to be less potent (van Megen et al 1994).
This was probably due to differences in experimental design between two research
groups. It may also have been caused by pharmacological differences in dilution and
storage of the pentagastrin and CCK4, because when the dry powder is diluted in
saline, the substance is very unstable. The described lower panic rates on pentagast-
rin as compared with CCK4 were later followed by a desciption of lower panic rates
following CCK4 administration also. Finally, two groups studying pentagastrin and
CCK4 induced panic both found a rather similar panic rate between both substances,
when using the same experimental design. Our panic rate is comparable to the
panic rate reported by Bradwejn et al (Bradwejn et al 1991b). Furthermore, penta-
gastrin is commercially better available than CCK4, for the use in humans, because
pentagastrin (Peptavlon®) has been used as a diagnostic tool for gastric acid deter-
mination. 
It has been stated that the ideal pharmacological panic provocation model should
meet several criteria (Gorman et al 1987; Guttmacher et al 1983). It should be safe,
it should mimic naturally occurring anxiety, and therefore, it should foster both
peripheral and central manifestations of anxiety. Furthermore, the panic attack
should be similar to the patient’s spontaneous panic attack. The symptoms induced
should be either short lived or readily reversible, and they should be replicable. It
should differentiate between normals and those with pathology. Effective antipanic
agents should be able to block the pharmacologically induced panic of the provoca-
tive agent. Furthermore, treatment strategies that are known to be ineffective
against PD symptoms, should equally not be effective in blocking the pharmacologi-
cally induced panic. Pentagastrin challenge fulfills most of these criteria.
Pentagastrin is safe in humans, as demonstrated by the fact that it was used as a
diagnostic agent. CCK4 was used many times by different groups to induce panic
attacks, and no adverse events were discovered. Pentagastrin and CCK4 mimic
anxiety by inducing both affective and somatic symptoms of PD. Moderate to inten-
se fear, or fear of dying or going crazy should be present. Furthermore, at least four
of the DSM-IV derived somatic symptoms have to be present. Even with these strin-
gent criteria nearly 100% of PD patients experiences a panic attack after injection of
pentagastrin or CCK4. Pentagastrin and CCK4 mimic the patient’s spontaneous
panic attack. The pentagastrin induced panic attacks were rated as very similar to
spontaneous panic attacks, but more severe and shorter, as if a spontaneous panic
attack was compressed in a very short time span. This was observed before in other
studies (Abelson and Nesse 1994; Bradwejn et al 1991b; Bradwejn et al 1992a;
Koszycki et al 1991; van Megen et al 1994; van Megen et al 1996b). Moreover, it has
been reported (Bradwejn et al 1991b; 1992a) that CCK4 does not induce a stereoty-
ped response in PD patients, but mimics the individual symptom profile usually
experienced by each individual patient. The phenomena induced are very short-lived,
they last only about two to five minutes. The effects of pentagastrin and CCK4 are
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reliable, as shown to be replicable in the same individuals on two separate occasi-
ons (Bradwejn et al 1992b). In some of the studies significantly different responses
for pentagastrin and CCK4 were observed for patients with PD, as compared with
healthy control subjects or subjects suffering from other anxiety disorders (Bradwejn
et al 1991b; Brawman et al 1997). In addition, the incidence of panic attacks was
markedly increased in patients compared to control subjects or subjects with other
anxiety disorders (Bradwejn et al 1991b; Brawman et al 1997; van Megen et al 1994).
Different reports show that antipanic agents can block the effects of pentagastrin
and CCK4 (Bradwejn and Koszycki 1994a; Shlik et al 1997; van Megen et al 1997a).
Premedication with different substances without known antipanic activity showed
that these agents are unable to block panic attacks induced by pentagastrin and
CCK4 (Bradwejn et al 1994a; van Megen et al 1997b). 
The effect of CCK4 was also compared with other valid pharmacological models of
panic (Guttmacher et al 1983). It has been compared with 35% CO2 inhalation in
both patients with PD (Bradwejn and Koszycki 1991) and in healthy control subjects
(Koszycki et al 1991). In PD patients CCK4 induced more symptoms and the symp-
toms also were more intense. Furthermore, the number of panic attacks induced by
CCK4 was higher as compared to 35% CO2. The symptom profile that emerged was
the same after both CCK4 and CO2. In healthy volunteers CCK4 induced more inten-
se panic symptoms than 35% CO2, but it was equipotent with respect to the fre-
quency in inducing panic attacks. 
CCK is a neurotransmitter present in the human central nervous system, for which
neuronal pathways and receptors have been identified. CCK is synthesized and sto-
red in nerve terminals and cell bodies, it is released by depolarization, it has specific
binding sites, it can affect the firing rate of other CNS neurons and its effects can be
modulated by analogues (Bradwejn et al 1990). Biochemical and electrophysiologi-
cal data suggest interactions between CCK and multiple neurotransmitter systems,
including serotonin, noradrenaline, GABA and dopamine. 
It is uncertain how CCK4 can induce panic and anxiety in humans. It cannot pass the
blood brain barrier and therefore a direct central effect is unlikely, unless CCK binds
to the CCK-receptors located in the circumventricular organs that lack a blood brain
barrier, for example the area postrema. Evidence for this idea was found in animal
studies (Karkanias et al 1989). Another explanation for the panic inducing effect of
CCK is cognitive mediation. Clark (1993) suggests cognitive mediation of the peri-
pheral manifestations of panic attacks to be the underlying working mechanism of
all biological challenge tests. Bradwejn and colleagues (1991b) describe that some
of their subjects clearly indicated that the subjective experience of anxiety induced
by CCK4 preceded the physical symptoms. Therefore, they suggest that a more direct
central effect of CCK4 is possibly the anxiety inducing mechanism. This problem can
only be solved by more extensive research. 
CCK is especially abundant in brain regions involved in the fear network in the brain,
including the brainstem, hippocampus, amygdala and cerebral cortex (Karkanias et
al 1989; LeDoux 1998). These are the brain regions also frequently implicated in the
pathobiology of anxiety and panic in neuroimaging studies. In our previous studies
we also detected significant increases and decreases in the rCBF of most of these
brain regions (Boshuisen et al 2002). During pentagastrin induced panic in PD
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patients as compared to a resting situation we found increased rCBF in the parahip-
pocampal gyrus/fusiform gyrus, the prefrontal cortex, the left orbitofrontal cortex,
the left inferior frontal gyrus, the cerebellum and the left basal ganglia. Regions with
decreased rCBF during panic compared to rest were the superior frontal gyrus, the
medial and inferior temporal lobe, the thalamus, the hippocampus, the insula and
the orbitofrontal/prefrontal cortex (Boshuisen et al, submitted). This activation pat-
tern was similar to the pattern we observed in PD patients during anticipatory anxie-
ty (Boshuisen et al 2002) and in control subjects during pentagastrin induced anxi-
ous arousal (Boshuisen et al, submitted). Consequently, the differences between the
rCBF patterns probably have to be attributed to differences in the intensity of the
experienced anxiety. In this respect it is tempting to speculate that panic and anxiety
are not different entities, but neuronal fear network threshold related differences.
After crossing a certain threshold, anxiety may become panic. It is possible that the
threshold of anxiety in PD patients is lower than in healthy control subjects. One of
the working mechanisms of antipanic drugs can be that they heigthen the threshold
for the development of anxiety (Boshuisen et al, submitted).
It has been suggested before that the intensity of panic or anxiety, especially resul-
ting from pharmacological provocation, is influenced by cognitive mediation and
anticipation (Bradwejn et al 1991b; Clark 1993; Cowley et al 1987; van Megen et al
1994; Yeragani et al 1988). In some studies differences were found in panic rate
between patients with high anxiety ratings and patients with low anxiety ratings
(Yeragani et al 1988), while in other studies no differences were observed in the
panic attack rate (Bradwejn et al 1994b; van Megen et al 1994). 
One of the limitations of this study is that the spontaneous panic attacks in this
study occurred during high anticipatory anxiety, before the pentagastrin was injected
(Boshuisen et al 2002). Anticipatory anxiety has been suggested (Deakin 1991;
Deakin 1999) to bring about a less likely situation for panic attacks to occur, and
thus this might be a reason that the spontaneously occurring attacks in the scanner
are not completely comparable with naturally occurring attacks. However, our sub-
jects rated these panic attacks as very similar to their naturally occurring attacks, as
they did with the pentagastrin induced panic attacks. Furthermore, only six patients
experienced a spontaneous panic attack and only five of these were scanned becau-
se of injection pump failure in one subject. Therefore the group is relatively small.
Nevertheless, no suprathreshold clusters were observed, showing that there were no
significant rCBF differences between the spontaneous and the pentagastrin induced
panic attacks. 
In conclusion, in this paper no significant differences in rCBF could be observed
between pentagastrin induced panic attacks and spontaneously occurring panic
attacks, and thus this study provides further evidence for the use of pentagastrin as
a pharmacological challenge agent in PD. 
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Chapter 6
Summary and concluding remarks
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The original aim of the research founding this thesis was to characterize the neuro-
biological substrate of panic disorder (PD), and to characterize the effects of treat-
ment on the recovery of the affected circuitry. Along the way, the focus partially shif-
ted to the larger concept of the neurobiology of anxiety. When studying the patterns
of brain activation before, during and after a pentagastrin challenge in PD patients
and healthy volunteers we discovered that different states of anxiety showed a simi-
lar pattern of brain activation, wherein the same brain areas were involved. LeDoux
(1996) described a fear network in the brain, based on clinical and preclinical
research, by which conditioned as well as unconditioned stimuli produce anxiety. A
few years later, Gorman et al (2000) revised their neuroanatomical hypothesis of PD
(Gorman et al 1989), and described the anxiety in PD in the same terms. The
amygdala plays an important central role in the fear network in the brain. In the
amygdala, signals from sensory cortical regions and from the thalamus, hippocam-
pus, insula and prefrontal cortex come together and are recognized as anxiety-rela-
ted. The amygdala projects to brain areas as the locus coeruleus, the hypothalamus
and the periaqueductal gray matter (PAG) to generate fear behavior and endocrine
and autonomic responses. Furthermore, projections from the amygdala to the orbi-
tofrontal cortex and the anterior cingulate cortex were shown (see also the introduc-
tion of this thesis). Damasio et al (2000) discuss different emotions (anger, fear,
sadness and happiness), based on a theoretical framework which proposes that all
emotions are part of a multitiered and evolutionary set neural mechanism aimed at
maintaining organism homeostasis. They argue that different emotions engage
(activate or deactivate) cortical and subcortical regions concerned with representing
and/or regulating this organism homeostasis, namely the insular cortex, the secon-
dary somatosensory cortex, the anterior and posterior cingulate cortex, the hypotha-
lamus and nuclei in the brainstem tegmentum (upper pons and midbrain). Most of
these regions have been implicated in the fear network in the brain, as described by
LeDoux (1996). In our study, all brain regions affected by pentagastrin were also
part of this fear network. However, it is difficult to interpret increases and decreases
in blood flow in functional imaging studies (1999). Malizia (1999) reviews a number
of caveats that apply to the definition of the direction of change in the final calculati-
on of brain activity. This leads some investigators to believe that in studies of affect
or mood the direction of the change could be of less heuristic value than the locati-
on of the changes. Therefore, in the following part, changes in blood flow are not
discussed specifically as increases or decreases but only in terms of activation diffe-
rences, to facilitate reading. 
In chapter three we reported anticipatory anxiety in both PD patients and healthy
volunteers, and we analyzed the differences in brain activation between PD patients
and healthy volunteers at rest. The PD patients in our study experienced a higher
level of anticipatory anxiety than the normal control subjects, as witnessed by the
higher number of experienced panic-related symptoms in the prechallenge conditi-
on. The same rCBF pattern was observed in rest, when comparing PD patients with
healthy control subjects, a situation in which PD patients are subject to their normal
baseline level of anxiety, while the control subjects are at rest, feeling no anxiety at
all (Boshuisen et al 2001). We discovered that during anticipatory anxiety the follo-
wing regions showed altered brain activity: the precentral gyrus, the inferior frontal
82
The Anxious Brain
17355 Bosh B  22-10-2003  14:20  Pagina 82
gyrus, the insula, the amygdala, the parahippocampal gyrus, the hippocampus, the
temporal lobe, the orbitofrontal cortex, the anterior cingulate gyrus, the hypothala-
mus, the thalamus and the midbrain. At rest, we discovered the following differen-
ces in rCBF between untreated PD patients and healthy volunteers, reflecting a pro-
bable trait difference related to the presence of the anxiety disorder, and thus related
to the feeling of anxiety: the precentral gyrus, the insula, the parahippocampal gyrus,
the hippocampus, the temporal lobe, the orbitofrontal cortex, the thalamus and the
midbrain. 
In chapter four we described panic induced by pentagastrin in PD patients, and
compared these data with the anxious arousal experienced by healthy volunteers
during a pentagastrin challenge. A similar pattern of anxiety related brain activity
was seen during pentagastrin-induced panic, noticed by the large increase in symp-
tom experience and anxiety in the PD patients, and during pentagastrin-induced
anxious arousal, as shown by the increase in symptom experience and by the small
increase in anxiety in the healthy control subjects (Boshuisen et al submitted). In
the PD patients we found changes in the rCBF in the inferior and superior frontal
gyrus, the insula, the parahippocampal gyrus, the hippocampus, the medial and
inferior temporal lobe, the orbitofrontal cortex, the thalamus, the basal ganglia and
the cerebellum whereas in healthy volunteers we noticed changes in the rCBF in the
precentral gyrus, the superior frontal gyrus, the insula, the amygdala, the parahippo-
campal gyrus, the inferior and superior temporal lobe, the orbitofrontal cortex, the
anterior and the posterior cingulate cortex, the hypothalamus, the basal ganglia, the
cerebellum. In the fifth chapter of this thesis we reported partial normalization of
the rCBF pattern in PD patients after successful pharmacological treatment with the
SSRI sertraline. The findings show that the rCBF differences observed between PD
patients and healthy control subjects are at least partially state dependent, and
change when anxiety diminishes. The fact that the normalization of the rCBF pattern
is only partial could reflect trait differences between PD patients and control sub-
jects. It is conceivable that a follow up period of 12 weeks is too short to achieve
complete normalization of the activation pattern in the brain. Longer follow up pe-
riods can control for this and show if complete normalization is possible. Up until
now, no neuroimaging studies with long follow up intervals have been published. 
Finally in chapter six, we described the rCBF pattern during a spontaneous panic
attack and compared this to the panic induced by pentagastrin. No significant diffe-
rences were shown in the rCBF pattern related to the experience of a spontaneous
panic attack as compared to the pentagastrin induced panic attack. Both in sponta-
neous panic and in pentagastrin induced panic we observed a similar pattern of
brain activation. Activation differences during pentagastrin induced panic were seen
in the precentral gyrus, the inferior frontal gyrus, the amygdala, the parahippocam-
pal gyrus, the hippocampus, the medial and superior temporal lobe, the orbitofron-
tal/prefrontal cortex, the anterior and posterior cingulate gyrus, the thalamus and
the cerebellum after pentagastrin challenge. During spontaneous panic activation
differences were seen in the precentral gyrus, the inferior and medial frontal gyrus,
the hippocampus, the anterior and posterior cingulate gyrus, the medial and supe-
rior temporal lobe, the prefrontal/orbitofrontal gyrus, the thalamus and the cerebel-
lum. 
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We observed an unexpected decrease of the rCBF in the amygdala in PD patients
during anticipatory anxiety, and furthermore we observed an increase in the amygda-
la of healthy controls subjects during anxious arousal, while this could not be obser-
ved in PD patients. The amygdala is considered to be crucial in the experiencing of
anxiety and fear, and plays a central role in the fear network in the brain (Davis 1997;
LeDoux 1996; LeDoux 1998; Windmann 1998) (see also the introduction of this the-
sis). One may expect increased levels of activity in the amygdala in PD patients,
because of this key role of the amygdala in the acquisition and expression of fear
(LeDoux 2002). Increased blood flow in the amygdala region is frequently reported
in some but certainly not in all anxiety-related studies (Liberzon et al 1999; Pissiota
et al 2002; Tillfors et al 2001). Our finding that activation of the amygdala is not
present during pentagastrin induced panic attacks in PD patients might be explai-
ned by the fact that the amygdala in PD patients is already habituated to anxious
arousal in connection with panic. It is hypothesized that the amygdala is specifically
involved in the initial acquisition of emotional learning, a phase PD patients have
passed, while the situation may be new to the healthy control subjects. In an experi-
ment by Cheng et al (2003) subjects receiving paired presentations of a conditioned
stimulus and a shock showed greater amygdala activation than subjects receiving
unpaired presentations, thereby exhibiting that the amygdala is important for the
expression of learned behavioral responses during Pavlovian fear conditioning.
Inhibition of the amygdala could be a consequence of the increased rCBF of the pre-
frontal cortex, due to a cognitive representation of anticipatory anxiety, present in
PD patients but not in healthy control subjects. This inhibition of the amygdala by
the prefrontal cortex has been observed previously in rats, monkeys and also in
humans (Hariri et al 2003; Kalin et al 2001; LeDoux 1998; Ochsner et al 2002). In
our studies activity in the prefrontal cortex is observed and could thus be an expla-
nation for the absence of activity in the amygdala. The role of the amygdala and the
prefrontal cortex in anxiety is discussed in a review by Davidson, in which these
issues are also addressed (2002).
The remarkable similarities in the rCBF pattern in different forms of anxiety as
observed in the studies presented here, were also observed by Reiman (1997).
Reiman (1997) reviewed six of his PET studies that investigated brain regions parti-
cipating in emotion, anxiety and anxiety disorders. He concludes his paper by outli-
ning a fear network in which the different areas and their potential functions are
described as being involved in anticipatory anxiety, during panic and in panic disor-
der patients compared to control subjects. However, the conclusions of Reiman
(1997) are based on studies with different designs, and the involvement of only a
few fear network related brain regions could be demonstrated. Conclusions in this
thesis are based upon studies with a similar design, wherein rCBF differences were
consistently shown in most of the fear network related brain regions in different
anxiety states.
As explained in the introduction of this thesis, the disorder of PD as it is nowadays
categorized in the DSM-IV only exists for several decades. From the DSM-III (1980)
onwards the diagnosis is delimited from the anxiety neurosis. The DSM-III came
forth from the Research Diagnostic Criteria (RDC) (Spitzer et al 1978), and both
classification systems were a result of the development of a taxonomy that could be
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accepted by the psychiatric community at the time. Furthermore, a process of scien-
tification of the psychiatric profession started. Research in psychiatry became mainly
focused on the search for biological parameters explaining psychiatric disorders,
supported by the developments in psychopharmacology. We presently tend to think
in this categorical differentiation of anxiety disorders, but several groups have argu-
ed for the so-called neurotic disorders to be dimensionally organized (Goldberg
1996; van Praag et al 1987; van Praag 1989; 1990). The categorical or nosological
model has great advantages: it allows us to identify relatively homogenous patient
groups for research and it is a quick short-hand for clinicians (Goldberg 1996).
However, the long-term usefulness of such a model is debated, especially for illnes-
ses such as anxiety and mood disorders (Goldberg 1996; Kendell 1975; van Praag et
al 1990; van Praag 2000). 
Klein and Klein (1989), favoring the nosological approach, discuss the utility of the
panic disorder (PD) concept by stating that spontaneous panic is not simply a seve-
re form of ordinary anxiety or generalized anxiety disorder (GAD), but is distinguis-
hable by the pattern of development, the psychopharmacological responsivity and
familial aggregation. According to them it is often mistakenly thought that panic is
simply the quantitative extreme of generalized anxiety. They state that the central
distinction between panic and anxiety is the sudden crescendo and the spontaneity
of the panic attack. This concept of PD as a stable clinical entity is supported by the
data of O’Rourke et al (1996). This group states that it is difficult to reconcile their
data, derived of the present state examination, with the view that PD is but one facet
of a general neurotic syndrome. 
Goldberg (1996), favoring the dimensional approach to anxiety disorders, argues
that dimensional models are a way of trying to account for variations between the
myriad different sets of symptoms offered by patients in the most economical way.
According to him, these dimensional models offer considerable advantages over
categorical models when relating continuously distributed social variables to clinical
variables. He declares: “comorbidity for example, has some meaning if we are refer-
ring to combinations of diabetes and schizophrenia, or even of depression and alco-
hol dependence, but it is surely stretching the concept to absurdity to allow one or
two symptoms from correlated domains to produce the phenomenon. The size of
comorbidity between anxiety and depression is not a measure of the frequency with
which two independent morbid conditions coexist; it merely indicates the position
of an arbitrary dividing line on a dimension, which could equally easily, and plausi-
bly, be drawn elsewhere.” In different papers concerning the topic of the denosologi-
zation of psychiatry, van Praag (1987; 1989; 2000) argues for a reaction model in-
stead of the nosological approach. The reaction model conceives abnormal psychic
states as reaction patterns to noxious stimuli. Noxious stimuli can disarrange vari-
ous neuronal circuits and various psychological systems. The degree of the neuronal
disruption varies as a function of ego strength, strength of the stimuli and neuronal
adaptability. Therefore, according to van Praag (2000), psychiatric conditions lack
symptomatological consistency and predictability. He argues in favor of verticaliza-
tion of syndromes, the dissection of syndromes into their component parts, namely
the psychological dysfunctions (i.e. functionalization of the diagnosis), and use
these psychological dysfunctions as subjects for research into psychiatric disorders. 
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The outcome of the different studies of this thesis, concerning the activation of fear
network related brain regions during anxiety, led us to believe that panic and anxiety
are not different entities, but neuronal fear network threshold related differences.
After crossing a certain threshold, anxiety may become panic. It is also conceivable
that the threshold of anxiety in PD patients is lower than in healthy control subjects.
Based upon this one may argue that antipanic drugs exert their clinical effects by vir-
tue of increasing this threshold, for example by improving cerebral plasticity
(Saarelainen et al 2003). Therefore, this thesis favors the notion of a more dimen-
sional approach to the diagnosis of anxiety and the concept of anxiety disorders in
psychiatry. This notion is corroborated by the outcome of a recent study by Mataix-
Cols et al (Mataix-Cols et al 2003), finding support for a dimensional model of
obsessive-compulsive disorder. They observed the same brain regions implicated in
the mediation of anxiety in response to symptom-related material in healthy volun-
teers as were previously discovered in OCD patients. 
Suggestions for further research
More research in this field is needed to support the idea of a more dimensional con-
cept of anxiety, instead of the nosological definitions of anxiety disorders as can be
found in the DSM-IV (1994). This can be done by repeating the experiments in diffe-
rent anxiety disorders as categorized in the DSM-IV, especially the distinction
between panic disorder and generalized anxiety is in this respect interesting, becau-
se these two disorders are seen as two fundamentally different concepts of anxiety.
Furthermore, several parts of the experiments founding this thesis can be changed,
to elucidate subjects that are still unclear, or improve the impact of the data gathe-
red. 
It would be interesting to assess autonomic functions more precisely in the different
experiments, by measuring skin conductance response, continuous heart rate and
blood pressure, contingent with heart rate variability. The somatic component of
anxiety (e.g. the increased autonomic nervous system reaction) over time almost
disappeared in the categorical model of anxiety disorders, but for patients this is
still a key component of anxiety. 
According to neuroimaging methods, it is preferable to use fMRI in future experi-
ments, because this technique provides better spatial resolution than PET, and expe-
riments can be repeated more often because of the absence of radiation. Difficulties
in this respect are the practical aspects of the injection of pentagastrin and the
monitoring of the different functions. Furthermore, many patients with anxiety disor-
ders are afraid of small spaces, and therefore do not want to participate when the
experiment is performed in the MRI scanner. Partially, this problem can be solved by
making a structural MRI scan of every subject in addition to the PET scan, and cor-
relating the PET and MRI data. Then the brain regions with increased or decreased
rCBF can be localized more accurately. 
We chose a double-blind procedure to administer pentagastrin to the subjects.
During the experiments we discovered that pentagastrin is such a powerful panic
inducing agent, that after injection it is immediately clear if a subject received penta-
86
The Anxious Brain
17355 Bosh B  22-10-2003  14:20  Pagina 86
gastrin or placebo. A single-blind procedure is easier performed and has the advan-
tage that the researcher can plan the panic induction. Some subjects were so anxi-
ous while anticipating a possible panic attack during pentagastrin, that they expe-
rienced a spontaneous panic attack during placebo injection in the second gift. The
number of subjects with spontaneous panic attacks might have been much higher
when a single-blind procedure was used and all subjects had received placebo
during the second gift and pentagastrin during the third gift. 
In addition to the placebo gift, it might be interesting to compare the effect of pen-
tagastrin with the effect of thyrotropin releasing hormone (TRH). Coupland et al
(1996) discovered that in healthy volunteers TRH induces similar objective and sub-
jective symptoms as pentagastrin. The main differences between TRH and penta-
gastrin were that TRH induced more urinary urgency and pentagastrin induced
dyspnoea and anxiety, and more tingling in the extremities. 
The mechanism of action of CCK4 and pentagastrin in anxiety induction is still
unclear. Radioactive labeling of pentagastrin or CCK4 would be a nice way to observe
if these substances act directly in the central nervous system, or if cognitive mediati-
on is a more likely mode of action. Labeling of CCK4 or pentagastrin has not been
conducted yet. CCK receptor antagonists have been labeled for the use as CCK
receptor ligands in PET studies, but the results for the CCK2 receptor are not very
hopeful. Biodistribution studies showed very low brain uptake after intravenous
injection in the rat (Haradahira et al 1998). 
PD has a higher incidence in women than in men. Gender differences should be
addressed in research of this kind, even more because gender differences also exist
in cerebral blood flow (George et al 1996). Unfortunately this subject is beyond the
scope of this thesis, but we are planning to address this subject in future research. 
Conclusion
The outcome of the different studies of this thesis led us to believe that panic and
anxiety are not different entities, but neuronal fear network threshold related diffe-
rences. After crossing a certain threshold, anxiety may become panic. It is conceiva-
ble that the threshold of anxiety in PD patients is lower than in healthy control sub-
jects. More research is needed to further elucidate this subject, nevertheless this
thesis provides a conceptual framework suitable as a starting point. 
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Paniekstoornis is een aandoening die in Nederland bij ongeveer 600.000 mensen
voorkomt. Paniekstoornis wordt gekenmerkt door het plotseling (aanvalsgewijs) en
zonder duidelijke oorzaak optreden van lichamelijke verschijnselen als bijvoorbeeld
hartkloppingen, benauwdheid, pijn op de borst, tintelingen in handen en voeten,
duizeligheid, trillen en zweten. Naast deze lichamelijke verschijnselen is er ook spra-
ke van angst (voor controleverlies of om dood te gaan) of in ieder geval een sterke
mate van ervaren ongemak. In het diagnostisch handboek dat in de psychiatrie het
meest gebruikt wordt, de DSM-IV (1994), wordt bovendien als voorwaarde gesteld
dat er sprake moet zijn van anticipatie angst: de voortdurende angst dat opnieuw
een aanval zal optreden. Deze angst leidt bij veel mensen tot vermijding van situa-
ties waarin men vermoed dat de kans groter is om opnieuw een paniekaanval te krij-
gen, of waar men het gevoel heeft onvoldoende hulp te krijgen bij het optreden van
een paniekaanval. Een groot deel van de patiënten met paniekstoornis, ongeveer de
helft, blijft daarom thuis en durft niet meer alleen de straat op. Dit noemen we ago-
rafobie. Meestal komen agorafobie en paniekaanvallen gezamenlijk voor, maar ago-
rafobie kan ook zonder paniekaanvallen voorkomen. 
Met betrekking tot de oorzaken en de behandeling van angst, en meer specifiek
paniekstoornis en agorafobie, zijn in de loop der tijd verschillende theorieën
gevormd. In de inleiding van dit proefschrift wordt kort deze ontwikkeling beschre-
ven. De laatste jaren wordt steeds meer duidelijk dat emotionele processen, zoals
onder andere angst, verbonden zijn met biologische processen. De ontwikkeling van
de geneeskunde, met steeds betere methoden om biologische processen in kaart te
brengen, geeft ons de mogelijkheid om door middel van onderzoek deze verbinding
tussen emotionele processen en biologische processen verdergaand te onderzoe-
ken. Ongeveer 15 jaar geleden moesten wij in het humane onderzoek nog genoegen
nemen met het onderzoek van afgeleide processen, zoals het onderzoek van bepaal-
de stoffen in lichaamsvloeistoffen (bloed, urine, hersenvocht) en farmacologische
provocatietesten, of waren we afhankelijk van proefdieronderzoek. Tegenwoordig is
de techniek dusdanig ontwikkeld, dat het mogelijk is door middel van beeldvormend
onderzoek een indruk te krijgen van structurele en functionele veranderingen in de
hersenen. De combinatie van beide soorten van onderzoek biedt mogelijkheden
voor het verkrijgen van steeds meer inzicht in de gebeurtenissen in ons lichaam.
Naar aanleiding van deze uitbreiding van mogelijkheden is het onderzoek ontwik-
keld dat in dit proefschrift staat beschreven. Door een combinatie van een farmaco-
logische provocatietest en beeldvormende techniek werd getracht meer inzicht te
krijgen in wat er gebeurt in de hersenen tijdens angst en paniek. 
In de inleiding van dit proefschrift staat beschreven welke verschillende methoden
van onderzoek in de loop der tijd bij paniekstoornis en andere angststoornissen zijn
gebruikt, en welke resultaten daarbij behaald werden. Een belangrijke plaats is inge-
ruimd voor de methoden die ook gebruikt werden voor dit proefschrift: 1. de farma-
cologische provocatietest, in het bijzonder het gebruik van cholecystokinine (afge-
kort CCK4) en pentagastrine, en 2. het functionele beeldvormende onderzoek van de
hersenen, de functionele neuroimaging en in het bijzonder de zogenaamde water
PET scan (H215O PET (positron emission tomography)). Er is veel onderzoek gedaan
naar het opwekken van angst en paniek door middel van farmacologische provoca-
tie, en uit dit onderzoek blijkt dat CCK4 en pentagastrine goede methoden zijn om
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bij patiënten met paniekstoornis een paniekaanval op te wekken die sterk lijkt op de
aanval die zij “spontaan” beleven. Om praktische redenen van verkrijgbaarheid is in
het onderzoek voor dit proefschrift pentagastrine gebruikt. De PET scanner is een
positronen scanner. Dit betekent dat de proefpersoon die in de scanner ligt positro-
nen moet uitzenden die opgepikt worden door de scanner en omgezet in beelden.
Dit gebeurt door de proefpersoon een licht radioactieve, snel vervallende vloeistof in
te spuiten (radioactief gemaakt water in het geval van dit onderzoek). De radioactivi-
teit wordt door het bloed verspreid, en door vervolgens een plaatje te maken van de
verdeling van de radioactiviteit krijgt men een beeld van de verdeling van het bloed
in het lichaam. Het idee achter dit type onderzoek is dat processen in ons lichaam
afhankelijk zijn van bloed. Er is een voortdurende afwisseling tussen verschillende
delen van het lichaam die meer of minder zuurstof nodig hebben en daardoor meer
of minder bloedtoevoer nodig hebben. Uitgangspunt voor het functionele neuroima-
ging onderzoek is dat delen van de hersenen die meer bloeddoorstroming hebben
actief zijn in het proces dat onderzocht wordt, en delen van de hersenen waar de
bloeddoorstroming minder is of niet veranderd ook minder betrokken zijn bij het
onderzochte proces. In de afgelopen tien jaar speelt het functionele neuroimaging
een steeds belangrijker rol bij het onderzoek naar de relatie tussen angst en andere
emotie’s, en het functioneren van de hersenen. 
Verschillende oudere onderzoeken (o.a. dierproeven en post-mortem onderzoek)
wezen er reeds op dat een aantal hersenstructuren een belangrijke rol lijkt te spelen
bij angst en paniek. De betrokkenheid van deze hersenstructuren werd grotendeels
bevestigd door het neuroimaging onderzoek, maar er was geen overkoepelend
onderzoek waarin een algemeen patroon, een neuronaal circuit dat betrokken is bij
angst (angst netwerk) in de hersenen, werd bevestigd. Wel is door Ledoux in het
begin van de 90-er jaren een angst netwerk model opgesteld naar aanleiding van
zijn en andermans bevindingen, uit voornamelijk dierproeven. De hersenstructuren
die hierin genoemd worden, worden over het algemeen genoemd als behorend bij
het limbisch systeem. Het gaat om de volgende hersengebieden: de prefrontale cor-
tex (zowel het orbitale als het mediale gedeelte), de temporaal kwab met de gyrus
parahippocampalis, de amygdala en de hippocampus, de gyrus cinguli, de voorste
basale kernen, de hypothalamus en de thalamus. In afbeelding 1 is te zien waar deze
gebieden gelegen zijn in de hersenen.  
De grondslag voor de verschillende onderzoeken, die de basis vormen van dit proef-
schrift, was om ondersteuning te vinden met behulp van neuroimaging onderzoek
voor het bestaan van een dergelijk angst netwerk in de hersenen. Het bestaan van
dit angst netwerk werd op verschillende manieren onderzocht. Door patiënten met
paniekstoornis te vragen om een provocatietest te ondergaan onder de PET scan,
konden zowel de paniekaanval (geïnduceerd door pentagastrine), alsook de antici-
patie angst (vlak vóór de toediening van de pentagastrine) én de situatie in rust
worden geëvalueerd. De situatie in rust was belangrijk als basis waartegen de ande-
re condities afgezet konden worden, en daarnaast ook omdat in de literatuur gesug-
gereerd wordt dat patiënten met paniekstoornis altijd leven met een basaal soort
anticipatie angst (aangezien zij volgens de DSM-IV definitie altijd bang zijn voor een
nieuwe aanval). Dit laatste aspect kon uitgezocht worden door de vergelijking van
de bevindingen bij patiënten met paniekstoornis met die bij gezonde proefperso-
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nen. De gezonde proefpersonen werd gevraagd om eenzelfde protocol te onder-
gaan: ook zij kregen het provocatiemiddel toegediend onder neuroimaging. In de
verschillende hoofdstukken worden al deze condities met elkaar vergeleken. Het
inleidende hoofstuk besluit dan ook met een overzicht van de experimentele studies
die in het proefschrift behandeld worden in de verschillende hoofdstukken. 
Aan het onderzoek deden in totaal 20 patiënten met paniekstoornis mee en 21
gezonde vrijwilligers. Het grootste deel van de proefpersonen deed één keer mee
met het onderzoek, maar er waren ook 6 patiënten die bereid waren twee maal de
pentagastrine provocatie test in de PET scanner te ondergaan, een keer voor en een
keer na het gebruik van medicatie. Vanwege het onderzoek werden van de proefper-
sonen meerdere scans gemaakt: een scan voor de injectie van pentagastrine, een
scan tijdens de injectie van pentagastrine en een scan na de injectie van pentagastri-
ne. Verder werd na elke scan de hartslag en de bloeddruk van de proefpersonen
gemeten en werd een vragenlijst (met de afkorting API) afgenomen om de achterha-
len hoe het angstniveau van de proefpersoon was en of deze een paniekaanval had
gehad. 
In hoofdstuk twee wordt beschreven in welke hersengebieden de bloeddoorstroming
verandert door anticipatieangst. Hiervoor werden de scans van voor de pentagastri-
ne injectie van de patiënten met paniekstoornis vergeleken met de scans van voor
de pentagastrine injectie van de controle proefpersonen. De hersengebieden waarin
verschillen werden gevonden in anticipatieangst tussen de patiënten en de controle
proefpersonen waren de volgende: de gyrus precentralis, de gyrus frontalis inferior,
the amygdala, de insula, de gyrus parahippocampalis, de bovenste temporaal kwab,
de hypothalamus, de gyrus cinguli anterior en een deel van de hersenstam (het mid-
brein). In deze studie werd ook gekeken naar de situatie in relatieve rust: de scans
van na de pentagastine provocatie van de paniekstoornis patiënten werden vergele-
ken met die van de controle proefpersonen. Er was ook in rust nog een verschil te
zien in de bloeddoorstroming van bepaalde hersengebieden tussen patiënten en
controles, mogelijk door de al eerder genoemde continu aanwezige angstcompo-
nent. Het ging hierbij om de volgende hersengebieden: de gyrus precentralis, de
gyrus frontalis inferior, de insula, de gyrus parahippocampalis, de bovenste tempo-
raal kwab, de gyrus cinguli anterior en de middenhersenen. Opvallend hierbij is dat
vrijwel dezelfde hersengebieden betrokken zijn bij de anticipatie angst zoals geme-
ten voor de pentagastrine provocatie en het basale angstniveau zoals dat aanwezig
is bij patiënten met paniekstoornis in rust. 
In hoofdstuk drie wordt de door pentagastrine geïnduceerde paniek geëvalueerd.
Hierin wordt beschreven wat er precies gebeurd tijdens een pentagastrine provoca-
tie test. Van de 17 patiënten met paniekstoornis kregen er 16 een paniekaanval na de
pentagastrine injectie, terwijl er van de 21 controleproefpersonen slechts twee aan
de criteria voor een paniekaanval voldeden. De paniekaanval ging gepaard met een
verhoogde hartslag en bloeddruk. Ook de spanning bij de proefpersonen die niet in
paniek raakten liep op, zoals gemeten met de API, en ook bij hen bleken bloeddruk
en hartslag verhoogd te zijn ten opzichte van rust. In dit hoofdstuk werd onderzocht
in welke hersengebieden de bloeddoorstroming verschilde tijdens paniek in patiën-
ten met paniekstoornis vergeleken met de door pentagastrine geïnduceerde span-
ning bij gezonde proefpersonen. In de volgende gebieden waren verschillen te zien:
106
The Anxious Brain
17355 Bosh B  22-10-2003  14:20  Pagina 106
de gyrus parahippocampalis, de orbitofrontale cortex, het cerebellum, de temporaal
kwab, de pons, de thalamus en de amygdala. Verder hebben we bekeken bij de
patiënten met paniekstoornis waar tijdens een paniekaanval de bloeddoorstroming
ten opzichte van rust veranderd was. Dat bleek te zijn in de volgende gebieden: de
gyrus parahippocampalis, de prefrontale cortex, de orbitofrontale cortex, gyrus fron-
talis inferior, het cerebellum, de basale ganglia, de gyrus frontalis superior, de tem-
poraal kwab, de thalamus, de hippocampus en de insula. Van de gezonde proefper-
sonen werden de scans gemaakt tijdens de pentagastrine provocatie test ook verge-
leken met de rust situatie. De spanning die opgeroepen werd door de provocatie
leidde ook hier tot veranderingen in bloeddoorstroming in dezelfde hersengebieden,
te weten: de temporaal kwab, de basale ganglia, het cerebellum, de gyrus parahippo-
campalis, de amygdala, de orbitofrontale cortex, de hypothalamus, de gyrus cinguli
anterior, de gyrus precentralis, de gyrus frontalis superior, de insula, de gyrus cinguli
posterior en de orbitofrontale cortex. Opvallend was dat bijna alle hersengebieden
waarvan we vanuit modellen en eerder onderzoek wisten dat ze betrokken zijn bij
het ervaren van angst, in deze vergelijkingen ook daadwerkelijk verandering van de
bloeddoorstroming lieten zien. Bovendien vonden we in alle gevallen ongeveer het-
zelfde patroon van verandering van bloeddoorstroming: tijdens de anticipatie angst,
in rust bij paniekpatiënten, tijdens een paniekaanval geïnduceerd door pentagastrine
en tijdens de door de pentagastrine provocatie veroorzaakte spanning bij gezonde
controles. 
In hoofdstuk vier worden de resultaten beschreven van een onderzoek naar het
effect van antidepressieve medicatie bij paniekpatiënten. De meest voorgeschreven
medicatie bij patiënten met paniekstoornis zijn de antidepressiva, en met name de
zogenaamde SSRI’s (serotonine heropname remmers). We hebben een groep
patiënten met paniekstoornis gedurende twaalf weken behandeld met één van deze
middelen, sertraline (Zoloft). Een groot deel van de patiënten had baat bij dit mid-
del: de paniekaanvallen traden minder vaak op en werden minder ernstig. Helaas
waren slechts zes patiënten bereid om een tweede keer een pentagastrine provoca-
tietest in de PET scanner te ondergaan. Van deze zes patiënten hebben we de scans
van de eerste en de tweede keer (dus voor en na behandeling) met elkaar vergele-
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ken. De conclusie die uit de resultaten valt te trekken is dat er bij patiënten met
paniekstoornis een partiële normalisatie plaatsvindt van de bloeddoorstroming in de
hersenen, zowel in rust als tijdens de pentagastrine provocatie. Slechts twee van de
zes patiënten kregen de tweede keer weer een paniekaanval op pentagastrine, terwijl
de eerste keer alle zes de patiënten een paniekaanval kregen. Bovendien was de
paniekaanval bij de twee patiënten die wel angstig werden duidelijk minder hevig
dan de eerste keer. Er was slechts een partiële normalisatie te zien. Dit kan een
gevolg zijn van het feit dat er na 12 weken voor de tweede keer gemeten werd.
Wellicht hadden we bij later meten meer normalisatie gezien. Het kan ook zijn dat
de hersengebieden waarin geen normalisatie werd gezien een soort kenmerk (trait)
vormen van patiënten met paniekstoornis. Mogelijk ligt in deze hersengebieden de
sleutel tot de vraag waarom sommige mensen wel paniekaanvallen en paniekstoor-
nis ontwikkelen en anderen niet. 
In het vijfde hoofdstuk werd de vraag onderzocht in hoeverre een door pentagastri-
ne geïnduceerde paniekaanval bij patiënten met paniekstoornis nou overeenkomt
met een spontane paniekaanval. Een zestal patiënten kreeg terwijl ze in de PET
scanner lagen een spontane paniekaanval tijdens één van de scans. De kenmerken
en de scans van de spontane paniekaanvallen zijn vergeleken met die van de door
pentagastrine geïnduceerde paniekaanvallen bij dezelfde patiënten. Er bleken geen
verschillen aantoonbaar in de bloeddoorstroming en de bloeddruk van de patiënten.
Wel was er een klein verschil in de API en in de hartslag te zien: de door pentagastri-
ne geïnduceerde paniekaanvallen werden als heviger ervaren dan de spontane
paniekaanvallen. De resultaten van deze vergelijking leveren extra steun voor het
gebruik van pentagastrine als paniek provocatie middel; het cerebrale doorbloe-
dingspatroon verschilt immers nauwelijks van dat van “spontane” paniekaanvallen.  
In het laatste hoofdstuk worden de conclusies uit de verschillende hoofdstukken
samengebracht en bediscussieerd in het licht van de theorie. Dit leidt tot de conclu-
sie dat de bloeddoorstroming telkens in dezelfde hersengebieden verandert tijdens
verschillende vormen van angst, en dat dit bovendien vrijwel alle gebieden zijn die
ook vanuit de theorie steeds weer genoemd worden als zijnde betrokken bij angst.
Wij vermoeden daarom dat paniek en angst, in termen van het neuronale circuit dat
geactiveerd wordt, niet zozeer verschillen als soms wel gedacht wordt. Het lijkt erop
dat patiënten met paniekstoornis slechts weinig verschillen van gezonde proefperso-
nen. Wellicht is er eerder sprake van een soort drempel in het angst netwerk in de
hersenen. Bij het overgaan van deze drempel verandert angst in paniek. Het is
mogelijk dat de “angstdrempel” in patiënten met paniekstoornis lager is dan bij
gezonde personen. Farmacotherapie, en wellicht ook andere vormen van therapie,
zou deze “angstdrempel” kunnen verhogen, waardoor paniek minder snel ontstaat.
In toekomstig onderzoek met behulp van neuroimaging zou meer aandacht besteed
moeten worden aan deze kwetsbaarheid van patiënten met paniekstoornis. 
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Na ampel beraad heb ik besloten me toch te conformeren aan de standaard.
Bovendien realiseer ik me dat het dankwoord één van de meest gelezen delen van
het proefschrift is. Vandaar dus bij deze:
Jurjen, Jelmer en Ilke, jullie zijn de belangrijkste personen om te noemen. Zonder
jullie zou er geen proefschrift en geen dankwoord zijn. Bedankt voor jullie zijn.
Jurjen, ik weet hoe belangrijk het voor jou was om een tastbaar resultaat te hebben
van mijn inspanningen van de afgelopen jaren. Ik heb het voor jou afgemaakt en
twijfel nog steeds of het de inspanningen waard was. De tijd zal het leren. 
Het allerbelangrijkst zijn naast mijn gezin: mijn familie en vrienden. Lieve allemaal:
jullie zijn enorm belangrijk voor me. Ik kan niet beloven dat er nu ineens zeeën van
tijd komen, maar in ieder geval wel meer dan het afgelopen jaar. Alle goede voorne-
mens die ik ieder jaar weer heb om meer contact te hebben (zowel in kwantitatieve
als in kwalitatieve zin) maken nu in ieder geval iets meer kans om tot uiting te
komen in actie. 
Hans, als promotor en werkgever, bedenker van het onderwerp en motivator, ben je
uiteraard ook essentieel geweest voor de tot stand koming van dit werk. Bedankt
voor alle inspanningen. Ook van jou in je latere rol als supervisor van Ps4B heb ik
veel geleerd. 
Gert, copromotor, altijd aanwezig om te enthousiasmeren, lang voordat de promo-
tie een feit was al bezig de stress te reduceren. Ik wordt regelmatig herinnerd aan
één van je vele waardevolle opmerkingen. 
Zonder de medewerking van de patiënten met paniekstoornis en de andere proef-
personen is geen onderzoek mogelijk. Het was altijd weer een hele klus om de men-
sen te vinden die wilden meedoen. Bedankt voor het belangeloos ondergaan van de
zeer onprettige pentagastrine provocatie test in de PET scanner. 
Mijn collega’s en ex-collega’s, op alle fronten (AIO’s, post-docs/UD’s/UHD’s, med-
werkers PET centrum, artsassistenten, maatschappelijk werkers, psychologen, secre-
tarieel medewerkers, verpleegkundigen, supervisoren, portiers, Jan Bakker), inmid-
dels zijn jullie met zoveel: jullie maken het dagelijks werk grotendeels de moeite
waard. Zonder de mogelijkheid om van me af te praten was dit er niet gekomen. Ik
ben blij een aantal van jullie ook onder mijn vrienden te kunnen rekenen. Carla: ook
onze gesprekken hebben bijgedragen tot het uiteindelijke resultaat, bedankt. 
De medewerkers van het PET centrum dank ik verder hartelijk voor de ondersteu-
ning bij de planning en uitvoering van de PET scans. 
De verschillende geneeskunde studenten die hun wetenschapsstage bij mij hebben
gedaan dank ik voor de hulp en ondersteuning bij de dataverzameling. 
Dick Veltman: bedankt voor de ondersteuning die je geboden hebt bij mijn vragen
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over SPM en dataverwerking. Door jouw uitleg werd het weer een stuk duidelijker. 
De leden van de leescommissie dank ik voor het lezen van het manuscript en voor
hun waardevolle commentaar. 
Opleider, Prof. Dr. Rob van den Bosch, bedankt voor de mogelijkheid om vier maan-
den onbetaald verlof te nemen, ook al was het toen nog steeds niet helemaal klaar,
en voor het feit dat ik die maanden niet hoef “in te halen”. 
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Curriculum Vitae 
Marjolein Boshuisen werd geboren op 11 september 1969 in Driebergen-Rijsenburg.
Zij verhuisde al snel naar het Limburgse land, alwaar zij in Heerlen aan het Grotius
College haar diploma Gymnasium β behaalde. In 1987 ging zij gezondheidsweten-
schappen studeren aan de Universiteit Maastricht (in die tijd nog Rijksuniversiteit
Limburg geheten). In september 1992 studeerde zij af in de richting Geestelijke
Gezondheidkunde, na een onderzoeks- en een praktijkstage bij de RIAGG Midden-
Limburg in Weert, en een jaar keuzevakken in de ontwikkelingspsychologie en de
cognitiewetenschappen gevolgd te hebben in Utrecht. Eveneens in september 1992
startte zij met de studie Geneeskunde aan de Universiteit Maastricht. In juni 1997
behaalde zij haar artsdiploma. Tijdens beide studie’s deed zij verschillende studen-
tassistentschappen zowel in onderwijs als in onderzoek, en werkte zij enige tijd als
testassistent bij de RIAGG in Maastricht. 
In augustus 1997 startte zij als assistent in opleiding bij de Rijksuniversiteit
Groningen op de afdeling Biologische Psychiatrie, onder leiding van Prof. Dr. J.A.
den Boer, met het onderzoek dat beschreven staat in dit proefschrift. Na vier jaar
onderzoek startte zij in september 2001 met de opleiding tot psychiater in het
Academisch Ziekenhuis Groningen. Van september 2002 tot en met december 2002
kreeg zij van haar opleider de gelegenheid om enkele maanden onbetaald verlof op
te nemen om dit proefschrift af te ronden. 
Zij is in 2000 gehuwd met Jurjen Klumperbeek, en heeft twee kinderen (Jelmer,
geboren in 1997 en Ilke, geboren in 1999).
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in rCBF of panic disorder patients due to effective treatment with sertraline.
Boshuisen, ML, ter Horst, GJ, den Boer, JA. 
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• World Congress of Biological Psychiatry, 1-5 july 2001, Berlin, Germany, abstract/pos-
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• Congress of European Association of Neuropsychopharmacology, october 2001,
Istanbul, Turkey, abstract. Pentagastrin induced panic is not significally different
from spontaneous panic attacks. Boshuisen, ML, ter Horst, GJ, den Boer, JA. 
• WetenSAPdag Nederlandse Vereniging voor Psychiatrie, 2 november 2001,
abstract/oral presentation. Paniek in de PET scan. Boshuisen, ML. 
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Regions more activated (red) or deactivated (green) in PD patients compared to 
control subjects during anticipatory anxiety. The darker the color the more 
superficial the areas are located. 




Regions more activated (red) or deactivated (green) in PD patients compared to 
control subjects in rest, after a pentagastrin challenge. The darker the color the 
more superficial the areas are located. 
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Fig. 2-3 Fig. 2-4
Deactivation of the amygdala during Activation of the anterior cingulate
anticipatory anxiety in PD patients cortex during anticipatory anxiety 
compared to control subjects. in PD patients compared to
control subjects. 
Fig. 3-4: Activation of the amygdala in control subjects (N=21) but not in PD 
patients (N=16) during pentagastrin administration; for the 
corresponding Talairach coordinates see table 2
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Fig. 3-3: rCBF differences during pentagastrin challenge, PD patients (N=16) 
compared with healthy control subjects (N=21); relative increases in rCBF 
during pentagastrin in patients compared to control subjects are shown 
in red, relative decreases in rCBF during pentagastrin in patients 
compared to control subjects are shown in green (the corresponding 
coordinates of the peak voxels are shown in table 2)
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Fig. 4-3:  rCBF differences during pentagastrin challenge pretreatment versus
posttreatment, 6 PD patients; relative decreases in rCBF during pentagastrin 
challenge posttreatment compared to pretreatment are shown in red, relative 
increases in rCBF during pentagastrin challenge posttreatment compared to 
pretreatment are shown in green (the corresponding coordinates of the peak 
voxels are shown in table 2).
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